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General introducti on
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Cost-effectiveness analysis as part of the evaluation of medical innovations has 
become well accepted and widely applied in several European countries, including 
the Netherlands. Although cost-effectiveness analysis is relatively well researched and 
provides a generally trusted estimate of the cost-effectiveness of a medical innovation, 
the underlying method is based on several assumptions. One important assumption is 
that costs and effects are constant over time. In reality however, and especially during 
the short run, variations in costs and effects might occur, for example due to learning 
effects and suboptimal occupancy rates. 
As decision makers in health care are under increasing budget pressures, the accuracy 
of cost-effectiveness outcomes in the short run is becoming more and more important. 
Currently, potential discrepancies between short run and long run outcomes are 
assumed to be irrelevant to the implementation decision. However, no insight is available 
into the magnitude of these discrepancies, as well as how decision makers may react 
to unexpected (financial) disappointments after implementing an innovation. Hence, 
there seems to be a need for methodology to quantify the discrepancies between short 
run and long run cost-effectiveness outcomes and assess their implications for decision 
making.
Increasing health care expenditures
In the Netherlands, health care spending has risen substantially over the last 60 years. 
During the last 10 years, spending increased on average by 4.4% every year, excluding 
inflation. It is expected that this trend will continue in the future. For example, the 
CPB Netherlands Bureau for Economic Policy Analysis predicts a rise in health care 
expenditures of 2.6% to 4.2% per year [1]. The Dutch National Institute for Public Health 
and the Environment (RIVM) is less optimistic, forecasting an annual increase of 5% [2]. 
In the Netherlands, 13.2% of national income is spent on health care [3]. If the trend of 
the last 10 years continues, this percentage will increase to 31% in 2040. For an average 
family this would mean that in 2040 they would spend roughly half of their income on 
health care. The trend of increasing health care expenditures is not confined to the 
Netherlands. Indeed, the two underlying factors contributing the most to rising health 
care consumption, an aging population and the continuous inflow of expensive medical 
innovations in the health system, are also present in many other countries [4, 5]. 
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Cost-effectiveness analysis as a means to allocate scarce health care resources
This thesis will concentrate on a targeted measure to manage health care expenditures, 
namely the economic evaluation, or cost-effectiveness analysis, as a means to aid in the 
decision whether or not to adopt a medical innovation and include it into the benefit 
package. The continuous inflow of medical innovations into the health care system is an 
important driver for increasing health care costs [5]. These innovations can increase the 
life expectancy of a specific patient population, thus also extending the period a patient 
requires medical care. Moreover, these innovations enable cure and care for patients 
with certain diseases that were untreatable in the past. Therefore, a lot of diseases 
that were acute in the past have become chronic. Often, these innovations are more 
expensive or lead to a higher volume of treatments compared to current practice. On 
the other hand, an innovation can also reduce the costs of care, and can be effective in 
reducing mortality and increasing quality of life for the patient. In fact, the majority of 
medical innovations are both, more effective but also more expensive as compared to 
current practice [6]. Therefore, determining whether or not an innovation’s added value 
is worth the extra costs is often not an easy task. As the number of health care innovations 
has increased dramatically while at the same time health care budgets are getting 
more and more restricted, the use of cost-effectiveness criteria in assessing medical 
innovations has increased considerably over the past decade [7, 8]. Cost-effectiveness 
analysis (CEA) has become a key method in several European countries as well as in 
Canada and Australia to help decision makers allocate resources in health care [9]. For 
example in the UK, the National Institute for Health and Clinical Excellence (NICE) uses 
cost-effectiveness, expressed as cost per quality adjusted life year gained, as a criterion 
for coverage recommendations to the National Health Service [10]. Also other European 
countries, including France, Germany, and Sweden, operate national health technology 
assessment (HTA) systems comparable to NICE to inform reimbursement and pricing 
decisions, and in more decentralized countries, such as Italy, regional authorities are 
increasingly adopting HTA [11]. An exception to this trend is the US, where the Patient 
Protection Affordability and Care Act has banned the use of cost-effectiveness analysis 
as a means to determine coverage or reimbursement of health care interventions [12]. 
In the Netherlands, the Dutch Health Insurance Board (CvZ) uses the cost-effectiveness 
criterion in their advice to the minister about the inclusion of (expensive) intramural 
and orphan pharmaceuticals in the benefit package. The fact that cost-effectiveness is 
becoming more and more important as a criterion for financing a medical innovation in 
the Netherlands is perhaps best illustrated by plans of the Dutch Labour Party (PVDA) 
and People’s Party for Freedom and Democracy (VVD) to legally establish that medical 
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innovations should be cost-effective [13]. In this light, it is imperative that outcomes 
generated by CEAs are accurate and that transparency exists about the occurrence and 
possible implications of any flaws or key assumptions in its methodology.
Cost-effectiveness analysis methodology
To assess the role of time in CEAs, this thesis reflects on a number of aspects unaccounted 
for in the traditional CEA model. In a standard CEA, differential costs and effects are 
calculated as the difference in average costs and effects between the alternative options. 
These differential costs and effects are combined into an incremental cost-effectiveness 
ratio (ICER), which represents the ratio of differential costs to differential effects:  
Here, ∆C and ∆E represent the differential costs and effects between the innovation and 
the technology to be substituted. The lower the ICER, the more the innovation moves 
towards being cost-effective when compared to care as usual. Introducing a threshold 
parameter completes the cost-effectiveness decision rule. In this thesis the focus will be 
on assumptions that are made when calculating the cost-effectiveness of an innovation. 
These assumptions are made on the level of the CEA model itself. Hence, this thesis 
will concentrate on the underlying principles that govern the calculation of an ICER 
from a set of variables and on one of the assumptions in particular, namely that cost-
effectiveness outcomes are constant over time. This assumption can have important 
implications for the validity of cost-effectiveness results. 
Assumptions underlying cost-effectiveness analysis
The CEA model stems from microeconomic theory which makes certain assumptions 
about technology. An important assumption is that technologies are convex [14], 
meaning that when one has two ways to produce y units of output, then the weighted 
average of these production processes will produce at least y units of output. For 
technologies where the production process can be scaled up and down easily, convexity 
is a natural assumption. The convexity assumption holds for a long run equilibrium but 
not necessarily for the short run. In the context of CEA, assuming convexity implies that 
production factors in health care technologies are infinitely divisible and are operating 
at constant returns to scale [15, 16]. Furthermore, a set of convex technologies imply 
that production factors for these technologies are always operating at full capacity, i.e., 
∆C CNEW - COLD
∆E  ENEW - EOLD
ICER = =
     11
1
there are no inefficiencies after technological substitution. Hence, in the calculation 
of the ICER it is assumed that all production factors for the old technology are freed 
up and can be used to finance the new technology, that all potential efficiency gains 
are realized immediately, and that no excess capacity for the new technology exists. 
Another important implication of how CEAs are executed is that learning inefficiencies 
associated with the technological substitution cannot be identified. This is a result of 
the fact that in the standard CEA method costs and effects are averaged over time and 
consequently assumed to behave constant. Differences in costs and effects between 
the old and the new technology can indeed, given certain assumptions, be expected 
to approximate a steady state, meaning that efficiency gains accumulate at a constant 
rate. Therefore, standard CEA considers costs and effects, and hence the resulting cost-
effectiveness outcome, as unchanging quantities which are constant over time. 
Discrepancies between short run and long run cost-effectiveness outcomes
In the short run, a steady state will rarely be reached. For example, the existence of 
fixed factors of production for the old technology leads to indivisibilities of production 
factors and diseconomies of scale and scope, subsequently resulting in non-convexities 
during this time frame [17, 18]. Furthermore, an innovation that is implemented 
gradually will not operate at full capacity in the short run, leading to diseconomies 
of scale and reduced effectiveness during this prolonged implementation period. 
Moreover, evidence suggests that learning effects are very relevant for medical devices, 
in particular surgical interventions, and frequently cause suboptimal performance in 
the short run [19]. Taken together, there is reason to believe that discrepancies exist 
between short run and long run cost-effectiveness outcomes which are not taken 
into account in the current CEA model. As in a real world context where the market 
for health care technologies is very turbulent, some technologies may never reach a 
steady state during their economic lifetime, and decision makers increasingly display a 
predominantly myopic focus, short run outcomes of CEAs will become more and more 
important. 
Objectives and outline of the thesis
The main objective of this thesis is to obtain more insight into the role of time in cost-
effectiveness analysis in health care. More specifically, this project had the following 
research aims: (1) to identify and discuss the most important factors responsible for 
short run deviations from cost-effectiveness outcomes, (2) to assess the possible 
consequences of these deviations by developing mathematical models to quantify 
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potential short run inefficiencies, (3) to explore the possibilities for proactive policies to 
minimize the impact of short run inefficiencies, and (4) to explore the optimal timing of 
adoption (from a local perspective) as well as the additional challenges that arise when 
evaluating an innovation in a pre-adoption stage.
Chapter 2 of this thesis will give an introduction into the discrepancy between short 
run and long run cost-effectiveness, and highlights the potential consequences of short 
run inefficiencies. In this chapter a case is made to explicitly take into account time 
in economic evaluations in health care. Chapters 3, 4, and 5 describe deterministic 
mathematical modeling studies to quantify short run inefficiencies. In chapter 3 a model 
is presented to quantify efficiency losses due to fixed factors of production. Chapter 4 
extends this approach by introducing a model that is able to calculate efficiency losses 
due to a gradual implementation process. Delayed adoption of an innovation can result 
in a co-existence of the old and new technology, an important source for short run 
inefficiencies. The influence of learning on short run inefficiencies is modeled in chapter 
5. In chapter 6 the consequences of short run inefficiencies are discussed in light of 
policy makers’ desire to receive cost-effectiveness outcomes on short notice. Chapter 7 
presents a mathematical model that enables the decision maker to answer the question 
‘when’ to adopt a medical innovation as well as the standard question ‘whether’ to 
adopt. In chapter 8 the early economic evaluation of a point-of-care chip for heart 
failure patients is discussed. This chapter explains the additional challenges that arise 
when evaluating a medical technology in a pre-development stage and presents a step 
wise approach to deal with these challenges, which for example includes the question 
what the potential headroom is for this particular technology. A general discussion of 
the studies presented in this thesis as well as a future perspective on the role of time in 
cost-effectiveness analysis is given in chapter 9.
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Abstract
Cost-effectiveness analysis as a means to evaluate medical innovations has become 
well accepted in the UK and several other Western countries. An important assumption 
underlying this method is that costs and effects are constant over time. In reality 
however, and especially during the short run, variations in costs and effects are likely 
to occur. These variations can lead to considerable deviations from the outcome of a 
conventional economic evaluation, which in turn may lead to serious implementation 
problems at a local level. Explicitly taking time into account in economic evaluations in 
health care may enhance its usability for both societal and local decision making, and 
may ultimately smoothen the adoption of new and basically cost-effective health care 
technologies. 
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Introduction
Cost-effectiveness analysis (CEA) as part of the evaluation of medical innovations has 
become well accepted and widely applied in several European countries. For example 
in the UK, the National Institute of Clinical Excellence (NICE) uses cost-effectiveness 
outcome, expressed as cost per quality adjusted life year gained, as a criterion for 
coverage recommendations to the National Health Service. In the Netherlands the 
Dutch Health Insurance Board (CVZ) uses the cost-effectiveness criterion in their advice 
to the minister on adding new technologies to the benefit package. In line with this 
development, research into CEA methodology has played a major role in the field of 
health economics in the past decades, focusing on a wide range of issues, like quality 
of life measurement and value of information research. Most of this research has been 
directly or indirectly aimed at improving the validity of cost-effectiveness outcomes. 
This large attention for economic evaluation in health care has brought us a method, 
the cost-effectiveness analysis, that is relatively well researched and provides a 
generally trusted estimate of the cost-effectiveness of a medical innovation. However, 
cost-effectiveness analysis is based on several assumptions. One important assumption 
is that costs and effects are constant over time (i.e. the rates at which costs are incurred 
and health outcomes are obtained will not vary during the lifetimes of the competing 
technologies). In reality however, and especially during the short run, variations in 
costs and effects might occur, for example due to learning effects and suboptimal 
occupancy rates of factors of production. Here we will show that in the short run, cost-
effectiveness may deviate considerably from the outcome of a conventional economic 
evaluation, and we will discuss the implications of such deviations. Building on these 
observations we will argue that taking time into account in economic evaluations will 
1) make societal cost-effectiveness outcomes more realistic, and 2) could mean a step 
forward in bridging the gap between societal and local decision making, hereby making 
cost-effectiveness outcomes more usable for all kinds of decision makers.
 
The role of time in cost-effectiveness analysis
Standard CEA is conducted from a societal perspective and includes a cost and benefit 
assessment for society in general. In practice, standard CEA starts by collecting all the 
relevant costs and effects for the health care technologies over a relevant time period 
and subsequently averages these total cost and effects over this period. Next, differential 
costs and effects are calculated as the difference in average costs and effects between 
the alternative technologies. These differential costs and effects are combined into an 
incremental cost-effectiveness ratio (ICER), or an incremental net monetary benefit 
(INMB). The ICER represents the ratio of differential costs to differential effects, and 
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the INMB is acquired by multiplying the cost-effectiveness threshold by the differential 
effects and subsequently subtracting the differential costs [1]. In utilizing the ICER or 
the INMB, differences in costs and effects between alternative medical innovations are 
considered to be constant over these innovations’ respective lifetimes. This means that, 
following implementation of an innovation, possible efficiency gains are assumed to 
accumulate at a constant rate, which is found in the preceding trial or modeling study. 
Thus, average costs and effects found in the trial period are assumed to be representative 
for the average costs and effects over the technology’s lifetime. Therefore, standard CEA 
inherently focuses on the long run consequences of adopting a technology. In the long 
run, the technology’s costs and effects can indeed be expected to reach or approximate 
a steady state, so from a long run perspective the modus operandi from standard CEA 
seems very justifiable. However, in reality, a technological switch will usually give rise to 
a phase where the average costs and effects (and consequently the cost-effectiveness) 
vary and have not reached a steady state yet. Therefore, although using constant ICERs 
and INMBs may be convenient, the assumption of constant marginal cost-effectiveness 
outcomes is an idealization and is not very realistic as it neglects the short run where 
the old and new technology often co-exist. However, the question is how much of 
a problem this is in practice: To what extent does marginal cost-effectiveness of the 
technologies that are being compared vary over time, and how well does the presumed 
steady state situation approximate the actual time-dependent path?
Short run versus long run cost-effectiveness
As mentioned before, the CEA framework considers costs, effects and hence cost-
effectiveness outcomes as unchanging quantities in some steady state. However, this 
steady state is only achieved when all of the shadows of the previous technology have 
disappeared, in other words, when 1) the new technology is fully functional, 2) staff has 
mastered the new technology, 3) a more or less constant occupancy rate for the new 
technology has been achieved, 4) all costs for the old technology have dissipated, and 5) 
there is no spillover of effects from the old technology into the new situation anymore. 
As stated earlier, in the short run time period, these conditions are not met. During 
this time period costs may be induced for both technologies, and clinical effectiveness 
for the new technology is likely not to be optimal yet [2]. This may very well result in a 
negative deviation from the long run cost-effectiveness outcome during the short run. 
This is illustrated in figure 1: time dependent paths are depicted for the average costs 
and average effects of both health technologies and for the resulting ICER. Here it can 
be seen that the ICER is indeed less favorable in the short run as compared to the long 
run steady state.
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A multitude of reasons could contribute to these deviations, such as learning effects, rigid 
labor contracts, effects from the old technology spilling over into the new technology’s 
period, fixed production factors for the old technology that may become a deadweight, 
a temporary coexistence of the two technologies leading to diseconomies of scale (for 
instance, due to a gradual implementation of the new technology combined with a 
gradual dismantling of the old technology’s infrastructure), budget restrictions within 
the relevant planning period, etcetera [3-5]. Hence, it seems that short run deviations 
from the long run oriented cost-effectiveness model could indeed be substantial. This 
will especially be the case if the short run is a substantial part of a technology’s economic 
lifetime. Economic theory generally states that the short run becomes irrelevant if the 
long run is sufficiently long. However, given the turbulence with respect to technological 
change that can be seen in certain health care areas, we expect that the short run 
might be relevant for a relatively large amount of innovations. Of course, the magnitude 
and importance of these deviations in a particular CEA depend on the specifics of the 
technologies and settings under consideration. Here it helps that the nature and impact 
of these factors might to some extent be predictable and systematic. For example, short 
run cost-effectiveness outcomes for surgical procedures that require a lot of time to 
master will display a large deviation from long run outcomes, due to a longer surgery 
duration and a higher number of complications in the short run. On the other hand, 
a substitution of one drug for another will probably bring about relatively small short 
run deviations, as it seems hard to see which of the abovementioned reasons could 
contribute substantially, except possibly learning effects due to initial dosing difficulties. 
A good example to illustrate the occurrence of short run deviations when introducing 
a new technology is the conversion from analog screen film mammography (SFM) to 
digital mammography (FFDM) in the Dutch population based breast cancer screening 
program. Here a preliminary study was performed to assess the attainability of 
Figure 1 Average costs (panel a) and effects (panel b) for the new and the old technology over time, 
and the resulting ICER (panel c) as a function of time
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converting to a filmless digital screening program [6]. In this study, annual savings 
associated with abandoning the old SFM technology were estimated at €13,270,000 
and annual extra costs for adopting the new FFDM technology were estimated at 
€12,285,000. Hence, the Dutch government concluded that substituting SFM for 
FFDM would yield net annual savings of €985,000. Although estimations suggested 
that the transition phase would last three years, the anticipated net annual savings 
were assumed to be realized immediately. This assumption is consistently applied in 
standard CEA, even in projects where a significant change in infrastructure necessitates 
a long phase-in process, implying coexistence of two technologies potentially leading 
to diseconomies of scale. As several exogenous factors (e.g. European tender rules) 
delayed the adoption and stretched the transition process, potentially obsolete SFM 
equipment did not immediately become a deadweight. However, due to the extension 
of the transition process, short run losses associated with coexistence of SFM and FFDM 
are likely to have caused serious inefficiencies during the transition phase. 
In order to actually develop a time-dependent cost-effectiveness  model and quantify 
short run deviations from the steady state, the approach that is outlined here will have 
to be further specified and quantified through mathematical modeling. In a tentative 
paper [2], a three step model has been developed which operates by firstly determining 
the initial efficiency losses inflicted by deadweight fixed production factors for the 
old technology, then secondly adjusting for refilling and writing off freed capacity 
over time, and thirdly calculating the length of the short run time frame in which the 
efficiency losses exist. This model was applied to two cases: substituting in-hospital 
dialysis for continuous ambulatory peritoneal dialysis, and digitizing a radiography 
department. In the dialysis case it was shown that the short run INMB decreased by 
8.6% compared to the steady state INMB. The radiography case illustrated that short 
run deviations can indeed become very substantial, as incorporating these deviations 
changed the cost-effectiveness outcome from favorable to unfavorable [2]. The model 
mentioned above could be extended further by allowing for delayed adoption of the 
new technology and hereby making it possible to calculate short run efficiency losses 
for a technology that is implemented gradually. Such a model would operate by taking 
into account the rate of implementation of the new technology and depreciation of 
capital of the old technology in order to integrate the INB functions for both the old as 
well as the new technology into one time-dependent INB function. One could also think 
of incorporating learning effects into a model. One could reason that learning leads 
to an overestimation of costs and an underestimation of effectiveness during the trial 
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period and that these deviations from the steady state cost-effectiveness outcomes can 
be modeled as a function of clinical trial length. Although time has not been much of 
an issue in economic evaluation in health care up to now we consider it possible and 
important to develop models that are able to incorporate, and thereby make visible, 
short run deviations from the steady state.
Consequences for local decision making
Besides making societal cost-effectiveness analysis more valid, another reason 
why incorporating time in cost-effectiveness analysis could be relevant, is to bridge 
the gap between societal and local decision making. As mentioned before, cost-
effectiveness analysis is a method to assist decision making on the subject of adding 
health technologies to the benefit package. In doing so, cost-effectiveness analysis 
adheres to a societal perspective. However, the consequences of decision making 
at the societal level are felt at different levels in the health care system. The societal 
decision to add a new technology to the benefit package might put pressure on local 
health care providers, such as medical doctors, hospital managers, prescribing advisors, 
hospital pharmacists and directors in public health, to supply the new technology 
instantaneously. However, if short run consequences on costs and effects are not 
communicated to such providers, unanticipated losses might lead to second thoughts 
about implementation of an in essence cost-effective innovation, even potentially 
denying patients their access to more efficient health care. Failing to acknowledge 
short run aspects in cost-effectiveness analysis may raise doubts about the validity of its 
outcome, and may also lead to disappointment with economic evaluations in general, 
as evidence on cost-effectiveness is of less interest to decision makers who are focusing 
on the short run [7]. Indeed, a prominent argument of health care decision makers to 
resist the use of CEA is the disconnect between formal CEAs, with a societal perspective 
and a long run orientation, and the short term perspective on decisions within health 
care organizations [7-9]. Due to ever increasing budget pressures, local decision 
makers will be forced to focus on short run results. This is confirmed by studies such 
as Drummond et al., which revealed that in the UK, 30% of local decision makers state 
that being unable to take a long-run view, due to the importance of their annual budget, 
is an important obstacle in the use of economic evaluations [10-12]. Also, a recent 
small study aimed to determine if financial managers in the Dutch health care system 
focus on short run or long run efficiency showed similar results (Radboud University 
Nijmegen Medical Centre, working paper, van de Wetering et al). Therefore, it seems 
that the real problem articulated by local decision makers is that, given their short run 
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orientation, CEAs are seen as insufficiently valid for their organization. Incorporating 
short run deviations in the cost-effectiveness model might therefore improve trust in 
the validity and consequently the usability of the ICER.
Conclusions
Taking into account the short run by explicitly modeling time in cost-effectiveness 
analysis could lead to more accurate and realistic estimates of cost-effectiveness of 
medical innovations. This would at least entail making a distinction between the short 
run and the long run. When short run deviations from standard CEA occur, they are 
often unanticipated and could very well slow down the adoption of new and basically 
cost-effective health care technologies. To enhance trust in CEA it is important to gain 
insight into the major factors potentially contributing to short run efficiency losses. All 
in all, having a framework for cost-effectiveness analysis that incorporates time and 
quantifies short run deviations could help to prevent unpleasant surprises and provide 
the implementation decision process with more valid cost-effectiveness data. In the 
Netherlands the importance of potential short run deviations in cost-effectiveness 
analysis has been recognized and is in fact added to the new version of the Dutch 
manual for costing research in health care [13].
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Abstract
Important assumptions that underlie cost-effectiveness analysis (CEA) are that 
production technologies are convex and that production processes always perform at 
constant returns to scale. However, in the short run these assumptions are likely to 
be violated. Therefore, CEAs might overestimate cost-effectiveness in the short run. To 
come up with a more precise cost-effectiveness outcome we present a model that is 
able to correct the long run incremental net benefit (INB) for short run inefficiencies. 
This provides decision makers with a more realistic view of the expected efficiency 
gains. This model starts by determining the initial efficiency losses inflicted by inflexible 
resources. Then the model is made dynamic in order to adjust the efficiency losses 
by allowing for refilling and writing off freed capacity. Finally the model calculates the 
length of the short run time frame in which such efficiency losses exist, and a correction 
term with which the usual long term INB should be adjusted to account for short run 
inefficiencies. The model is applied to two cases: Dialysis and digitizing a radiography 
department. The dialysis case shows moderate short run efficiency losses while in the 
radiography case short run efficiency losses are sufficiently large to cause a switch in 
cost-effectiveness from favorable to inefficient in the short run.
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Introduction
In most western countries consensus exists on the fact that the decision on 
implementation of new technologies should be influenced by cost-effectiveness 
information. The evaluation of new technologies and their implementation is generally 
discussed in the context of (Extra-) Welfare Economics where welfare losses are 
considered sunk in the short run [1, 2]. In fact this is completely in line with micro 
economic theory [3]. Cost-effectiveness analyses (CEAs) assume convex technologies 
and a convex production set, so that all production factors must be perfectly divisible, and 
production of the old technology can be scaled down to any lower level without getting 
inefficiencies due to unused excess capacity. This implicates that the production factors 
of the inefficient technology can be used entirely for the more efficient technology [4]. 
In the long run, where all factors of production are considered variable, this is correct 
but taking into account the environment in which the decision-maker operates this long 
run perspective will often not be applicable [5, 6]. In a competitive market, a firms’ 
inability to make a shift from an old (common practice) technology to a new, more 
efficient technology will result in exit or major restructurings. In a non-market industry, 
like healthcare, similar rigidities may persist without exit or corrections, unless managers 
identify their sources and apply appropriate remedies. Consequently, the assumptions 
that are generally made in CEAs are often not applicable in the real world situation 
[7]. Indivisibilities of production factors, rigid labor contracts and budget pressures 
are all factors that make it impossible to assume away inefficiencies in the short run. 
When these inefficiencies present themselves, they are often unanticipated and could 
very well slow down adoption of the new and cost-effective technology [8-10]. Also, 
Lord et al. recognized that fixed costs can introduce vertical discontinuities to the cost-
effectiveness frontier and that the curvature of the expansion path in cost-effectiveness 
space depends on marginal cost behavior. They also stated that in the short run this 
vertical shift will be subject to a time delay, and that the additional costs of this delay 
should be taken into account before deciding to introduce a new technology [11].
We therefore argue that, under certain conditions, the short run time frame becomes 
important. Where in the short run, due to fixed factors of production, the cost function 
has two components: fixed and variable cost; in the long run all costs are considered 
variable. Consequently the long run state of production is a state of replication 
of production processes, i.e. of constant returns to scale. In the short run however, 
reconfiguration of production processes plays a more important role than replication. 
So, we define the short run as the time from implementation of the new technology 
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up to the moment at which the old technology once again is operating at constant 
returns to scale, as is assumed in CEA. In the short run, not all freed resources of the old 
technology can immediately be shifted to the new technology, in contrast to the long run 
where it is assumed that all production factors will make a frictionless change from the 
old to the new technology. Hence, considering a local and a short run perspective, there 
is reason to believe that CEAs of certain technologies overestimate potential benefits 
of the new technology [9]. As the above considerations already suggest, the short run 
inefficiencies that we investigate in this study originate from the cost structure of the old 
technology, here we do not look at inefficiencies that are related to the cost structure 
of the new technology or to the effect side of the model. The purpose of this paper is 
to present a model that is able to correct the long run cost-effectiveness outcome for 
short run inefficiencies and thereby present decision makers with a more realistic view 
of the expected efficiency gain; consequently providing an incentive that guides local 
decision makers in developing tailored implementation strategies for new technologies. 
Furthermore the model will be applied to two cases: the switch from an in-hospital to a 
home-based dialysis modality and digitizing a hospital radiography department.
This paper is structured as follows. In sections 2 and 3 a model is constructed that 
is able to determine and correct for short run inefficiencies in CEAs. In section 2 we 
provide a quantification of the initial efficiency losses inflicted by inflexible resources. 
In section 3 the model is made dynamic by introducing a time variable, and allowing for 
refilling and writing off of freed capacity. Here we also calculate the length of the short 
run time frame in which excess capacity exists, as well as a correction term with which 
the long term incremental net benefit (INB) should be adjusted to account for short run 
inefficiencies. In section 4 we apply the model to the cases of dialysis and radiography.
Inefficiencies in the short run
We can represent the cost-effectiveness of old versus new technology using the 
incremental net benefit (INB). Here we write ∆C to denote the cost difference and ∆E for 
the effectiveness gain (or loss) when comparing the new versus the old technology. Now 
let K be the willingness to pay (WTP) threshold for a marginal effect, so that the decision 
rule for determining that a new technology is more cost-effective reads       ≤ K. 
This decision rule can be rewritten as ∆C ≤ K ∙ ∆E, or as K ∙ ∆E - ∆C ≥ 0. The left-hand side 
gives us the incremental net benefit:
    INB(K) = K ∙ ∆E - ∆C    (1) 
∆C 
 ∆E 
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Note, however, that ∆C = Cnew - Cold, so the above formula for the INB assumes that after 
a switch no costs for the old technology will have to be incurred anymore. In the long 
run this will indeed be the case, but in the short run this need not to hold. Let’s define 
α as the percentage of the old technology’s costs that cannot be freed or transferred to 
the new technology in the short run, in case the old technology is not in use anymore. 
Now the INB in the short run becomes:
   INB(K)short run = K ∙ ∆Eshort run - ∆Cshort run 
   = K ∙ ∆E short run - (Cnew - (1 - α) Cold)    (2)
We define β as the difference between the short run INB and the long run INB:
   β = INB(K)short run -  INB(K)long run
   
  = K ∙ ∆E short run - (Cnew - (1 - α) Cold) - (K ∙ ∆E long run - (Cnew - Cold)) (3)
As we have stated earlier, this model focuses on the input side of the health production 
function (i.e. costs) and assumes health effects to be constant over time. Therefore we 
assume that ∆Eshort run = ∆Elong run, so that (3) becomes:
   β = - (C new - (1 - α) Cold) + (Cnew - Cold)
    β = - Cold ∙ α    (4)
A dynamic model to calculate short run welfare losses
In the previous section the implicit assumptions were made that, following the shift 
from the old to the new technology, the capacity for the old technology would remain 
fully intact, and that the freed capacity for the old technology would never be refilled 
with new patients. We now relax these assumptions, and consider that new patients 
may apply in the short run for the old technology after capacity has been freed, and that 
total capacity for the old technology may diminish by writing off and not reinvesting 
in the old technology. Let’s assume the investment in the old technology is financed 
by a loan which payments (including interest) follow the amortization pattern of the 
technology. Furthermore, it is assumed that this pattern is proportional to the process 
with which the capacity of the old technology diminishes. To model this we first 
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introduce a time variable t and denote the moment when the shift from the old to 
the new technology is made by t = 0. We then denote μ(t) as the total capacity of the 
old technology at time t (which we assume to be non-negative and non-increasing), 
and similarly denote ν(t) as the use of the old technology at time t (which is assumed 
to be non-negative). Here it is assumed that ν and μ use the same scaling; that is, ν is 
measured in the same units as μ (be it in terms of numbers of treated patients, or in 
numbers of treatments given per unit of time, etc.). Hence ν = μ means that all capacity 
is used, and the fraction     denotes the occupancy factor of the old technology. Since 
μ represents capacity, we also assume that ν(t) ≤ μ(t) will always hold. We can now 
reformulate the definition of α as the percentage of the old technology’s costs that 
cannot be transferred to the new technology, in case the capacity of the old technology 
remains fully intact: µ(t) = µ(0) for all t, and in case all of this capacity remains unused: 
ν(t) = 0 for all t.
In order to generalize the α variable for the new situation where the old technology’s 
capacity may be refilled and diminished, we now define α’(t) as the percentage of the 
old technology’s total costs that cannot be reallocated to the new technology after 
correcting for capacity refill and diminished capacity at time t. Then, for the formula of 
α’(t) we can write 
ν 
μ 
μ(t) - ν(t)       μ(t)
     μ(t)          μ(0) 
α’(t) =   ∙  ∙ α (5)
This formula will now be explained. The main idea is that the inefficiency loss of shifting 
to a new technology is proportional to the amount of excess capacity for the old 
technology; inefficiency losses only arise because of capacity that is still there but that is 
not being used, and not because of capacity that is being used or that no longer exists. 
In the formula two terms are entered multiplicatively; the first term                adjusts for 
any refilling of the (decreased) capacity while the second term          adjusts for the decreased 
capacity since time t = 0. If α in the previous section represented the percentage of the 
old technology’s costs that cannot be freed in the situation where the capacity of the 
old technology remains intact and this capacity is never refilled, then it would seem 
natural that the quantity         ∙ α would give the percentage of the old technology’s costs 
(for the capacity at t = 0) that cannot be freed in a situation where the capacity of the 
old technology is never refilled, but where this capacity has diminished by a factor       .
Given this last interpretation of the term          ∙ α, we can now similarly adjust for refilling 
by entering the term        since of the diminished capacity µ(t) only the fraction
 remains unused. From the above we can see that efficiency losses are mitigated 
μ(t) - ν(t)  
μ(0)    
μ(t)  
μ(0)    
μ(t)  
μ(0)    
μ(t)  
μ(0)    
μ(t)  
     μ(t)    
μ(t) - ν(t)  
     μ(t)    
μ(t) - ν(t)  
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by decreased capacity and by increased use: the smaller μ is, the smaller α’ will be, and 
the larger ν is (provided that ν ≤ µ), the smaller α’ will be. 
Equation (5) can be rewritten to obtain the simpler formula:
From the above formula we see that the inefficiency loss at time t is proportional to the 
term                which represents the existent excess capacity at time t as a fraction of 
the original capacity at t= 0. Note that under the assumptions of the previous section 
(µ(t) = µ(0) and ν(t) = 0), we return to the basic α’(t) = α, so indeed we see that α’ is a 
generalization of α.
Extending our model by taking into account the usage and amortization of freed 
capacity, β can similarly be generalized to a variable β’(t), which becomes:
    β’(t)= -Cold∙ α’(t)= -Cold∙                 ∙α  (7)
The above formula is time-dependent, and as a final step we now introduce an aggregate 
measure for the total welfare losses due to excess capacity during the short run. This 
short run will start at time 0 and end at time τ, the point in time where excess capacity 
no longer exists. We take β’, the average of β’ over the time interval from 0 to τ for such 
an aggregate measure:
   β’ =    ∙     β’(t)dt  
Thus, there is excess capacity for τ periods, and during these τ periods the welfare 
losses will on average amount to β̅’ per period. We know that β’(t)=-Cold∙ α’(t), and if we 
similarly define α̅’ as the average of the function α’(t) over the time interval from 0 to τ, 
α̅’=     ∙     α’(t)dt, then we see that β̅’ is proportional to α̅’: 
μ(0)    
μ(t)  
μ(t) - ν(t)     
     μ(0)          
α’(t) =  ∙ α (6)
     μ(0)    
μ(t) - ν(t)  
     μ(0)    
μ(t) - ν(t)  
τ
1 ∫
0
τ
τ
1 ∫
0
τ
β̅’ =    ∙     β’(t)dt =    ∙     - Cold ∙ α’(t)dt = - Cold ∙           α’(t)dt = - Cold ∙ α̅’  (8)τ
1 ∫
0
τ
τ
1
0
∫ τ τ1 ∫0
τ
Working out a linear model
In the above subsection we have modeled how efficiency losses due to excess capacity 
are influenced by changes in capacity and use of the old technology. Thus far we have 
treated the capacity and usage variables in a completely general form. However, in 
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order to be able to apply the model to actual cases we need to make it more specific. 
Therefore we continue by making assumptions about how the usage and the capacity 
variables of the old technology change over time. The appropriateness of specific 
assumptions about how these variables change with time may depend on the specifics 
of the application under consideration, for simplicity we work out a linear case here.
First, we assume that, from time 0, amortization leads to a linear decrease of the 
capacity of the old technology and define 
    μ(t) = μ0 + γt     (9)
where μ0 > 0 denotes the total capacity at t = 0 and the factor γ denotes the rate at 
which capacity is written off. It is assumed that γ < 0 so that the total capacity indeed 
decreases over time. We similarly assume that the use of the old technology will change 
linearly after time t=0:
    ν(t) = ν0 + εt     (10)
where ν0 (with 0 ≤ ν0 < µ0 ) is a factor denoting the use of the old technology at t = 0, and 
-∞ < ε < ∞ denotes the demand change per period. Note that ν may either decrease, 
remain constant or increase over time. The value for ν0 will in turn depend on two factors: 
1. The number of patients that previously used the old technology and who do not 
make the switch to the new technology. 
2.  The number of patients that are on a waiting list. We assume that freed capacity 
is immediately refilled with patients that are readily available to make use of the 
old technology.
The demand change parameter ε depends on the number of newly arriving patients 
per period for the old technology, and on the number of patients that exit per time 
unit1. Thus as time progresses, µ(t) decreases and ν(t) may increase, remain constant or 
decrease. We will see that α’ will eventually always become zero, indicating that there 
are no longer any efficiency losses due to unused available capacity. Now let’s define t = 
τ as the time point where all excess capacity has disappeared. It is at this point in time 
τ, where the old technology is once again performing at constant returns to scale, that 
we can say that we have left the short run and have entered the long run time frame. 
1. The interpretations of the model parameters seem to suggest a situation of continuous or repeated 
treatments, such as in case of chronic illnesses. However, the model could also represent a situation 
of  single treatments.
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At time τ there is no more excess capacity, so it must be true that ν(τ) = µ(τ). We will 
now distinguish two cases with respect to the situation at time τ: the case where ν(τ) = 
µ(τ) > 0, and the case where ν(τ) = µ(τ) = 0. The two cases are graphically represented in 
figures 1 and 2 below and analyzed separately.
In the first case, where ν(τ) = µ(τ) > 0, we must have that ν is either increasing, constant, 
or decreasing sufficiently slowly, so that ν crosses µ before µ becomes 0 (see figure 1). 
To calculate τ in this case we solve for ν(τ) = µ(τ), hence
μ0+ γt = ν0+ εt
which gives
μ0 - ν0 = (ε - γ) t
so that 
        τ =       (11)
Having derived the time point τ where the old technology no longer has excess 
capacity, we proceed by determining α’(t) and the average α̅’ of the function α’ over 
the time interval from 0 to τ. We know that
Integrating this over the time interval from 0 to τ, we get 
 =     ∙      (μ0 - ν0) τ -      (ε-γ) τ
2   =       (μ0 - ν0 ) -     (ε - γ) τ  =
  (μ0 - ν0) -      (ε-γ) τ               = α  
ε - γ
μ0 - ν0
μ(t) - ν(t)        μ0 + γt - ν0 - εt         μ0 - ν0 - (ε - γ)t
     μ(0)                   μ0           μ0          
α’(t) =  ∙  α =  ∙  α =  ∙  α
[α̅’ =     ∙     α’(t)dt =     ∙      α ∙          dt =     ∙         (μ0 - ν0)t -      (ε - γ)t2 
  
τ
1 ∫
0
τ
τ
1 ∫
0
τ μ0 - ν0 - (ε - γ)t           α         
                    μ0                  μ0                                   τ
1
2
1  ]0
τ
τ
1
μ0
α [ 2
1 ] μ0
α
2
1[ ]
μ0
α [ 2
1 ]ε - γ
μ0 - ν0
  2μ0
μ0 - ν0
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In the last step we have used the equation that was derived for τ.
Finally, for the average of β’, from (8) and (12) we get: 
  β̅’ = - Cold ∙ α̅’ = -            ∙ α ∙ Cold    (13)
It may seem surprising that in the above formulas for α̅’ and β̅’ we do not see the 
parameters γ and ε appear, and that the average welfare losses only depend on µ0 and 
ν0. Note however, that the length of the short run τ does depend on γ and ε. Hence, 
while in the linear case the average short run welfare losses per period are independent 
of how µ and ν change over time, the change parameters do help determine the number 
of periods in which these average welfare losses per period will be incurred.                                                 
Figure 1 Graphical representation of τ when ν(τ) = µ(τ) > 0
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In the second case, where ν(τ) = µ(τ) = 0, the function ν must either be constant with 
ν0 = 0, or it will have ν0 > 0 and be decreasing sufficiently fast so that µ is still positive 
when ν becomes 0 (see figure 2). To calculate τ in this case we solve for μ(τ)= μ0 + γτ = 
0, which gives  
           τ =      (14)
We then proceed to determine α’(t). However, α’(t) will now be a two-part function. 
This function shows a kink at the time point when the function ν becomes 0, as can be 
seen in figure 2, we denote this point in time by σ.2 Before time σ, α’(t) is the same as in 
the first case above. However, between times σ and τ the function ν(t) will be equal to 
0, so that α’(t) equals µ(t)/µ(0). Thus,
       ∙ α,  for 0 ≤ t < σ
  α’ (t) =
      ∙ α,  for σ ≤ t < τ
Then, for the average α̅’ of the function α’ over the time interval from 0 to τ, we need 
to calculate two integrals.
α̅’ =    ∙     α’ (t)dt =     ∙        α’ (t)dt +     α’ (t)dt  = ∙∙∙ =       -       ∙ α
And finally, for the average welfare loss during the short run, we get
β̅’ = α̅’ ∙ - Cold = -       -  ∙ α ∙ Cold      (15)  
       
-γ
μ0
2. From ν(σ) = ν0 + εσ = 0 we get that σ = ν0/-ε
            μ0
μ0 - ν0 - (ε - γ) t
            μ0
       μ0 + γt{
[τ1 ∫0
τ ∫
0
σ
τ
1 ∫
σ
τ ] [ 21 μ0ε
ν0γ
2
2 ]
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2
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Figure 2 Graphical representation of σ and τ when ν(τ) = µ(τ) = 0
Applying the generic model to different cases 
The end stage renal disease case
Patients suffering from end stage renal disease (ESRD) require renal replacement 
therapy (RRT). This can either be a kidney transplant or dialysis. The global average 
prevalence for dialysis is estimated at 215 patients per million. By the year 2010, it is 
expected that two million patients will use some form of dialysis worldwide [12]. When 
dialysis is considered, we distinguish in-hospital hemodialysis (IHD) and peritoneal 
dialysis (PD), a form of home dialysis. Several studies have shown superior cost-
effectiveness for PD compared to IHD [13, 14]. However, IHD is still by far the most 
widely used treatment modality in most western countries. Worldwide, at the end of 
2004, IHD was used to treat 89% of dialysis patients while 11% were treated by PD 
[12]. This apparent contradiction is often attributed to psychosocial or disease-related 
reasons like for example a clinical problem that forces the patient to choose an in-
hospital treatment. However, it seems unlikely that such reasons would entirely explain 
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the extremely unfavorable implementation of PD. An additional explanation might be 
a systematic overestimation in the outcomes of the cost-effectiveness analyses (CEAs) 
that compare in-hospital and home modalities. This overestimation could be related 
to the fact that cost effectiveness analyses (CEAs) fail to take into account short run 
inefficiencies, which make the transition to home modalities less attractive for local 
providers.
First we will look at the cost structures for both modalities, and we will derive α. 
Table 1 displays the normalized costs associated with IHD and continuous ambulatory 
PD (CAPD), the most common form of PD. These data are derived from the study of 
Baboolal et al. [15], which was performed in the UK. The nature of the costs, either 
fixed, variable or semi-variable is also displayed. Costs associated with equipment, 
training of patients and overheads are considered fixed, costs for consumables, like 
solutions, drugs and disposable equipment are variable. In microeconomic theory, staff 
is considered a flexible production factor, although this to a certain extent depends 
on the kind of labor contracts. Dialysis teams are specialized and these teams have 
essentially the same tasks for the different modalities. Therefore, in this case staff 
can be considered a flexible production factor when a transfer between modalities is 
concerned. However, it will be hard to deploy these teams in other departments of 
the hospital. So when a transfer to another type of department is concerned staff can 
be considered an inflexible production factor. In reality, depending on the duration of 
their labour contracts nephrology nurses may be retrained; however this will take time. 
During this period productive alternative employment is scarce with consequently very 
low (zero) opportunity costs. We therefore assume that dialysis teams that are deployed 
in other departments in the hospital will produce no output (assumed to be employed 
as trainees) in the short run.
* These costs are based on patients receiving three dialysis sessions per week in the hemodialysis 
modalities.
Table 1. Summary of normalized annual treatment costs for different dialysis modalities
IHD CAPD
Resource items Nature of costs Norm. Costs* Norm. Costs
Equipment + Overheads Fixed 0.232 0.022
Consumables Variable 0.379 0.734
Staff semi-variable 0.389 0.244
TOTAL 1 1
Absolute cost estimate (€) 38,951 (£35,023) 17,316 (£15,570)
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If we look at a switch from IHD to CAPD, we can distinguish a number of aspects:
1. Costs for patient training: these investment costs are negligible: €56 per patient.
2.  The abandoning of equipment + overheads in the hospital environment: 23.2% of 
total costs for IHD are not transferable to CAPD. This is because the two modalities 
use different dialysis machines. 
3.  Costs for staffing. Part of the staff can be transferred from IHD to CAPD. However, 
CAPD is less labor-intensive, and assuming equal salaries for IHD and CAPD staff, 
only      ∙ 100%=             ∙ 100% = 27.9%  of the IHD staff can be 
transferred to CAPD care. Consequently, 72.1% of personnel cannot be transferred 
which leads to an additional 0.389*72.1% = 28.0% of total costs for IHD which are 
not transferable to CAPD because of staffing issues.
In summary, 23.2 + 28.0 = 51.2% of total costs for IHD cannot be reallocated from IHD 
to CAPD in the short run, hence α = 0.512. From this we see that a substantial portion of 
costs cannot be reallocated from an in-hospital modality to a home modality in the short 
run. So it would appear that net monetary benefits in the short run are significantly 
smaller than in the long run.
Having derived α for a specific case, let’s consider a scenario where 20% of IHD patients 
shift to CAPD. We would now like to correct the CEA for inefficiencies present in the short 
run time frame. However, to do this we still need to fill in the other model parameters.
•	  Since patients with ESRD will not survive without RRT, there is virtually no waiting 
list.  And 20% of IHD patients shift to CAPD, so if we set μ0 = 1, we get ν0 = 0.8.
•	  In the past ten years the number of patients on dialysis has on average increased 
by 3.2% annually in the Netherlands. We assume this increase to be independent 
of the different modalities, so that ε = 0.032 annually. 
•	  We assume the average depreciation period for IHD equipment to be 10 years, 
hence γ = - 0.1. 
•	  For the effectiveness gain ∆E of switching from IHD to CAPD we take the value of 
0.05 QALYs, as found in a study by de Wit et al. who did an economic evaluation 
of ESRD treatment in the Netherlands [16]. 
Since the use of the old technology is increasing, we need to apply equation (11). 
The length of the short run time frame τ in years follows from 
τ =           , giving τ = 1.52 years. Then, calculating α̅’ yields α∙    = 0.051. We can now 
calculate the average efficiency loss during the short run: 
β̅’= - Cold ∙ α̅ = - €38,951 * 0.051 = - €1,987.
0.389∙38,951         15,151
0.244∙17,316           4,225
 ε-γ                     2μ0
μ0-ν0                            μ0-ν0
     39
3
To give the reader an idea of how big a number this is: assuming a WTP value of 30,000 €/
QALY we calculate INB(K)long run = €30,000 ∙ 0.05 - (€17,316-€38,951) = €23,135. So when 
20% of the patients switch from IHD to CAPD,                    ∙100% = 8.6% of the incremental 
net benefit in the long run cannot be achieved due to short run inefficiencies.
The digital versus analog radiography case
The radiology department in a hospital can be characterized as the central diagnostic 
department to which many patients are referred by other clinical departments within 
the hospital as well as general practitioners outside the hospital both for diagnostic as 
well as therapeutic processes. This case study focuses on projectional radiography: this 
modality is used to evaluate the heart, lungs and skeleton to check for pathology of the 
skeletal system (bone fractures) but is also useful for detecting some disease processes 
in soft tissue. A notable example is the very common chest X-ray, which can be used to 
identify lung diseases such as pneumonia, lung cancer or pulmonary edema, and the 
abdominal X-ray, which can detect intestinal obstruction, free air and free fluid. 
In 1999 a study was published comparing the costs and revenues of an analog and 
a digital radiographic system in an Italian hospital [17]. Both operating as well as 
investment costs were analyzed for chest and skeletal examinations. It was concluded 
that although investment costs were higher for digital radiography, operating costs were 
on average lower and the advice was given to invest in digital technology (see table 2). 
Expected costs per year for the analog system were €179,097. Fixed costs consisting 
of the development machine, the loading system and the cassettes and screen-plates 
were €35,934. The remaining costs were variable consisting of staffing (radiologists, 
auxiliary and technician), maintenance, electricity and film costs. This gives us 
α=                       = 0.2. Furthermore, the life years gained and QALYs generated by both systems 
were assumed to be identical. Main argument is that the largest motivator for healthcare 
facilities to adopt digital radiography is its potential to reduce costs associated with 
processing, managing and storing films [18]. Furthermore, no substantial evidence could 
be found in the literature on a significant difference in clinical effectiveness between 
conventional and digital radiography: most studies comparing digital with conventional 
radiography focus on cost minimization.
€23,135
€1,987
€179,097
   €35,934
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Table 2. Annual savings with digital radiography
Digital system Analog system Δ
System costs (assuming a 
depreciation period of 4 
years) 
€54,352 €35,934 €18,418
Film costs €24,552 €55,612 - €31,060
Staff €69,722 €69,722
Overheads €21,433 €17,829 €3,604
Annual savings €9,038
Now let us consider a switch from an analog to a digital radiography department. 
Because after implementation all patients will be treated using digital equipment, 
100% of the total capacity will be digitized, and therefore 0% of the capacity of the old 
technology will be occupied. This is only the case if all capacity for the old technology 
is replaced by the new technology instantaneously and there is no further demand for 
the old technology. This gives us ν0=0 and ε=0, and again we set μ0=1. Furthermore the 
average depreciation period for the existing analog equipment is 4 years, so γ = - 0.25.
In this case, the use of the old technology is fixed at zero. Calculating the length of the 
short run gives us τ = 4 years, which is in this case, not surprisingly, equal to the average 
depreciation period for the analog equipment. Determining the percentage of the costs 
for the analog system that cannot be reallocated to the digital system during the short 
run gives us α̅’ =      α = 0.1. We can subsequently derive the short run efficiency losses: 
β̅’ = -€179,097*0.1 = -€17,910. We now calculate the long run incremental net benefit; 
this gives: INB(K)long run = €30,000 ∙ 0 - (170,059 - €179,097) = €9,038. So from the decision 
rule associated with incremental net benefit in the long run (INB > 0) it follows that a 
switch from analog to digital radiography would be cost-effective in the long run, but 
also that this switch would fail to be cost-effective during the short run as 
INB(K)short run = INB(K)long run + β̅’= €9,038 - €17,910 = -€8,872 < 0.
Discussion 
We have observed that a shift of 20% of all patients from IHD to CAPD leads to a 
moderate potential efficiency loss. As CAPD is still dominating IHD as cost-effectiveness 
is concerned, this efficiency loss would be no reason to make policy changes on societal 
nor on local level. However, for other technology changes where cost-effectiveness is 
not so clear or where there is much debate about potential implementation in clinical 
practice it would certainly be relevant to calculate short run inefficiencies. This gives 
2
1
     41
3
policymakers on different levels 1) a more substantiated view of the expected efficiency 
gains and 2) can prove useful in developing tailored implementation strategies for 
innovative technologies. An example of such a strategy would be to apply a more 
gradual implementation path to the new technology adapted to account for time till 
reinvestment in the old technology.
This study indicates that for the other case, digitizing a radiography system, short run 
inefficiencies are much more important for the cost-effectiveness outcome, as it results 
in a switch from being cost-effective to not being cost-effective. A local decision maker’s 
incentive may dictate a different decision than would be dictated by the long run cost-
effectiveness outcome. In this particular case financial constraints in combination with 
ongoing financial obligations from past investment in the old technology may lead local 
decision makers to temporary stick with the old project, depending on their perceived 
balance between short run losses and long run gains. However, we acknowledge that 
cost-effectiveness outcomes are only part of the decision: connection to other ICT 
systems, faster data transfer to other caregivers and imaging enhancement techniques 
are other important reasons that also influence the decision whether or not to adopt 
a digital radiography system. In our model, the main reason why cost savings in the 
short run are significantly smaller than in the long run is inflexibility of production 
factors and associated reallocation problems. So the percentage of the old technology’s 
costs that cannot be reallocated to the new technology is the main driver for short run 
inefficiencies. We know that filling up freed capacity has the potential to decrease these 
inefficiencies. The main factors that exert influence on the length of the short run, and 
therefore on the extent to which inefficiencies in the short run can be minimized are: 
•	 The percentage of freed capacity, e.g. the amount of capacity freed as a 
consequence of the shift in demand from old to new technology.
•	 The presence of a waiting list, which can dim short run inefficiencies by rapidly 
filling up freed capacity.
•	 Natural flow of patients. 
•	 Amortization rate of capacity.
We can also link the length of the short run to the expected economic lifespan of the 
new technology. If the short run is long compared to the expected economic lifespan 
of a new technology, then short run welfare losses will be a particularly big problem, 
and more of a barrier for implementation. Something similar holds for patient flow and 
amortization rate: if patient inflow is low or even negative and if amortization rate is low 
the short run will be long, leading to larger welfare losses.
Every model is, due to underlying assumptions, a simplified representation of reality. Of 
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course this also applies to our model. The formulas derived in this paper for the length 
of the short run and for the average welfare loss during the short run depend critically 
on our model assumptions, such as that capacity is diminished and refilled linearly. Here 
other assumptions could be made, which would lead to other formulas, and perhaps 
to other conclusions. An aspect that was not taken into account in our model is that of 
potential welfare losses caused by using the new technology at suboptimal capacity. 
However, because welfare losses will only be increased when we include inefficiency 
losses for the new technology, we could view the welfare losses as determined in our 
model as a conservative estimation of the real short run welfare losses. Furthermore, 
we only considered the cost side of the health production function, neglecting for 
example the influence of learning effects. We acknowledge the potential consequences 
of for example learning effects for the outcomes of our calculations, that most likely 
will show a further decrease of the short run INB. However the inclusion of changing 
health effects in the short run is currently beyond the scope of our model. Taken all 
this into account our approach should be regarded as conservative concerning the 
determination of short run inefficiencies. 
The efficiency losses as calculated in this paper are in a sense part of the losses that 
arise from a non-optimal implementation process. This brings up the question how this 
research contrasts to value of implementation analysis. Fenwick et al., 2008 propose a 
framework that builds on Bayesian value of information analysis expanded to incorporate 
decisions regarding investment in implementation activities, through an assessment of 
the expected value of implementation strategies [19]. Our approach as well as the value 
of implementation (VOIM) approach tries to correct the long run INB outcome for short 
run inefficiencies (imperfect implementation). The major difference between both 
approaches is that Fenwick et al., adhere to the concept of cost-effectiveness analysis 
assuming convex technologies whereas we relax this assumption. So the VOIM approach 
produces in some cases (non-convex technologies) too optimistic results. However, the 
VOIM method as described by Fenwick et al. is flexible and the information resulting 
from our approach can be incorporated in their approach. 
Further research should be directed at examining other cases of technology substitution 
and determining other important factors influencing the length and impact of the short 
run time frame on implementation. Furthermore, it can be investigated if and how 
freed up capacity for the old technology can be re-used in order to minimize efficiency 
losses and the effects this will have for the model and its outcomes.
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Abstract
This paper examines short run inefficiencies that arise during gradual implementation 
of a new cost-effective technology in healthcare. These inefficiencies arise when health 
gains associated with the new technology cannot be obtained immediately because 
the new technology does not yet supply all patients, and when there is overcapacity 
for the old technology in the short run because the supply of care is divided among 
two mutually exclusive technologies. Such efficiency losses are not taken into account 
in standard textbook cost-effectiveness analysis in which a steady state is presented 
where costs and effects are assumed to be unchanging over time.
A model is constructed to quantify such short run inefficiencies as well as to inform 
the decision maker about the optimal implementation pattern for the new technology. 
The model operates by integrating the incremental net benefit equations for both the 
period of co-existence of mutually exclusive technologies and the period after complete 
substitution of the old technology. It takes into account the rate of implementation of 
the new technology, depreciation of capital of the old technology as well as the demand 
curves for both technologies. The model is applied to a real world case of converting 
from screen film to digital mammography in the Netherlands.
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Introduction
The adoption of innovative medical technology is found to be a major factor contributing 
to rising costs in the medical sector [1]. This has made the economic evaluation of a new 
medical technology top priority when considering adoption in common practice. The 
most commonly used technique for the economic evaluation of a new technology in 
health care is cost-effectiveness analysis (CEA). Standard CEA [2, 3] assumes immediate 
and perfect substitution of the new technology for the old. However, in the short run 
following implementation of a new technology, it is very well possible that usual care 
or the old technology operates in conjunction with the new technology to meet patient 
demand. The assumption that technological substitution will take place instantaneously 
is an idealization: In reality, implementing a new technology in health care will take time, 
for example because of learning processes and organizational changes that need to be 
made. In this paper, we assume that the decision to implement a new technology on 
the basis of favorable cost-effectiveness  has already been made. As a consequence of 
this decision, a source for possible variations in cost-effectiveness outcomes is spillover 
of effects from the old technology into the new situation [4]. This can happen when the 
old and new technology co-exist for a certain period of time. During this period costs 
may be induced for both technologies, and clinical effectiveness for the new technology 
is likely not to be optimal yet. When both the old as well as the new technology are 
operational during the implementation period of the new technology, this has two 
important implications for the outcome of the economic evaluation. 
First, full capacity for the old technology is no longer needed as patients are transferring 
to the new technology. Standard textbook economic evaluation assumes that all 
production factors are perfectly divisible, and production of the old technology can 
be scaled down to any lower level without getting inefficiencies. This implicates that 
the production factors of the old technology can be used entirely for the new and 
more efficient technology. However, during the short run time frame following the 
introduction of the new technology some production factors of the old technology are 
not perfectly flexible. When these fixed factors of production are present in the old 
technology, inefficiencies will arise [5, 6]. 
Second, during the implementation period the new technology may not have enough 
capacity to supply the entire relevant patient population from the moment of 
implementation. This will then result in a gradual patient population switch from the 
old to the new technology. Therefore, until the new technology has enough capacity to 
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supply all patients, a portion of the patient population is still using the old technology. 
As a result, the aggregated cost-effectiveness outcome for the patient population will be 
suboptimal during the implementation period because the healthcare provider cannot 
reap the full benefits of the new and more cost-effective technology.
The inefficiencies as described above are dependent on a number of features of the 
involved technologies as well as the implementation process of the new technology. 
When these inefficiencies are made explicit and are quantified, the decision maker could 
develop a more accurate view about the short run consequences of the technological 
substitution. As financial resources in health care are scarce and technological 
innovation present decision makers with more and more alternatives, the short run 
economic performance of the new technology becomes more and more important. 
When estimations predict the new technology is economically not performing as well 
as expected, stakeholders with a predominantly economic interest might take ad hoc 
measures to increase the immediate economic performance of the care process. The 
consequence might be a stagnation of the diffusion process with a longer period of co-
existence of mutually exclusive technologies and related inefficiencies. 
In this paper we aim to obtain more accurate predictions about short run costs and 
effects by modeling inefficiencies that arise during gradual implementation of a new 
technology. Here we implicitly assume that the decision to adopt the new technology 
on the basis of favorable cost-effectiveness has already been made. To predict short 
run costs and effects we develop a time-dependent cost-effectiveness  model which 
takes into account inefficiencies resulting from gradual implementation of the new 
technology. Furthermore, we aim to inform the decision maker about the optimal 
implementation pattern that minimizes short run inefficiencies. Using our model an 
expression is formulated that minimizes any short run inefficiencies and gives the 
decision maker information about the most optimal rate of implementation. Finally, 
we apply the model to a real-world case of converting from screen film to digital 
mammography. 
A model to quantify short run incremental net benefits during implementation of a new 
technology 
Standard textbook CEA looks at the long term or steady state costs and effects of both 
the new and the old technology:  Cn, Co, En and Eo, respectively. Then the steady state 
incremental net benefit (INB) is given as a measure of cost-effectiveness by:
 INB(K) = K ∙ ∆E - ∆C = K ∙ (En - Eo) - (Cn - Co)
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Here K denotes the willingness-to-pay for a unit of effect [2]. If INB(K) > 0 the new 
technology will be considered cost-effective.
Time-dependent implementation and depreciation
In this paper we will develop a model that can be used to calculate the short run 
INB, taking into account the temporary coexistence of two technologies during the 
implementation phase and the inefficiencies that may result from a shift from an old 
to a new technology. As was mentioned in the introduction, during most technology 
shifts the new technology will have to be implemented gradually. We model this by 
introducing a time variable t and postulate a function l(t) that represents the proportion 
of capacity supplied by the new technology. This function is assumed to increase during 
the implementation phase, until it reaches one (i.e. complete substitution). Since the 
new technology cannot satisfy all demand at once, there will be a transition period, in 
which the old and the new technology coexist. As a consequence of the introduction 
of the new technology there will be a decreasing need for the old technology, which is 
denoted n(t). Assuming total demand to be constant, demand for the old technology is 
given by n(t) = 1 - l(t).
Also, up until time t=0 the whole market was supplied by the old technology, and we 
assume that the old technology’s capacity will decrease gradually. Here we use the 
function m(t) to denote the old technology’s capacity that is available at time t. We 
assume that m(t) ≥ n(t) will always hold (since the whole market will have to be served). 
Whenever m(t) > n(t) is true, we see that there is an excess capacity of m(t) - n(t). 
An instance of such excess capacity can be seen in figure 1 by the vertical difference 
between the lines for m and n. In case there exists excess capacity, we assume that the 
available capacity for the new technology is fully employed, so that there is in fact only 
excess capacity for the old technology. 
In order to use our model in practice, we need to make some assumptions with respect 
to the forms of the functions l, m and n. Here we will assume linearity, in order to make 
the model more tractable and easier to understand. For other functional forms a similar 
type of reasoning could be followed. In all of the subsections of the model part of the 
paper we will start with the general case, deriving formulas in terms of the functions l, 
m and n, and then apply them to our more specific linear case. 
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The moment at which implementation of the new technology starts is chosen to be t=0, 
so that l(0) = 0. We suppose that the time frame in which implementation takes place 
is predetermined, and denote the point in time where all patients have switched to 
this new technology by λ so that l(λ) = 1. Thus it follows that the proportion of capacity 
present for the new technology can be described by the function l(t) =     , for 0 ≤ t ≤ λ.3 
As a consequence, for n(t) = 1 - l(t) we now get n(t) = 1 -     . 4  Furthermore, until t = 0 the 
old technology supplies all demand, so that m(0) = 1. We denote the point in time 
where all capacity of the old technology will have totally depreciated by μ (note that in 
all cases we assume that m ≥ l, and thus that μ ≥ λ). Thus the m function reads:
   m(t) = 1 -      for  0 ≤ t ≤ μ    (1)
All of these time-dependent patterns for the linear case are depicted in figure 1.
λ
t
λ
t
μ
t
3. Of course, since l represents a proportion, it holds that l(t)=1 for t ≥ λ.
4. The quantity n is a proportion, so that n(t)=0 for t>λ.
Figure 1. The transition phase: available capacity for the new technology (l), necessary capacity for the 
old technology (n), and available capacity for the old technology (m).
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Time-dependent INBs
Now that we have modeled how the technology transition from old to new takes place, 
we see that the levels at which the old and the new technologies contribute to the total 
market supply and to the total costs are time-dependent. This means that costs and 
effects will change over time, and consequently the INB will also be time-dependent. 
Let Eo and En denote the (steady state) effects of the old and the new technology 
respectively. We now proceed by specifying the effects E
mix
 (t) at time t during the 
transition phase, which is given by:
   E
mix
 (t) = l(t) En + n(t) E0 = l(t) En + (1 - l(t)) E0  (2)
since at time t a proportion of l(t) is supplied by the new technology, and n(t) is supplied 
by the old technology (the remaining capacity for the old technology m(t) - n(t) is 
redundant and consequently does not contribute to the effects). Hence, to compare 
the effects during the transition phase with the effects of the old situation, we compute
 ∆E
mix
 (t) = E
mix
 (t) - E0 =  l(t) En - l(t) E0 = l(t) (En - E0) = l(t)∆E  (3)
where ∆E = En - E0 still denotes the effectiveness gain in the long run.
As for costs, the reasoning and the equations are similar, but somewhat more 
complicated due to excess capacity for the old technology. Co and Cn denote the costs of 
the old and the new technology, and  ∆C = Cn - C0 denotes the long run cost difference. 
We now proceed by defining α as the percentage of costs for the old technology that 
cannot be transferred to the new technology (we can think of α as roughly the portion 
of total costs made up by fixed costs). Hence, for old technologies that consist only out 
of variable costs (e.g. disposables), this means that α equals zero whereas for capital 
intensive technologies the value for α will approach one. Now, during the transition 
period the costs C
mix
 (t) are given by: 
  C
mix
 (t) = l(t) Cn + (1 - l(t)) C0 + {m(t) - n(t)} ∙ α ∙ Co  (4)
To see the rationale for this equation, at time t the new technology contributes a 
proportion of l(t), and we assume that the costs for this share can simply be obtained 
by multiplying this proportion with the steady state costs of the new technology for 
supplying the whole market.  Similarly, 1 - l(t) is the proportion of the market that is 
supplied by the old technology at time t, and again this is multiplied by the steady state 
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costs of the old technology for supplying the whole market. Furthermore, at time t 
there is an excess capacity of {m(t) - n(t)}, and in our model this will contribute to the 
mix of costs as well. We assume that the investment that was used to finance the old 
technology is not (completely) paid off yet. That is, we assume that the investment 
in the old technology was financed by a loan for which payments (including interest) 
follow the depreciation or amortization pattern of the technology and that this pattern 
is proportional to the rate with which the capacity of the old technology diminishes. 
Therefore, for excess capacity only the portion α of costs for the old technology will be 
incurred (as only fixed costs will be incurred for excess capacity).
Then, subtracting Co, the difference in costs between the transition phase and the old 
situation is given by
  ∆C
mix
 (t) = C
mix
 (t) - C0 = l(t) ∆C + {m(t) - n(t)} ∙ α ∙ Co  (5)
Now that we have defined ∆E
mix
 (t) and ∆C
mix
 (t), we are ready to present the time-
dependent INB during the short run:
 INBSR (t) = K ∙ ∆Emix (t) - ∆Cmix (t) = K ∙ l(t) ∆E - l(t) ∆C - {m(t) - n(t)} ∙ α ∙ Co
   = l(t) ∙ INBLR - {m(t) - n(t)} ∙ α ∙ Co   (6)
Thus, during the transition phase we see that the short run INB depends on the 
implementation rate of the new technology l(t) and on the excess capacity of the old 
technology. 
Looking at figure 1 excess capacity is represented by the vertical difference between 
the lines for m and n. However, we see that in the linear case n is kinked in λ, and that 
for determining excess capacity we need to distinguish two stages. The function l(t) will 
also differ across these stages. Therefore, to write out the short run INB for the linear 
case we will first describe these two stages and formulate the rate of implementation 
l(t) and the excess capacity for each stage separately. 
The first stage is the stage in which the new technology is being implemented, and it 
lasts from time 0 to time λ. For 0 ≤ t ≤ λ the function l is given by l(t) =     . Furthermore, 
m(t) = 1 -     and n(t) = 1 -     , so that the time-dependent overcapacity is given by 
m(t) - n(t) =    -    . We see here that as technology substitution takes place, excess 
λ
t
λ
t
μ
t
μ
t
λ
t
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capacity will steadily increase because depreciation of the old technology cannot keep 
up with the outflow of patients to the new technology, i.e. because μ > λ.
In the second stage the new technology is fully implemented and operating at constant 
returns to scale, so l(t) = 1. However, in this stage the capacity for the old technology 
is still decreasing since it has not fully depreciated yet. Thus, the second stage lasts 
from time λ until time μ. We then get that m(t) = 1 -    and that n(t) = 0, so that the 
overcapacity is given by m(t) - n(t) = 1 -    . Hence, in this phase the excess capacity 
equals the actual capacity for the old technology, which steadily decreases until it is 
fully depreciated.
Combining stages 1 and 2 we obtain the following two part equation for the time-
dependent INB:
      INBSR(t) = l(t) ∙ INBLR - {m(t) - n(t)} ∙ α ∙ Co
  ∙ INBLR - (    -    ) ∙ α ∙ Co        for  0 ≤ t ≤ λ 
 
              INBLR - (1 -    ) ∙ α ∙ Co           for  λ < t ≤ μ
The average short run INB
The short run INB changes over time, and to summarize the INB during the transition 
phase in a single number, we can aggregate the INB over the whole time period where 
the two technologies coexist (from time 0 until time μ), and obtain a quantification of 
the average INB over the transition period:
  (IN̅̅B̅SR =    ∙     (l(t) ∙ INBLR - {m(t) - n(t)} ∙ α ∙ Co)dt
     = ∙    l(t)dt -         ∙ {m(t) - n(t)} dt   (8)
The term     {m(t) - n(t)}dt in the above equation represents the total excess capacity 
during the transition period. To give the reader an idea how to interpret these equations, 
a graphical representation of the two factors that determine the short run INB is given in 
figure 2. Here the vertically hatched area is proportional to the efficiency losses due to the 
combination of overcapacity and fixed factors of production in the transition phase, i.e. 
μ
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proportional to -       ∙   {m(t) - n(t)}dt. The horizontally hatched area is proportional 
to the efficiency gains of the new technology relative to the old technology 
given the implementation pattern l(t) of the new technology, i.e. proportional to 
         ∙     l(t)dt.
We obtained a two part equation for the time-dependent INB, as expressed in equation 
(7). Then, working out the integrals from equation (8), we arrive at5
 
  (IN̅̅B̅SR = (1 -      ) INBLR - α ∙ Co ∙ (    -      )   (9)
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Figure 2 Additional benefits obtained during the transition phase compared to the old situation (the 
horizontally hatched region) and short run inefficiencies due to excess capacity (the vertically hatched 
region).
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Optimizing implementation of the new technology
If we take a close look at the parameters in equation (9), it seems reasonable to assume 
that only λ and hence the implementation function l can be varied by the decision maker 
in order to influence the magnitude of the short run INB. Thus, in order to choose an 
optimal implementation speed, equation (9) should be maximized over λ.  
Varying the speed of implementation has two opposing effects: maximizing efficiency 
gains due to the new technology necessitates rapid implementation of the new 
technology, while minimizing overcapacity for the old technology dictates adapting 
the demand for the old technology (and thereby the supply of the new technology) to 
its depreciation rate, i.e. slow implementation. Therefore, a trade-off has to be made 
between these two opposing forces. This dilemma can also be seen from figure 2: faster 
implementation means shifting λ to the left. This will result in a larger vertically hatched 
triangle, but also in a smaller horizontally hatched area. One would optimally like to 
have the horizontally hatched area as large as possible and the vertically hatched area 
as small as possible, but one cannot have both at the same time.  
In fact, in the linear case we already found an expression for IN̅̅B̅SR as a function of λ in 
equation (9), which can be rearranged as:  
         (10)
This rearrangement makes it possible to determine the optimal rate of implementation λ. 
As can be readily seen from equation (10), the short run INB is a linear function of λ, 
and the expression                determines the slope of this function. This means that this 
function is strictly decreasing when α ∙ Co < INBLR and strictly increasing when α ∙ Co > INBLR. 
Therefore, for maximizing the short run INB we arrive at the following decision rule:
If α ∙ Co < INBLR  then choose λ = 0.
If α ∙ Co > INBLR  then choose λ = μ.
2μ
α ∙ Co - INBLR
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In the first case it would thus be optimal to implement as fast as possible, in the second 
case, it would be optimal to adapt the implementation rate to the depreciation pattern 
of the old technology. Note also that this decision rule implies that λ has no internal 
optimum.6 
Of course, immediate implementation (with λ = 0) will in reality often not be feasible. 
Still, the linearity of IN̅̅B̅SR = (λ) implies that under such circumstances it is best to 
implement the new technology as fast as possible. A similar restriction may apply to the 
second case when λ = μ.
Applying the model to a real world case: Converting from Screen Film Mammography to 
Digital Mammography in screening for breast cancer
Screen Film Mammography (SFM) has long been the standard method in population 
based screening for breast cancer. SFM is a technique which uses X-rays to image 
the breast for suspicious breast cancer masses or microcalcifications [7]. In full-field 
Digital Mammography (FFDM), the basic principle is the same as with SFM. The major 
difference is that the receptor is a digital device instead of photographic film enabling 
an immediate conversion into a picture suitable for human vision on a high-definition 
computer screen. For a screening centre to turn completely filmless, a picture archiving 
and communication (PAC) system must be available to handle and storage the data. If 
a PAC system is not readily available, costs for printing exist in the short-run. Also, film-
based images are usually stored for a certain period of time (e.g. nine years in the UK) 
[8] and 15 years in the Netherlands (personal communication)). These films could be 
digitized and taken up in the PAC-system, but this is a very expensive procedure. If old 
films are not digitized, the quality of the screening process is degraded and archiving 
costs will remain for the remaining period resulting in diseconomies of scale [9, 10]. 
Another important factor contributing to diseconomies of scale is that screening units 
do not make an immediate switch to FFDM and that not all screening organizations 
choose or are able to digitize the previous exams. The reason for this is that a one to 
one transformation from SFM to FFDM is impossible because new devices have to be 
certified for use which takes a considerable amount of time. Furthermore an immediate 
transformation is often not achievable within the financial parameters of the screening 
organization. What results is that SFM and FFDM will exist next to each other in the 
transition phase [11]. Only when there are no more costs for SFM (which depends on 
the length of the transition phase and on the rate of depreciation of SFM capacity) and 
FFDM is performing at constant returns to scale will the short run have ended. 
6. Of course, in the rather unlikely case where α ∙ Co = INBLR, the short run INB function is constant in 
λ, and it does not matter how the implementation rate is chosen.
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In 2002, the Dutch government announced its intentions to implement digital 
mammography as soon as possible for the population based screening program. A 
preliminary study was performed aiming to assess the attainability of converting to a 
filmless, digital screening program [12]. This study assessed annual costs for a screening 
program at approximately €32,700,000. Annual savings from SFM were estimated to be 
€13,270,000 and annual extra costs for FFDM were estimated at €12,285,000 yielding net 
annual savings of €985,000. The transition phase, in which all centers would be digitized, 
as would the prior exams, was estimated to last three years. Transition costs consisted 
of pilot project costs, adaptation of the screening units (SUs), training radiologists and 
costs related to the project organization, and were estimated (considering a three year 
period) to be €6,600,000 [13]. 
In 2006, on average, all SFM equipment was depreciated (personal communication). 
From Ciatto et al. we can derive that the percentage of fixed costs for SFM is 27%. 
Recent studies concerning diagnostic accuracy confirmed that digital mammography as 
a screening technique in a population-based screening program is at least as accurate 
as SFM [14]. Thus, we make the conservative assumption that health effects are equal 
for SFM and FFDM. Now the incremental net benefits equal the net annual savings so 
that INBLR = €985,000. Also, we have Co = CSFM = €32,700,000 and α = 0.27. We know 
that the implementation period was estimated to last three years, which gives us λ = 3. 
Finally, as we know that in 2006, on average, all remaining SFM equipment was 
depreciated, we assume the average time period in which all SFM capacity is written off 
to last from 2002 to 2006; hence μ = 4 years.
Using (9) we can now calculate the average short run INB if the digital screening program 
was implemented according to Bakker’s estimates:
To calculate the short run efficiency losses for this situation we calculate the difference 
between the short run and the long run INB: IN̅̅B̅SR -  INBLR = - €488,000 - €985,000 = 
- €1,473,000 per year and last for 4 years. Hence the total efficiency losses in the short 
run time frame amount up to €5,892,000. So in this scenario the expected annual net 
savings of €985,000 would not be realized. Worse still, during the first 4 years after 
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implementation there would be an unanticipated net loss of €488,000. The question 
then arises if the Dutch government would be willing to bear these losses over this 
extended period of time, as this would mean that budgetary adjustments are needed 
in the short term. A possible consequence would be that implementation stagnates, 
leaving only part of the mammographic units digitized. An extreme, and unlikely, 
consequence could be that a complete reversal to SFM would be considered. Either 
option will result in inefficient provision of health care as both a partial implementation 
of FFDM as well as a complete reversal to SFM will lead to 1) the need to reinvest 
in cost-ineffective SFM equipment, and 2) the denial of full access to the more cost-
effective FFDM technology for both society and the medical profession.
Discussion  
The model presented in this paper complements the standard CEA and can be used 
to inform decision makers about the implementation process of a new technology by 
assessing inefficiencies in this process  and it can also help decision makers to design an 
implementation strategy that minimizes short run inefficiencies. Implications of short 
run efficiency losses are not limited to the adoption of health care technologies. In 
general it can be said that modernization of hospitals, but even nationwide registries like 
electronic patient records, are all susceptible to short run efficiency losses. Moreover, it 
can be stated that the larger the scale of the intervention, the higher the probability that 
gradual implementation will be necessary and that short run inefficiencies will occur. 
By taking into account short run efficiency, possible losses during the implementation 
period become more transparent, which can be helpful in communications between 
stakeholders (for example hospitals and health care insurers). We believe that once 
short run losses are revealed, stakeholders will more explicitly focus on (the economics 
of) implementation. This being said, we are fully aware of the fact that efficiency is just 
one of the many factors which will ultimately determine the rate by which an innovation 
is implemented. 
An extreme case that we have not considered yet is the situation in which the short 
run INB is negative but the new technology is cost-effective once the steady state is 
reached. The policy implications of such a situation would not be limited to delay or 
stagnation of implementation of the new technology, but could even lead to a reversal 
to the old, and on the long run less efficient technology. In order to make an informed 
decision in this case, it would be prudent for the decision makers to take into account 
the economic lifetime of the new technology and compare this to the estimated length 
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of the short run time frame. When it is expected that the economic lifetime of the 
new technology is relatively short in comparison with the period of time during which 
inefficiencies occur, this could be a well-grounded reason to halt the implementation 
of the innovation. 
We can distinguish between two sources of short run efficiency losses that arise during 
the implementation of new medical technology: 
•	 The old technology suffers from overcapacity during the transition phase which, 
combined with the presence of fixed factors of production, causes efficiency 
losses. These losses are dependent on the difference between the rate of 
substitution and the rate of depreciation for the old technology. 
•	 The new technology is not fully implemented yet during the transition phase. 
Consequently, efficiency losses arise because the full efficiency gains resulting 
from the new technology are being postponed.
In the model and in our example we consider the replacement of an existing technology, 
however short run efficiency losses may also occur when an innovative technology is 
introduced that has no predecessor that is being replaced. In this case, there is no old 
technology or the old technology does not suffer from excess capacity so no losses 
can be incurred due to overcapacity. Therefore, for new technologies that do not 
replace existing ones, efficiency losses can, according to our model, only arise as a 
consequence of efficiency gains being postponed because of gradual implementation 
of the innovation. Hence, here the optimal implementation strategy would obviously 
be to implement as soon and as fast as possible, in order to maximize efficiency gains. 
The model we developed has some important underlying assumptions such as for 
example linearity. The main reason for this was to make the model simple and tractable. 
In scenarios where linearity is not plausible it is fairly easy to adapt the equations 
for depreciation and implementation in order to obtain a model that better fits the 
decision maker’s situation. For example, a step function would probably be more 
plausible when looking at non convex technologies, but the resulting formulas would 
become much more complicated. As this paper is intended to be tentative in nature, we 
have chosen for the linear assumption. Another important assumption is that the rate 
of depreciation (the actual speed by which the old technology’s capacity decreases) 
equals the rate by which the old technology’s non-transferable costs decrease after the 
introduction of the new technology. While this seems a reasonable assumption (that 
the old technology’s costs in the new period are only incurred for the actual remaining 
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capacity), this assumption could also be relaxed. Instead of one variable m(t) that 
expresses both these aspects at the same time, we could also have separated these two 
aspects by modeling two different variables m1(t), denoting the decreasing capacity of 
the old technology, and m2(t), denoting the old technology’s non-transferable or fixed 
cost pattern over time. For simplicity we chose to let these coincide. 
As far as the applicability of the model is concerned, prospective information is 
essentially required on three parameters: the (projected) rate of implementation of 
the new technology, the (fixed) rate of depreciation of the old technology, and the 
fixed cost component of the old technology alpha. Alpha can be determined from the 
cost structure of the old technology. The rate of implementation would have to be a 
projection or an expectation. As for the rate of depreciation, we assume this to be equal 
to the rate by which the old technology’ capacity decreases after the introduction of the 
new technology. Hence, this rate could be obtained by investigating the cost structure 
of the old technology. We realize that in practice both these parameters would probably 
be obscured by uncertainty and that finding exact values could well be impossible. 
Therefore, a probabilistic extension of our model could make it more realistic and more 
useful in practice, which makes this an excellent topic for future research. However, 
a sensitivity analysis, possibly combined with expert opinion, could provide us with 
output over a plausible range of model outcomes.
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Abstract
We examine the implications of learning effects on the outcomes of cost-effectiveness 
analysis. Based on the Plateau model for learning a cost-effectiveness model is derived 
that is able to quantify the reduction in the incremental net benefit caused by learning 
during the trial period. We apply this model to a real-world case describing the economic 
evaluation of lobectomy by video assisted thoracic surgery for lung cancer and show 
that learning leads to considerable additional costs during the trial period compared to 
expert level. Taking into account learning in cost-effectiveness analysis reduces bias in 
the efficiency outcome.
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Introduction
The concept of learning is typically described as an increase in productivity when 
organizations or individuals gain experience in performing certain tasks. As organizations 
increase their production over time, the unit costs of production will decrease at a 
decreasing rate. Similarly, as production increases, quality measures will increase at 
a decreasing rate. This phenomenon is variously referred to as the learning curve, 
experience curve, or progress curve [1]. Learning curves have been documented in a 
wide array of industries, ranging from the production of complex machinery like aircraft 
and ships [2, 3], power plant operating reliability [4], to more recently its association 
with the health care industry [5, 6]. Productivity gains associated with learning can 
be quite large (productivity gains of 190% in the first year have been reported) but 
vary heavily between and within industries. Reasons for this variation may be due to 
employee turnover, transfer of knowledge, organizational forgetting, and failing to take 
into account external factors when estimating learning curves [1, 7].
The learning curve was introduced in 1936 when Theodore Paul Wright published an 
article in the Journal of the Aeronautical Science [8]. In this article, Wright described 
a basic theory for obtaining cost estimates based on repetitive production of airplane 
assemblies. The basic concept that serves as the basis of Wright’s learning curve theory 
is that the time or costs per unit produced decrease by a fixed percentage every time 
cumulative production output doubles. Wright showed in his study that the decrease in 
direct labor cost of airframe manufacturing decreased by 20% every time the cumulative 
production doubled. Based on his theory, Wright developed a model to quantify the 
effects of learning on the output of a production process when production increases. 
Nowadays, a wide variety of mathematical representations of the learning process exist. 
Common types of learning curves involve the log-linear, exponential, and hyperbolic 
models. As log-linear models describe most manual-based operations with acceptable 
precision while at the same time providing a non-complex mathematical structure, 
these models are mostly used to predict production rates in repetitive operations.
The most basic log-linear model is the Wright model. There are a number of variations 
to this model, often aimed at adapting the equation to specific applications. Examples 
include the Stanford-B model which incorporates worker’s prior experience, and the 
De Jong model that takes into account the role that machines can play in the learning 
process [9, 10]. Another example is the Plateau model, which adds a constant to 
describe steady state worker’s performance at which point essentially all learning is 
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concluded [11, 12]. For more information on these models and additional models the 
reader is referred to Anzanello et al., which provide an excellent overview of learning 
curves and their applications [13].
In the health care sector, learning effects are particularly visible in interventions where 
human actions have significant influence on procedural outcomes, for example when 
implementing complex new equipment or performing innovative surgical procedures. 
In a systematic review by Ramsay et al. it was found that surgical minimal access 
techniques (e.g. laparoscopic nephrectomy), other surgical procedures (e.g. heart 
transplantation), and diagnostic technology (e.g. interpretation of MRI scans) comprise 
the majority of innovations in the medical fields where learning can have a significant 
effect on outcome measures [14]. 
As learning effects are most prominent in the early clinical stages of an innovation, they 
tend to exert a large influence on the results of clinical trials. Initially, clinical personnel 
involved in the trial will perform suboptimal. Such a suboptimal performance is usually 
accompanied with an increase in costs (longer procedure times and higher complication 
rates) and a decrease in effects (lower quality of life outcomes and survival rates for 
patients), as compared to the performance of the innovation at later stages of adoption. 
As data collection for economic evaluations is commonly carried out alongside clinical 
trials, learning effects can therefore have a large influence on the costs and effects 
outcomes that serve as input for the cost-effectiveness analysis (CEA) of the innovation. 
Standard practice during CEAs is to collect all relevant resource consumption as well as 
effect measures and subsequently average these values over the number of procedures 
carried out in the trial. In doing so, estimates of the average total costs and effects per 
procedure are obtained, which are subsequently used to calculate the cost-effectiveness 
of the innovation. In doing so, standard CEA does not take into account any variation 
between subsequent procedures, and hence does not provide information about 
increased costs or reduced effectiveness that may occur during the learning period. As 
the influence of learning effects will decrease when production increases, a discrepancy 
will exist between the cost-effectiveness of an innovation during the trial and the cost-
effectiveness of this same innovation when the steady state7 is reached. Hence, not 
taking into account the effects of learning in standard CEA might lead to an unfavorable 
cost-effectiveness outcome for an innovation compared to when applied in common 
7. In this paper we use the term “steady state” to indicate that a procedure is carried out by personnel 
that is experienced to the greatest degree allowing productivity losses due to learning effects to 
become virtually non-existent.
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practice when the steady state is reached [15]. It is therefore imperative to assess the 
consequences of learning effects on the outcomes of cost-effectiveness (CE) studies, 
as failing to take into account variations in costs and effects because of learning might 
have important consequences for the validity of the study’s outcomes. 
In this paper our aim is to inform clinicians, decision makers and fellow researchers 
about the mechanisms by which learning effects can influence CE outcomes for an 
innovation. Furthermore, we seek to provide decision makers with a tool to assess the 
validity of CE outcomes by quantifying the effects of learning. To do this, we construct a 
model to quantify the influence of learning on costs and effects of an innovation during 
a clinical trial and demonstrate this model using a real-world case. 
Methods 
To assess learning effects two types of performance measures are used in the 
medical literature. First, proxies are used that are based on task efficiency (e.g. time 
required to complete a surgical procedure). Second, quality outcomes such as rate of 
complications are used [14]. Direct costs of treatment are often highly correlated with 
time to complete treatment [16], and complications often lead to higher costs for the 
health provider. This is particularly relevant in a prospective payment system, where 
hospitals are reimbursed for inpatient health care services using a predetermined rate 
set for treatment of specific illnesses. However, there is no real agreement on the most 
suitable measure of performance, so in this paper we will avoid this issue altogether by 
only taking into account total costs and effects for a procedure. This approach also fits 
well with the methods of data collection in an economic evaluation. 
Now if we want to take into account learning effects, it is necessary to calculate 
the aggregated costs per procedure during the trial and subsequently look into any 
systematic variations in costs for successive procedures. In most clinical trials, data 
is indeed collected on all cost components of the individual procedures as well as on 
the sequence of procedures (i.e. dates of procedures), hereby giving us insight in the 
variation in costs over time. In essence we are now looking for a pattern which may 
indicate a learning effect. If present, this learning effect will manifest itself by decreasing 
costs per procedure and/or increasing quality of care as the number of procedures 
increases. This variation in costs and/or effects provides us with the tools to construct 
a learning curve, which will allow us to estimate the average costs and effects of a 
procedure carried out at expert level and the number of procedures needed to achieve 
expert level.
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In our model we will use the Plateau model to describe the learning curve (note that 
for this moment we limit ourselves to an assessment of learning on costs) [11, 12]. The 
reason why we use the Plateau model as a basis to describe the learning curve is that it 
is simple, flexible and intuitive. Furthermore, although it has its roots in manufacturing, 
the Plateau model is adapted from Wright’s theory which in turn is considered to be 
appropriate to describe learning in health care [17]. In our model the learning curve is 
described as follows:
   AC = a’ ∙ xb + AC
exp
    (1)
Where AC = average cumulative costs per procedure,
 a’ = additional costs for the first procedure due to learning,
 x = cumulative number of procedures,
 b = rate of learning: log of percentage of learning for costs / log of 2 (-1 < b < 0), 
 AC
EXP
 = average costs per procedure at expert level (AC
EXP 
> 0).
As can be seen in equation 1, the Plateau model is adopted from Wright’s model by 
adding a constant to account for costs that are not influenced by learning (ACexp). 
Furthermore, a’ represents the additional costs for the first procedure due to learning. 
In doing so we essentially split up costs in a component a’ ∙ xb which represents the 
extra costs due to learning and a component ACexp which represents the average costs 
at expert level.
In figure 1 the average cumulative costs per procedure are plotted as a function of 
cumulative procedures carried out. Here the average cumulative costs per procedure 
are the average costs for a single procedure or the average costs for one procedure 
that is part of a badge or series of procedures. We use the variable x
trial
 to represent the 
number of procedures carried out in a clinical trial. We also plot the average total costs 
per procedure during the trial period, so for the first x
trial
 procedures, as these costs are 
used as a cost estimate in standard CEA.
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Figure 1 Average total costs per procedure during the trial and beyond
Looking at figure 1 we notice that the average costs per procedure during the trial 
(AC
trial
) will be larger than the average costs per procedure at expert level (ACexp). This is 
because the cost estimation in the CEA is based on trial data suffering from productivity 
losses caused by learning effects, whereas the marginal effect of learning on the 
innovation in its steady state has largely diminished. This results in a cost estimate that 
is too pessimistic for the innovation in its steady state. In figure 1 this steady state cost 
deviation C* is depicted as the vertical difference between both curves for x > x
trial
.
In practice the number of procedures carried out in a trial are rarely exactly equal to 
the number required to achieve expert level. Suppose for example x
trial
 = 30 in figure 1: 
Now the average costs per procedure during the trial will increase, resulting in an even 
greater cost deviation. For xtrial = 70 this deviation will obviously be smaller. So we can 
conclude that C* is, apart from being dependent on the shape of the learning curve, also 
depends on the relation between xexp and xtrial. Therefore, in the following paragraph, 
we will quantify the deviation in costs as well as effects in relation to the number of 
procedures in the trial.
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Quantifying the effects of learning on costs and effects in a clinical trial
To quantify the cost overestimation as a function of the number of procedures carried 
out in the trial we first determine the total costs in the trial: 
Now the average costs in the trial are:
And finally, the steady state cost deviation becomes:
         (2)
As can be seen the resulting cost deviation is a decreasing power function, which 
outcome will always be positive as the function is asymptotic at C* = 0. This means 
that costs incurred during the trial, and used to determine the cost-effectiveness of 
an innovation, are indeed an overestimation of the real costs for the innovation. The 
decreasing deviation in cost outcomes for larger trials can be explained by the fact that 
the effects of learning on costs will reduce as a consequence of an increasing number of 
procedures carried out at higher levels of experience.
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As stated earlier, basically the same principle applies for effects as it does for costs. 
However, when we again use the Plateau model, but now for effectiveness gain, we 
should rearrange it to:
    
    AE = AE
exp 
- c ∙ xd    (3)
Where AE = average effectiveness per procedure in quality adjusted life years,
 AE
EXP
 = average effectiveness per procedure at expert level in QALYs (AE
EXP
 > 0),
 c = reduced effectiveness for the first procedure due to learning effect,
 x = cumulative number of procedures,
 d = learning rate: log of percentage of learning for effectiveness / log of 2 (-1 < d < 0). 
From equation 3 we can deduce that the average effectiveness during the trial (AE
trial
) is 
smaller than the average effectiveness at expert level. This again results in a deviation E* 
of the long run steady state effectiveness of the medical intervention. To quantify this 
value E* we follow the same approach as when calculating the cost overestimation and 
first determine the total effectiveness gain in the trial: 
Which leads to the following expression for E*:
         (4)
From equation 4 we deduce that the resulting deviation of the effectiveness gain is 
an increasing power function, with an asymptote at E* = 0, guaranteeing a negative 
outcome. Again, this is quite logical as this means that for larger trials the influence of 
learning on the effectiveness gain in the trial is reduced. This reduction is, as is the case 
for costs, caused by an increasing number of procedures carried out at higher levels 
of experience, resulting in higher effectiveness gains. Thus if a trial is sufficiently large, 
learning does not significantly influence the validity of the cost-effectiveness outcome 
in the steady state.
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Influence of learning on incremental net benefits
We will now look into the consequences of these deviations in costs and effects for the 
incremental net benefit (INB) outcome. Therefore, we derive an expression for INB*, 
which represents the deviation in incremental net benefits from the steady state: 
         (5)
Equation 5 displays the deviation from the steady state INB caused by learning during 
the trial period. As can be seen the overestimation of costs and the underestimation 
of effects during the trial period amplify each other in the resulting reduction of the 
cost-effectiveness outcome. We also see that for trials involving an increasing number 
of procedures the negative influence of learning on the INB decreases (as b & d < 0). 
Decision makers should take this INB reduction into account when evaluating an 
innovation where learning effects are expected to occur. 
Estimating the shape and characteristics of the learning curve
A simple scatter plot displaying performance and experience of a newly adopted medical 
technology would certainly not always show such a nice and smooth pattern as in figure 
1. In reality such a scatter plot is likely to exhibit random variation around a trend line. 
Thus to work with the learning curve, we would like to be able to isolate the underlying 
trend line, somehow averaging out all the random variation around it. In accordance 
with much of the literature on learning curves, we assumed a specific relation of a 
power function with a constant for the learning curve as expressed in equation 1. Thus 
we would need to estimate all the parameters from this formula: the average costs 
per procedure at expert level AC
exp
, the additional costs for the first procedure due to 
learning a’ and the rate of learning b. 
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The following example illustrates how the parameters of the learning curve could be 
estimated. 
Putting theory into practice: the Video Assisted Thoracic Surgery Lobectomy
In this section we will apply our model to a real life economic evaluation of a complex 
clinical procedure. In patients with early stage lung cancer, surgical lobectomy is the 
treatment of choice. Traditionally, a lobectomy is performed by an open approach with 
chest wall muscle division and rib spreading, the so-called thoracotomy (usual care). 
Since 1990, video-assisted thoracic surgery (VATS) has emerged as an alternative method 
to perform a lobectomy. With VATS the procedure is performed minimally invasively; 
chest wall muscles are not divided and ribs are not spread. The feasibility and safety of a 
VATS lobectomy has been demonstrated and is considered equal to a thoracotomy [18, 
19]. VATS is probably a superior treatment over a conventional open procedure since 
several studies have shown advantages of VATS including better functional-, quality of 
life- and procedural parameters and shorter hospital length of stay [20, 21]. However, 
due to technical difficulties and a considerable learning curve, VATS lobectomy is not 
yet the standard of care.
For this example, we will describe the first 43 VATS lobectomy procedures performed 
between February 2010 and May 2012 at the department of Cardiothoracic Surgery, 
Radboud University Medical Centre. We use conversion of a VATS lobectomy to an 
open surgical procedure as a proxy for learning. Figure 2 displays the probability that 
a thoracoscopic procedure needs to be converted to an open procedure (Pconv) as a 
function of cumulative number of procedures. As can be seen the probability of 
conversion is relatively high at the start of the trial but gradually decreases over time. 
For simplicity, we will only take costs into account and hence will calculate the steady 
state cost deviation during the trial. Based on a reported longer hospital length of 
stay of two days for an open approach, the estimated additional costs per conversion 
amount up to €5,000 [22]. 
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Figure 2 Scatt er plot displaying probability of conversion
Using the constrained non-linear regression analysis functi onality in IBM SPSS v20.0.01 
in which we defi ne the functi onal form according to the Plateau model, we arrive at the 
following equati on for Pconv:
Pconv = 0.881 * x 
-0.453 + 0.059
Table 1 presents the 95% confi dence intervals and standard errors for the model 
parameters a, b, and c.
Table 1. Confi dence interval and standard error for model parameters
Parameter Esti mate Std. Error
95% Confi dence Interval
    Lower Bound              Upper bound
a  0.881 0.056  0.768  0.994
b -0.453 0.081 -0.617 -0.288
c  0.059 0.065 -0.072  0.190
0       10              20                    30                  40                  50
Cumulati ve number of procedures
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This gives the following equation for the average additional costs per procedure due to 
conversions: 
   ACconv = 5,000 * Pconv = 4,405 * x 
-0.453 + 295
Using the equation for Cconv we now calculate the average steady state cost deviation 
per procedure during the trial:
   C* =             * 43 -0.453 = 1,466  
So we can conclude that for this trial the average additional costs due to learning 
(assuming conversions are the only negative effect of learning) are €1,466.
-0.453+1
4,405
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Discussion
In this paper we studied the effects of learning on the outcomes of economic 
evaluations in health care. We saw that learning leads to an overestimation of costs and 
an underestimation of effectiveness during the trial period. Learning therefore leads to 
an inaccurate estimation of the cost-effectiveness of the innovation as the alternative 
technology (usual care) is usually free of any learning effects.
Another point of interest is that the duration of the associated clinical trial may have 
a profound impact on the relative influence of learning on the resulting CE outcome. 
For innovations that are very complex and which thus require a longer time period to 
reach expert level, a short trial may lead to extremely biased CE outcomes. On the other 
hand, for longer trials during which expert level is achieved relatively soon the effect of 
learning on CE outcomes will be negligible. In general, it can be stated that longer trials 
will reduce the effects of learning on the CE outcome. 
In the most extreme case, learning itself can cause a trial to be terminated prematurely, 
although at the time of termination the physicians might not recognize the importance 
of learning with regard to the clinical effectiveness of the innovation. This is extremely 
important, as possible (cost-) effective innovations might be abandoned at an early 
stage on the basis of unsound reasons. A possible example of such an innovation is 
laparoscopic Nissen fundoplication for gastro-oesophageal reflux disease. In 2000, 
a randomized clinical trial was carried out to assess the innovative and complex 
laparoscopic approach versus conventional open surgery [23]. This study was stopped 
prematurely because patients in the laparoscopic arm had a significantly higher risk of 
a primary endpoint complication. In a response to this study, six commentaries were 
published which all questioned the reasons to abandon the trial [24-29]. All of these 
commentaries emphasized the effect of learning as an explanation of the higher rate of 
adverse events in the laparoscopic arm. Furthermore, it was expected that as longer-
term data would become available, different conclusions might be drawn on the relative 
effectiveness of this surgical innovation.
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Perhaps the most important and difficult issue in dealing with learning effects 
is determining the shape of the learning curve and hence, the values of the model 
parameters. Although in theory this can be quite straightforward, reality learns that 
trial data often gives fuzzy results and contains a number of outliers, making it hard to 
accurately fit a curve. This problem is further increased by the fact that relatively little 
data points are available (over the entire range of learning) to construct the curve. 
This issue is illustrated by the VATS trial which is relatively short, and hence is the 
possibility that at the end of the trial period performance has not achieved or even 
approximated expert level yet. Hence, estimating the whole learning curve from the 
data in such a limited experience domain will involve much uncertainty around the 
parameter estimates. 
In this context it should be noted that there are some problems associated with the case 
that we use to illustrate the model. Since the data points that are plotted in figure 2 and 
used in the statistical analysis are moving average data, these data points are mutually 
dependent. The statistical techniques that we use do, however, assume independent 
observations. Therefore this case should be seen as an illustration of the model only.
Future research on cost-effectiveness should include learning parameters so that more 
accurate inferences on the cost-effectiveness outcome can be made. Furthermore, 
future research should be aimed at developing methods to monitor preserving of 
experience. This is relevant in light of the effort to decrease costs and improve quality 
of care by means of concentration and specialization of care processes. 
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Nowadays, regulators, funding bodies, and other financing parties are exercising a lot 
of pressure on researchers to provide proof on the cost-effectiveness of an innovative 
intervention in a (too) short time frame. The question is to what extent outcomes 
obtained in such a short time frame do justice to the actual cost-effectiveness of a new 
intervention. The majority of innovations in health care are complex in nature, meaning 
that they require considerable time and effort to implement. Even for rather common 
drugs such as statins and anticoagulants it is clear that ‘time to benefit’ is a crucial, 
though highly neglected, characteristic in medical decision making [1]. Hence, there 
might be reason to believe that a discrepancy exists between short- and long run cost-
effectiveness outcomes. As the delivery of results in a short time frame is getting more 
and more important for funders and decision makers, researchers should make a strong 
effort to provide insight into the usability of these short run outcomes in determining 
the cost-effectiveness of an innovation.
Short run inefficiencies in cost-effectiveness analysis
Cost-effectiveness analysis (CEA) as part of the evaluation of medical innovations, both 
in drug and non-drug interventions, has become well accepted and widely applied 
in several high-income countries. For example, in the UK, the National Institute of 
Clinical Excellence (NICE) uses cost-effectiveness outcomes as a criterion for coverage 
recommendations to the National Health Service. Standard CEA is usually performed 
alongside a clinical trial or effect study and aims to collect all relevant costs and effects 
for both alternative interventions over a representative time period. Cost-effectiveness 
of a new intervention relative to current practice is often expressed in a decision rule 
relating the incremental cost-effectiveness ratio (ICER) to some societal willingness to 
pay for a unit of effect like for example a quality-adjusted life year gained. In utilizing 
this ICER, costs and effects collected during the trial period are assumed to be constant 
over and representative for the economic lifetime of the intervention. However, this 
assumption is not always realistic as it neglects possible inefficiencies that occur 
during the transition phase, where additional costs are often unanticipated and clinical 
effectiveness for the innovation is often not yet optimal [2]. As most innovations are in 
a transitional state when evaluated, inefficiencies are likely to occur, and the resulting 
ICER might be an incorrect reflection of the actual cost-effectiveness of the innovation. 
The impact of these inefficiencies on the outcomes of economic evaluations in health 
care is strongly related to the timeframe available for evaluation. In order to be able to 
estimate the impact of short run inefficiencies, and thus assess the expected accuracy 
of a CEA, there needs to be transparency about the underlying factors that might cause 
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a discrepancy between the estimated ICER and the ‘true’ steady state ICER. Here, three 
drivers of short run inefficiencies are identified and discussed: learning effects, capacity 
constraints, and delayed time to benefit.
Learning effects
Learning can both take place at an individual as well as at an organizational level 
[3]. Learning effects are particularly visible in interventions where human actions 
have significant influence on procedural outcomes, for example when performing 
innovative surgical procedures or a switch from a 2D to a new 3D diagnostic modality. 
Learning effects arise because initially clinical personnel involved in a new and complex 
procedure will perform suboptimal. This suboptimal performance will manifest itself in 
longer procedure times, higher complication rates, and lower quality of life outcomes 
and survival rates for patients, as compared to the performance of the innovation 
when the learning curve has reached a plateau. As the alternative intervention (usual 
care) is usually free of any learning effects, not correcting for learning can lead to 
an inaccurate estimation of the incremental cost-effectiveness of the innovation. A 
well-known example is laparoscopic surgery, in which learning tends to exert a large 
influence on the results of clinical trials [4]. For example, Broeders et al. studied the 
impact of surgeon experience on 5-year outcome of laparoscopic Nissen fundoplication 
(LNF) for gastro-oesophageal reflux disease [5]. This study found a significant decrease 
in operating time, in-hospital complications, early dysphagia, and conversions from 
laparoscopic to conventional surgery. Here the impact of learning on trial outcomes 
and its consequences can be directly related to the original randomized controlled trial 
(RCT) which was prematurely terminated because LNF was associated with a higher risk 
to develop dysphagia [6]. The study of Broeders confirmed the criticism on the RCT that 
not taking into account learning had introduced bias causing inferior outcomes for the 
laparoscopic treatment arm.
Capacity constraints
When substituting one intervention for another, it is often assumed that the old 
intervention can be scaled down at the decision maker’s own discretion or be fully 
replaced without suffering financial losses due to excess capacity [7]. This is however 
dependent on the rate of implementation and whether the technology is divisible. 
When an innovation is rapidly implemented, not all resources of the old intervention 
can immediately be freed up to finance the innovation. For example, medical equipment 
not yet written off (e.g. older generation CT scanners) decrease the anticipated savings 
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in the short run [8]. On the other hand, when implementation commences in a more 
gradual fashion, for example due to organizational and infrastructural changes that need 
to be made, the innovation may not have enough capacity to supply all patients. This 
results in the need to keep the old and relatively inefficient intervention operational 
throughout the implementation period, resulting in both diseconomies of scale and 
the health care provider not reaping the full benefits of the new and more cost-
effective intervention. An illustrative example is the conversion from analog screen film 
mammography to digital mammography, which is a process that takes place in a gradual 
manner as the technological substitution takes place on a nationwide level [9]. 
Delayed time to benefit
Even when implementation of an innovation is optimal, a clinically meaningful therapeutic 
effect is not guaranteed to be immediately present. An example are statins, for which 
‘time to benefit’ has emerged as a useful concept to assess efficacy in specific settings 
over varying periods of time [10]. For example, treatments that lower LDL cholesterol 
in patients with coronary artery disease reduce these LDL levels dramatically within 
months. However, an actual reduction in angiographic disease progression may require 
three years [11, 12]. This has obvious implications for cost-effectiveness analysis where 
the main focus lies on final outcome measures such as quality of life and mortality. For 
innovations with long time to benefit on these outcome measures, cost-effectiveness 
will be underestimated during the evaluation period. 
Consequences of biased cost-effectiveness outcomes
The failure to address the short run – long run discrepancy in standard CEA can have 
important consequences. Most decision makers and funders tend to focus on short term 
results and demand these results on short notice [13]. This myopic attitude reduces the 
length of trial periods and outcome measurements. As short run inefficiencies are most 
prevalent and impactful during an innovation’s earliest stage of operation, reducing the 
length of evaluation periods will result in cost-effectiveness outcomes being biased even 
more against the innovation. This might lead to outcomes that seriously underestimate 
the cost-effectiveness of a new intervention in the short run, potentially resulting in 
second thoughts about the implementation of an in essence cost-effective innovation. 
Worst-case scenario is that such a ‘lag time bias’ in cost-effectiveness analysis will result 
in denying patients access to more efficient health care. Of course the opposite may 
also be true, in the sense that cost-effectiveness will decrease later on, for example by 
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extending the indication to other patient groups with less benefit. This is for example 
suspected in the recent case of transcatheter aortic valve replacement, but as far as we 
know, it has not been demonstrated in cost-effectiveness data [14]. 
Careful health technology assessment (HTA) of new medical interventions is increasingly 
important and more and more considered as obligatory for further implementation and 
reimbursement of health care innovations. We argue that the combination of a myopic 
focus of decision makers and the discrepancy between study outcomes and long term 
(steady state) cost-effectiveness of an innovation can lead to misguided decisions about 
the implementation of innovations in health care. The role of short run inefficiencies 
in the evaluation of an innovation offers ample opportunities for further research. We 
therefore urge policy makers and researchers to expand research in this important, but 
relatively neglected topic. HTA studies that blindly extrapolate short term outcomes 
may fail to deliver good estimates of cost-effectiveness, often underestimating the 
real effects of an innovation. Therefore we advocate to carefully take into account 
the different factors that may cause this lag time bias in the design and analysis of 
cost-effectiveness studies. We propose to ask some critical questions to professionals 
involved, before taking the short way to erroneous HTA results.
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Abstract
Cost-effectiveness analysis has become a widely accepted tool for decision making in 
health care. The standard textbook cost-effectiveness analysis focuses on whether to 
make the switch from an old or common practice technology to an innovative technology, 
and in doing so it takes a global perspective. In this paper we are interested in a local 
perspective, and we look at the questions of whether and when the switch from old to 
new should be made. We propose a new approach to cost-effectiveness from a local 
(e.g. a hospital) perspective, by means of a mathematical model for cost-effectiveness 
that explicitly incorporates time. We derive a decision rule for establishing whether a 
new technology should be adopted, as well as a general rule for establishing when it 
pays to postpone adoption by one more period, and a set of decision rules that can be 
used to determine the optimal timing of adoption. Finally we present an example that 
illustrates our model and how it leads to optimal decision making in a number of cases.
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Introduction
Cost-effectiveness analysis (CEA) as part of the evaluation of medical innovations has 
become well accepted in several European countries and in the US. Several Western 
countries have adopted cost-effectiveness analysis in their guidelines for reimbursement. 
Health economics has devoted a considerable proportion of its research effort to the 
theory and practice of economic evaluation in health care. Economic evaluation in 
health care is usually effectuated by the cost-effectiveness analysis. This method seems 
presently well established [1-3]. However, traditional CEA usually takes a global (i.e. 
societal or healthcare) perspective, rather than a local perspective (e.g. a hospital). 
Moreover, the standard textbook economic evaluation only focuses on whether to 
make the switch from an old technology to a new technology, and it does not give 
any guidance for deciding when to make the switch from old to new. CEA is usually 
used in the context of deciding to add an innovation to the benefit package, so that 
a societal or healthcare perspective is appropriate, and the when question does not 
seem particularly relevant. This when question is more applicable to a local health care 
provider deciding on the optimal adoption pathway for the new innovation, i.e. a local 
perspective. Suppose a (traditional) CEA finds that (on average) a new health technology 
has superior cost-effectiveness over an old technology from a global perspective. 
This does not necessarily imply that the new health technology will indeed be cost-
effective for each individual health care provider. Moreover, even if it is cost-effective 
on a local level and the decision is in fact made to replace the old technology with 
the new technology, then the question would arise when the new technology should 
be adopted. It makes sense that the traditional CEA does not try to answer the when 
question, since the answer to this question will likely depend very much on the specifics 
of a local health care provider. In this paper we distinguish three questions that should 
be answered before adopting a new technology in a certain local setting: 
1. From a global perspective the question should be answered whether the new 
technology is on average cost-effective, and thus whether the new technology 
should be rolled out. 
2. If the answer to the first question is yes, then the question whether the new 
technology should be adopted in a particular local setting should be answered.
3. If the answer to the second question is also yes, then the question when the new 
technology should be adopted in a particular local setting should be answered.
Standard textbook CEA can be used to answer the first question (and perhaps the 
second, but not the third), the current paper allows for answering questions 2 and 3. 
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In order to make the best use of the different hospitals’ given resources and starting 
positions, third party payers may also be interested in thinking about which hospital 
should adopt the new technology first, which hospitals should follow later, and which 
hospitals should not adopt the new technology at all. For instance, for some hospitals 
the demand for a certain technology may not be large enough to justify the investment 
costs, and in some hospitals the machinery that is used for the old technology may 
simply need to be replaced earlier than in other hospitals. In a competing health care 
environment, insurance companies will have incentives to contract more efficient 
providers. Our approach attempts to link these perspectives, making the method of 
cost-effectiveness analysis more relevant to a broader audience. 
In this paper we specifically have health technologies in mind that employ machineries 
involving substantial fixed costs, such as for example diagnostic devices or operation 
robots. These types of health technologies will thus only be usable for a limited 
period of time, the economic life. Therefore, our model does not apply to health 
technologies that do not involve an economic life and substantial fixed costs, such as 
most pharmaceuticals. 
When deciding on immediate versus delayed adoption, one could reason in two 
directions. Firstly, one could argue that it would be best to adopt directly in order to 
reap the additional benefits of the new technology as soon as possible. Alternatively, 
one could argue that it would be better to use up the old technology first, and thus to 
postpone adoption until the end of the economic life of the old technology. Indeed, 
these two types of considerations may be seen to reflect two opposing forces, and in 
any particular situation the question arises which of these forces will dominate. And 
there may even be cases where neither of these two views are leading us straight to an 
optimal solution, and where the two forces will keep each other balanced and lead to 
an intermediate optimum. 
In this paper we will provide a mathematical model to deal with such considerations in 
a quantitative manner, which may be used to determine the optimal timing of adoption 
for a new technology. Moreover, our model can also be used to investigate whether 
a new technology is cost-effective on a local level in the first place. An outline will be 
presented in the main text, the (mathematical) details can be found in the appendix. 
Thus, we aim to link the standard textbook economic evaluation to local health care 
provider decision making. 
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     Enew - Eold
Our approach may seem reminiscent of the real options approach to economic 
evaluation [4-6], since both deal with delaying adoption. However, there are important 
differences between the two approaches. First of all, unlike our approach, the real 
options approach takes a global perspective. In a real options framework (in the context 
of cost-effectiveness analysis) there is uncertainty about the NMB or ICER that will 
result when the new technology would indeed be implemented, and there is the ability 
to delay so that additional information will be obtained and the uncertainty around the 
NMB or ICER will decrease. The decision rule applied in the real options approach is: 
if an option value of delay outweighs costs of delaying, then it will be optimal to delay 
the decision rather than adopt [6]. Therefore, although in the real options approach 
there is the possibility to postpone adoption, cost-effectiveness is not inherently time-
dependent: the only difference between different adoption times is in the information 
and the uncertainty about the new technology when it will eventually be implemented. 
This is in contrast with our approach, which is truly intertemporal: some moments of 
adoption will inherently be more favorable than others, independent of uncertainty or 
additional information. In fact, our approach does not even deal with uncertainty, our 
model is (currently) deterministic; therefore the reasons for delaying will have nothing 
to do with obtaining additional information in the future, but rather with the fact that 
for some local health care providers quick implementation of a new technology will be 
beneficial whereas for others postponing switching technologies will be better.
The current paper represents a first step in a new direction. We have tried to emphasize 
the main idea and kept the model structure relatively simple. This paper is not intended 
to provide a definitive model, but rather to provide a new way to think about these 
issues and to serve as a starting place for further research.
The standard CEA framework 
Decision making on whether or not to adopt a new technology in health care is 
determined (or at least influenced) by the outcome of a cost-effectiveness analysis. 
Usually the cost-effectiveness is expressed in terms of the costs for the new and the old 
technologies Cnew and Cold and their effects Enew and Eold. From these, the incremental 
cost-effectiveness ratio (ICER) can be calculated, and the resulting decision rule can be 
stated as
     < λ, 
     Cnew - Cold
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where λ is the cost-effectiveness threshold. By some simple calculus this decision rule 
can be rewritten as λ (Enew - Eold) - (Cnew - Cold) > 0. In the left hand side of this equation we 
recognize the incremental net benefit INB which is the difference of the net monetary 
benefits in the new and the old situations, 
  INB = ∆NMB = NMBnew - NMBold = (λEnew - Cnew) - (λEold - Cold)
The decision rule that follows is
  if INB > 0 choose new project, if INB < 0 choose old project
Above we see the standard approach to economic evaluation in health care, and we 
can see that none of the underlying variables explicitly depends on time. Of course, the 
cost and effect variables are determined with respect to a certain evaluation period. 
However, this period will generally be chosen so that it will be long enough to give good 
estimates of the long run behavior of the two technologies.  Therefore, traditional cost-
effectiveness analysis essentially compares the long run or steady state net monetary 
benefits of the old and the new technologies. Moreover, traditional CEA usually takes a 
global (i.e. societal or healthcare) perspective.
Incorporating the timing of adoption into the CEA framework
In what follows we will use a local perspective and we are not only interested in what 
happens in the long run, but also in the short run. Therefore we will explicitly model 
time by means of a discrete time variable t. Suppose that a new technology is available 
and that it has an economic life of S periods, resulting in a stream of S net monetary 
benefits (NMBnew_0, NMBnew_1,…, NMBnew_S-1). The new technology may be adopted in 
any period, so it is important to note that NMBnew_0 need not necessarily be obtained 
in period 0; it refers to the new technology’s NMB in the first period of a stream for the 
old technology. Similarly, the old technology has an economic life of T periods , which 
would result in a stream of T net monetary benefits (NMBold_0, NMBold_1,…, NMBold_T-1). 
Here the same thing applies: NMBold_0 refers to the NMB in the first period of its 
economic life. For both the old and the new technology, each of these net monetary 
benefits is of the form NMBt = λEt - Ct, so that it captures all the costs and effects relevant 
to the technology. Contrary to the traditional setup, these costs and effects (and thus 
the NMBs) are time-dependent. This would for example allow for modeling a learning 
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curve on the effect side [7]. On the cost side this would allow for modeling variations 
due to phenomena like increasing maintenance costs for older pieces of machinery or 
periodic maintenance costs [7]. 
On whether to switch
First we will look at the whether question: should the new technology be adopted at 
all, is it cost-effective? To answer this question, there are two difficulties that we have 
to deal with: 1) evaluating streams of NMBs, for which the elements will be obtained at 
different points in time, and 2) evaluating streams with different lengths (since S need 
not equal T). The first issue can simply be resolved by accounting for time preference by 
using a discount factor [8]. That is, a benefit NMBold_t (or similarly for an NMBnew), when 
incurred in period t, will be discounted to period-0 terms through NMBold_t/δ
t, with δ > 1. 
After discounting all these discounted NMBs are comparable and can simply be added. 
As for the second issue, it seems obvious that comparing streams of different lengths 
is not a good idea. It would be possible to simply truncate both streams at some fixed 
moment in time, however it would seem arbitrary at which point these streams should 
be truncated. Instead, we have applied an idea from the capital budgeting literature 
[9-13], of simply extending the streams of NMBs infinitely into the future. That is, we 
assume that whenever the economic life of a technology is over, it will be replicated over 
and over again.  Thus, (infinite) streams of benefits will result. Of course this assumption 
of ad infinitum replication will not provide a realistic description of what will happen 
after adoption of the new technology. We adopt it here because it will allow us a fair 
and relatively simple way to compare streams with different lengths. We will elaborate 
on this in the discussion. 
Such an infinite stream of NMBs will be evaluated by means of the net present value: 
the sum of discounted (to period-0 terms) NMBs from this stream. By NPVnew we will 
denote the net present value of the new technology, when it is adopted in period 0 and 
extended infinitely,  and similarly for the old technology. In order to arrive at a formula 
for NPVnew, we will start with determining NPVnew_1, the net present value from the first 
cycle of the new technology, when adopted in period 0. In this case, the stream of benefits 
from one cycle of the new technology (NMBnew_0, NMBnew_1, NMBnew_2, …, NMBnew_S-1) 
is obtained in periods 0 through S-1, and would yield a net present value of:
         (1)
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The net present values from the second and later cycles of the new technology will 
result from the same stream of NMBs, except that it will be obtained in later periods 
and thus discounted more heavily.  It can be shown (see the appendix) that the infinite 
sum of discounted NPVs from all the cycles of the new technology will be:
         (2)
Of course, for the old technology a similar equation will hold:
         
where NPVold_1 = ∑t = 0 NMBold_t δ
t.
Because of the ad infinitum assumption the magnitudes of the NPVs will not be 
meaningful by themselves. What matters for decision making however, is which NPV is 
highest. Thus, the absolute numbers are not informative but the relative positions are, 
and these relative positions provide an accurate decision rule on when to adopt. Thus 
we are now ready to provide a decision rule for the whether decision:
 if NPVnew > NPVold            then adopt the new technology 
 if NPVnew ≤ NPVold      then do not adopt the new technology
On when to switch
Now, we turn to the when question: if it is optimal to adopt the new technology, when 
should the switch to the new technology in fact be undertaken? To answer this question, 
it is necessary to evaluate mixed streams of NMBs: streams that start with NMBs from 
the old technology and that end with NMBs from the new technology. 
Suppose that at t = 0 the old technology is already in place, and that at t = 0 the first T’ 
periods of a cycle have passed already. That is, the existing technology could maximally 
be used for another T - T’ periods, in which case it would result in a stream of net 
monetary benefits (NMB
old_T’+1
,NMB
old_T’+2
, …, NMBold_T-1). For simplicity of notation, let’s 
denote this stream instead as (NMBold_0, NMBold_1, …, NMBold_T̃) from now on. Note that 
(contrary to what we saw in the previous section) now NMBold_t)̃ will always be incurred 
in period t. Of course, the above stream will only be obtained if the old technology 
will in fact be operational until period T̃. If instead the new technology is adopted in 
an earlier period t’ < T̃, then the above stream of benefits is truncated at period t’ - 1. 
T = 1
{
̃ ̃
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Once the old technology’s economic life is over, there would certainly be no reason to 
reinvest in the old technology as the new technology is more cost-effective, so that the 
new technology will surely be adopted in period T̃ + 1 at the latest. Therefore T̃ + 1 is 
also the last switching time that we need to consider here. Figure 1 depicts the resulting 
streams of NMBs for all possible adoption times in an example where T = 3 and S = 4. 
Thus the question that arises is at what time the switch from old to new technology 
should be made. To answer this question we will once again look at (short term) cost-
effectiveness; which switching time will yield the highest total net monetary benefits?  
The cost structure for the old technology should exclusively consist of elements that 
will only be incurred in case this technology is still operating. That is, in our model it is 
possible to truncate the stream of NMBs for the old technology. Therefore, any costs 
that will have to be paid after period 0, irrespective of when the new technology is 
adopted, should be excluded from the cost structure of the old technology. These costs 
should be considered sunk, which is justified, since they have to be paid anyway, no 
matter what decision is taken (to start immediately or postpone). Therefore they will 
have no bearing on which decision is optimal [8]. Here we extend the use of the term 
net present value to mixed streams of NMBs as well. We write NPVt to denote the 
total (summed) discounted net monetary benefits that will result (in period t = 0 and 
later) when the switch from the old to the new technology is made at time t. Then, the 
question is which adoption time t* will yield the highest net present value, and would 
thus be the optimal choice. For NPV0 the new technology is adopted immediately in 
period 0, so we find that NPV0 = NPV
new.
We will now outline how the other NPVs can be calculated from the NMBs and the 
discount rate (for more details, see the appendix). If we compare the stream of benefits 
resulting from direct adoption and switching from old to new in period 1 (see figure 
1), then we see two differences. Firstly, the entire stream of benefits that would result 
under direct adoption will also be obtained when switching at t = 1, except that this 
stream (corresponding to the new technology only) will now be shifted forward by one 
period. And secondly, when switching at t = 1, NMB
old_0̃
 will additionally be obtained in 
period 0. It can be seen (see the appendix) that the net present values that will result 
from adoption in period 1 and in period 0 are related by:
         (3)
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This equation can be understood from the two differences between direct adoption 
and adoption at time 1 that were mentioned above, and from the fact that under 
exponential discounting a delay of 1 period always yields a difference in discounting of 
exactly 1/δ. Some simple calculus leads to the following criterion for when adoption at 
t=1 is more beneficial than direct adoption: 
          (4)
Similarly, if the switch from old to new is made in period 0 < t’ ≤ T̃, it can be seen that 
(see the appendix) the net present value that will be attained will be:
         (5)
Therefore, when comparing adoption in period t’ to adoption in period t’ + 1 we see 
similar changes. There would be no differences in the streams of benefits in periods 0 
through t’ - 1. However, under adoption in period t’ + 1 an additional benefit NMB
old_t’̃ 
would be obtained from the old technology. Also, the stream of benefits and costs from 
the new technology will be shifted forward a period, so that the  new technology’s total 
discounted benefits and costs will decrease by a factor (1 -    ). In mathematical terms, 
we can see that (see the appendix):
As in equation 2 we now see the appearance of a general rule:
         (6)
Figure 1 The configurations of per period NMBs for the old and the new technology over time, for 4 
different adoption periods.
δ
1
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This translates as: 
It pays to postpone adoption of the new technology by one more period if the gain of 
the additional net monetary benefit from the old technology due to this postponement 
outweighs the loss due to discounting the benefits of the new technology more heavily. 
And vice versa, postponing the adoption of the new technology by one more period is 
not beneficial if the net monetary benefit that will be obtained from the old technology 
in the corresponding period is smaller than the loss due to the delay of the effects of the 
new technology.
In the appendix an actual decision rule is provided for determining the optimal 
switching time, based on the above implications. The appendix will also provide more 
mathematically precise definitions and proofs of the above statements.
 
An illustration of the model
To illustrate our model we present the following simple example. Let’s consider two 
technologies, an old technology and a new technology. For both technologies the 
stream of effects and costs are displayed in table 1. 
For the old technology the pattern of effects is constant, as it is for costs, except for 
initial investment costs and increasing maintenance costs in the final two periods. For 
the new technology the cost structure exhibits additional periodical maintenance costs 
in the fourth period and investment costs in period 0, but on  the effect side we see 
that due to learning the initial effects are smaller. For three different values of λ, the 
resulting patterns of NMBs are also provided in table 1. NMBs are discounted by 5% 
every period, so that δ = 1.05. 
Table 1. Per period costs (in Euros), effects and the resulting Net Monetary Benefits for the old and the new 
technology. NMBs are calculated for three scenarios: (1) λ = 50,000, (2) λ = 120,000, and (3) λ = 25,000.
period Cold Eold NMBold
(1)
NMBold
(2)
NMBold
(3)
Cnew Enew NMBnew
(1)
NMBnew
(2)
NMBnew
(3)
0 22200 0.64 9800 54600 -6200 24000 0.63 7500 51600 -8250
1 7200 0.64 24800 69600 8800 7000 0.66 26000 72200 9500
2 7200 0.64 24800 69600 8800 7000 0.68 27000 74600 10000
3 7200 0.64 24800 69600 8800 7200 0.68 26800 74400 9800
4 7200 0.64 24800 69600 8800 7000 0.68 27000 74600 10000
5 8800 0.64 23200 68000 7200 7000 0.68 27000 74600 10000
6 8800 0.64 23200 68000 7200
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First we look at case (1), where λ = 50,000. For the old  technology using equation (1) we 
get for the first cycle NPVold_1 = (9800 +            +           +            +            +           +      
133,230 and using equation (2), over all cycles combined we get a total net present 
value of
   NPVold =   = 460,494.
Similarly, for the new project we get for the first cycle
 NPVnew_1 = (7500 +           +            +           +            +          )=123,271
and we get a total net present value of NPVnew =                 = 485,730. Thus, we see that 
the new technology is more cost-effective than the old, and that it would be optimal to 
eventually adopt the new technology.
Now we look at the when question. Suppose that at time 0 (when the decision on 
whether and when to adopt the new technology is faced) the old technology is already 
in place. That is, at time 0 a cycle of the old technology is already underway, and four 
more periods of this cycle remain. In table 1 this is indicated by the shading of the first 
three periods. Direct adoption of the new technology will yield NPV0 = NPV
new = 485,730. 
Using equation 3 it can be seen that postponement of adoption of the new project 
for 1 period results in a net present value of NPV1 = 24,800 +           = 487,400. And 
similarly, using equation 4, we can see that postponement of adoption for 2, 3 and 4 
periods yields NPV2 = 24,800 +               +          = 488,990, NPV3 = 24,800 + 
              +               +   = 488,905, and NPV4 = 24,800 +           +           +           + 
= 488,824 respectively. Obviously then, it is most beneficial for the health care provider 
to switch to the new technology at time t = 2. 
In the type of decision problems that we are studying in this article, the question is 
always which of the two effects dominate: (1) the desire to reap the new technology’s 
benefits as soon as possible or (2) the desire to postpone the investment costs of the 
new technology as long as possible. Apparently, in the present case the two forces 
balance out at time t = 2. 
Now we modify our example by  using a larger cost-effectiveness threshold λ = 120,000. 
The resulting NMBs are displayed in table 1 as case (2). Repeating all the calculations, 
we get NPVold = 1,401,294 and NPVnew = 1,466,285, so that it is optimal to eventually 
  1.05        1.052           1.053             1.054             1.055        
24800     24800     24800     24800     23200     23200
) =1.056
133,230
1 - 1⁄1.057 
26000     27000     26800     27000     27000  
  1.05        1.052           1.053             1.054             1.055       
123,271
1 - 1⁄1.056 
485,730
1 - 1⁄1.05 
24,800        485,730
   1.05            1.052 
24,800         23,200       485,730                   24,800    23,200   23,200   485,730 
   1.05            1.052          1.053                                           1.05        1.052     1.053          1.054
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adopt the new technology. As for the when question, we get that NPV0 = 1,466,285, 
NPV1 = 1,466,062, NPV2 = 1,465,849, NPV3 = 1,464,047 and NPV4 = 1,462,330, so that 
direct implementation is optimal. Instead, λ = 25,000 (which is case (3) from table 1), 
would yield NPVold = 124,494 and NPVnew = 135,532, so that the new technology is still 
more cost-effective. For the timing of adoption, we get that NPV0 = 135,532, NPV1 = 
137,878, NPV2 = 140,112, NPV3 = 140,640 and NPV4 = 141,143, so that in this case it 
would be optimal to postpone adoption as long as possible. In this case, (1 -    ) ∙ NPV0 
would become 6,454, which is smaller than NMBold in all periods, and the general 
rule from the previous section indeed implies that in this case it would be optimal to 
postpone adoption as long as possible.
Discussion
Our proposed new modeling approach bridges the gap between the standard textbook 
approach and locally-based cost-effectiveness, answering both the questions whether 
and when to adopt a new technology. In order to use our model in practice, what would 
be needed is time-dependent data on costs and effects. Typically, published CEAs do not 
present such data, they only provide data that are averaged over the entire duration of 
the study. However, if the raw data from a CEA would be rich enough, then it would be 
possible to derive the time-dependent information that can be used in our model [7]. 
Still, even then a trial will not provide all the information needed for our model. For 
instance, the economic lives of the technologies will be needed. Moreover, a trial will 
typically not last long enough to document a whole cycle of the new technology [7] 
or the end of the life of the old technology. Therefore, such trial data will have to be 
supplemented with additional information, such as more detailed data about the cost 
structures which could be supplied by the financial department of the hospital under 
consideration. 
A few assumptions that underlie our model merit discussion. Firstly, in its current 
form our model is deterministic, so that all the model components are supposed to be 
certain. This assumption is obviously not realistic. Of course, a probabilistic extension of 
our model would certainly be possible and could be the topic of future research. 
Also, as mentioned before, the assumption of constant replication ad infinitum will not 
provide a realistic picture of what will happen after adoption of the new technology.  This 
infinite replication is in fact hypothetical, and it is simply a computational tool that we 
borrowed from the capital budgeting literature [9-13]  to help us deal with projects that 
485,730
1 - 1⁄1.05 
1
δ 
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end at different points in time. In practice it is far more likely (if not certain) that at some 
point in the future the ‘new’ technology will itself be replaced by a ‘newer’ technology. 
If and when that happens, the time streams of costs and benefits associated with the 
‘new’ technology will abruptly stop. A situation like that could also be modeled, but 
it seems to especially make sense in a probabilistic setting as in practice one usually 
wouldn’t know when exactly the ‘newer’ technology will arrive on the scene. 
Our model assumes a discount factor that is constant over time and that is the same 
for costs and effects. This assumption could be relaxed in two ways: by allowing for 
separate discount factors for costs and effects, and by allowing for non-constant time 
discounting. Allowing for separate discount factors for costs and effects would certainly 
be a possibility, but this would require more notation, and make the equations more 
complex. For simplicity and clarity of exposition the model presented here works with 
equal discount rates for costs and effects. Under the alternative assumption of unequal 
discount rates for costs and effects the mathematics and the conclusions of the model 
would be similar. Moreover, it can be seen that this alternative assumption would lead 
to an interesting conclusion: if the discount factor for effects would be smaller than the 
discount factor for costs (a common assumption) then this would make postponing less 
likely to be beneficial than under equal discounting. Extending the model to allow for 
non-constant time discounting would also be possible, but this would certainly be much 
more difficult. In fact, in our approach it is exactly the constant discount rate that makes 
the model tractable, so relaxing this assumption would seriously complicate matters. 
Given the tentative nature of this paper, we have opted for simplicity, and thus for a 
discount rate that is common to both costs and effects and that is constant over time. 
Alternative assumptions could be the topic of future research.
Our model does not account for resale value of the replaced old technology. Modeling 
this would be possible, but it would complicate the model. Therefore in our model 
we assume the resale value to be zero. This seems a reasonable approximation, as 
machineries for health technologies are very sector specific, and given the appearance 
of a new and more cost-effective technology there will most likely be very little demand 
for the infrastructure of the old technology (perhaps except for countries that are much 
less developed, so that the resale value minus transportation cost are unlikely to be 
substantial).
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Finally, it is important to mention here that we acknowledge the fact that stakeholders 
such as patient organizations, politicians, health care professionals and local health 
care managers also attach importance to other factors besides efficiency. Of course, 
these matters are not and should not be decided upon solely on economic grounds. 
Nonetheless, we think that if a cost-effectiveness model does a better job of reflecting 
the actual decision problems that are faced by health care policy makers,  then its 
outcomes and recommendations will be more valuable and reliable, and it becomes 
more likely that these recommendations will in fact be considered in actual health care 
decision making.
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Methodological appendix
In this section we will provide the technical details of our model. We start with a discrete 
time variable t which runs through the set of periods {0, 1, 2, 3, …}. A new technology is 
available and has an economic life of S periods, resulting in a stream of S net monetary 
benefits (NMBnew_0, NMBnew_1, …, NMBnew_S-1). The new technology may be adopted in 
any period, so it is important to note that NMBnew_0 need not necessarily be obtained 
in period 0; it refers to the new technology’s NMB in the first period of a stream for the 
old technology. The existing technology has an economic life of T periods , which  would 
result in a stream of T net monetary benefits (NMBold_0,NMBold_1, …, NMBold_T-1). Here the 
same thing applies: NMBold_0 refers to the first NMB after adoption.  
On whether to switch
First we will look at the question whether to adopt the new technology. To answer this 
question, we make two assumptions: accounting for time preference by means of a 
discount factor in order to evaluate streams of NMBs, and extending the streams of 
NMBs infinitely into the future in order to be able to evaluate streams with different 
lengths (for more explanation on both issues, see the main text). Thus, (infinite) streams 
of benefits will result.
Such a stream of NMBs will be evaluated by means of the net present value: the sum 
of discounted (to period-0 terms) NMBs from this stream. By NPVnew we will denote the 
net present value of the new technology, when it is adopted in period 0 and extended 
infinitely,  and similarly for the old technology. In order to arrive at a formula for NPVnew, 
we will start with determining NPVnew_1, the net present value from the first cycle of the 
new technology, when adopted in period 0. In this case, the stream of benefits from one 
cycle of the new technology (NMBnew_0, NMBnew_1, NMBnew_2, …, NMBnew_S-1) is obtained in 
periods 0 through S - 1, and would yield a net present value of: 
The next step is to determine NPVnew_2 the net present value from the second cycle 
of the new technology. In this case, the stream (NMBnew_0, NMBnew_1, …, NMBnew_S-1) 
resulting from one cycle of the new technology will be obtained between periods S and 
2S-1 (rather than periods 0 through S-1). In the above case, for determining NPVnew_1, 
this stream of benefits minus  costs was paired with the vector (     ,      ,...,       ) for time 
discounting. However, for NPVnew_2 the same stream will result, but all elements are 
 1      1            1
δ0      δ1             δS-1     
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obtained S periods later, and it will be paired with the vector (     ,       ,...,        ) =        ∙
(     ,       ,...,         ) for time discounting to period-0 terms. Therefore, the net present value 
of the second cycle of the new technology will simply be given by NPVnew_2 =        ∙ NPVnew_1. 
Likewise, for the third cycle of the new technology, the net present value will become 
      ∙ NPVnew_1), etcetera. Thus, if the new technology is adopted in period 0 and extended 
infinitely, the total net present value that will be attained will be:
(Here the last equality uses the mathematical property that for 0 < x < 1 it holds that 
∑i=0 x
i = 1⁄
(1-x)
. To see this, note that (1-x) ∙ ∑i=0 x
i = ∑i=0 x
i - ∑i=0 x
i+1 = ∑i=0 x
i - ∑i=1 x
i = x0 = 1.) 
This proves formula 2 from the main text.
For the old technology a similar equation will hold: 
   NPVold = 
where NPVold_1 = ∑t=0 NMBold_t) ⁄ δ
t. 
Therefore, the decision rule for the whether decision reads:
 if NPVnew > NPVold               then adopt the new technology
 if NPVnew ≤ NPVold      then do not adopt the new technology 
On when to switch
Then, we turn to the when question: if it is optimal to adopt the new technology, when 
should the switch to the new technology in fact be undertaken? To answer this question, 
it is necessary to evaluate mixed streams of NMBs: streams that start with NMBs from 
the old technology and that end with NMBs from the new technology. We assume that 
at t = 0 the old technology is already in place, and that at t = 0 the first T’ periods of a 
cycle have passed already. That is, the existing technology could maximally be used for 
another T-T’ periods, in which case it would result in a stream of net monetary benefits 
(NMB
old_T’+1
, NMB
old_T’+2
, …, NMBold_T-1). From now on, let’s denote this stream instead as 
(NMBold_0,NMBold_1, …,NMBold_T̃). Now (contrary to what we saw in the previous section) 
NMBold_t ̃will always be incurred in period t. If the old technology will not be operational 
until period T̃, but instead the new technology is adopted in period t’ < T̃, then the above 
stream of benefits is truncated at period t’ - 1. Since the new technology will eventually 
 1      1            1              1
δS    δS+1           δ2S-1             δS 1     1            1          
δ0    δ1             δS-1 1
δS 
1
δ2S 
∞                    ∞            ∞           ∞               ∞           ∞
NPVold_1
1-1 ⁄ δT 
T-1
{
̃̃
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be adopted, T̃ is the last switching time that we consider. By NPV
t’
 we denote the net 
present value of the stream of net monetary benefits that starts with NMBs for the old 
technology and that switches to NMBs for the new technology in period t’. For NPV0 the new 
technology is adopted right away in period 0, so we find that NPV0 = NPV
new. For NPV1 the 
stream of NMBs will be (NMB
old_0̃
, NMBnew_0, NMBnew_1, NMBnew_2, …). Figure 1 in the  main 
text  depicts the resulting streams of NMBs for all possible adoption times in an example 
where T̃ = 3 and S = 4. If we compare the stream of benefits resulting from direct adoption 
and switching from old to new in period 1, then we see two differences. Firstly, the entire 
stream of benefits that would result under direct adoption will also be obtained when 
switching at t = 1, except that this stream (corresponding to the new technology only) 
will now be shifted forward by one period. And secondly, when switching at t = 1 NMBold_0 
will additionally be obtained in period 0. Therefore, the relation between NPV_1, the 
net present value that will result from adoption in period 1, and NPV0 from formula 3 
from the main text can be seen to hold by some simple rearranging:
This equation uses the fact that under exponential discounting a delay of 1 period 
always yields a difference in discounting of exactly    . We can see when it pays to 
postpone adoption of the new technology from period 0 until period 1 by comparing 
NPV1 and NPV0:
This proves the equivalence in formula 4.
Similarly, if the switch from old to new is made in period 0 < τ̃ ≤ T̃, then the net present 
value that will be attained will be:
This proves equation 5 from the main text. 
1
δ 
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And when we consider a postponement of adoption from period τ̃ until period τ̃ + 1, we get 
This proves equation 6 from the main text. 
Also note that all of the above equations will still hold if all of the ≥ signs are replaced 
by ≤ signs (in fact, all ≥ signs could be replaced by ≤ signs, by > signs, by < signs or by = 
signs, and all of the implications would still hold). Thus, for all 0 ≤ τ̃ ≤ T̃ we also get that 
NPV
τ̃+1
 ≤ NPV
τ̃
 = NMB
old_τ̃
 ≤ (1 -     ) ∙ NPV0.
The above implications can now be used to make inferences about the optimal switching 
time. We will distinguish a number of cases, depending on whether the NMBs that will 
accrue from the old technology will be larger or smaller than the threshold (1 -    )∙ 
NPV0. And for each case we will provide some simple decision rules with respect to the 
optimal choice of τ̃* (which we use to denote the first period in which to operate the 
new technology).
 I.  If NMB
old_τ̃
 ≥ (1 -     ) ∙ NPV0 for all τ̃, then τ̃
* = T̃.
 II. If NMB
old_τ̃
 ≤ (1 -     ) ∙ NPV0 for all τ̃, then τ̃
* = 0.
 
 III. If there exists some τ̃’ such that NMB
old_τ̃ 
≥ (1 - 1/δ) ∙ NPV0 for all τ̃ ≤ τ̃’
  and NMB
old_τ̃
 ≤ (1 -      ) ∙ NPV0 for all τ̃ > τ̃’, then τ̃
* = τ̃’ + 1.
 
 IV. If there exists some τ̃’ such that NMB
old_τ̃
 ≤ (1 -     ) ∙ NPV0 for all τ̃ ≤ τ̃’ 
  and NMB
old_τ̃
 ≥ (1 -     ) ∙ NPV0 for all τ̃ > τ̃’, then τ̃
* = 0 or τ̃* = T̃.
 V.  If there exist a τ̃’ and a τ̃’’ with 0 < τ̃’ < τ̃’’ < T̃ such that NMB
old_τ̃
 ≥ 
  (1 -     ) ∙ NPV0 for all τ̃ ≤ τ̃’ and all τ̃ > τ̃’’, and such that NMBold_τ̃ ≤ (1 -    ) ∙ 
  NPV0 for all τ̃’ < τ̃ ≤ τ̃’’, then τ̃
* = τ̃’ + 1 or τ̃* = T̃.
 
1
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1
δ 
1
δ 
1
δ 
1
δ 
1
δ 
1
δ 1
δ 
1
δ 
1
δ 
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 VI.  If there exist a τ̃’ and a τ̃’’ with 0 < τ̃’ < τ̃’’ < T̃ such that NMB
old_τ̃
 ≤ 
  (1 -    ) ∙ NPV0 for all τ̃ ≤ τ̃’ and all τ̃ > τ̃’’, and such that NMBold_τ̃ ≥ (1 -   ) ∙ 
  NPV0 for all τ̃’ < τ̃ ≤ τ̃’’, then τ̃
* = 0 or τ̃* = τ̃’’+ 1.
In case IV we do not provide an actual decision rule, but once we evaluate both NPV0 
and NPVT̃ we can see what the optimal switching time would be. In the same way 
optimal switching times can be found in cases V and VI. The above six cases are not 
exhaustive, but they are general enough to account for some straightforward patterns 
of net monetary benefits for the old technology. If NMB’s for the old technology are 
constant over all periods, then we are in case I or II (or both). Patterns of NMB’s for the 
old technology that are decreasing or increasing over time (e.g. linearly) could always 
be categorized as one of the first four cases: if the pattern of NMB’s does not cross the 
(1 -    ) ∙ NPV0 line then we are in cases I or II, if it does cross the(1 -    )∙NPV0 line we are in 
cases III or IV (see figure 1). A pattern of old technology NMB’s that first decreases and 
then increases (e.g. quadratically) can fall in cases I or II (if the pattern of NMB’s does 
not cross the (1 -     ) ∙ NPV0 line), in cases III or IV if the NMB’s cross the (1 -    ) ∙ NPV0 line 
once, and in case V if it crosses the line twice. A pattern of old technology NMB’s that 
first increases and then decreases can fall in cases I, II, III, IV or VI (again depending on 
how many times the pattern of NMB’s crosses the (1 -    ) ∙ NPV0 line).
As noted above, the present six cases are not exhaustive, since they do not incorporate 
patterns of NMB’s for the old technology that would cross the (1 -    ) ∙ NPV0 line more 
than two times. We do not provide explicit decision rules for such cases as there is no 
limit to the number of cases that would have to be considered, and since these decision 
rules would become increasingly complex. Moreover, although it is conceivable that 
such patterns would arise we think that it would be rather unlikely that we would come 
across such complex patterns. Nonetheless, one could proceed in a manner similar to 
that of the six cases for finding an optimal switching time. 
Figure 1 presents illustrations of Cases I (left), III (middle) and V (right). For each case, 
depicted are the pattern of NMB’s for the old technology and the (1 -    ) ∙ NPV0 line 
(above), and the resulting patterns of NPV’s (below), both as a function of t. The black 
dots depict the situation for the optimal switching time.
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7Figure 1 Graphical Illustration of Patterns of NMB and optimal switching time. 
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Abstract
Objectives:  Innovative point-of-care (POC) diagnostics are likely to have a strong impact 
on health care. The aim of this study is to conduct an early assessment of a point-of-care 
chip for the detection of a pathological deviation of the potassium levels in patients 
at increased risk, specifically in patients with heart failure (HF) requiring diuretics and 
ACE inhibitors that can both interfere with potassium levels, which may lead to serious 
clinical complications. This study also identifies the key factors that determine the 
success of the application under study.
Methods: A Markov health state transition model was developed representing the 
disease process. Model parameters were obtained from various literature sources and 
estimated using interviews and related data. Simulation was carried out for 60 cycles of 
1 month each. A discount rate of 3.5 % was used, both for costs and utilities. In order to 
assess uncertainty a probabilistic sensitivity analysis was carried out from which a cost-
effectiveness acceptability curve was derived. 
Results: For an anticipated number of 121 measurements per year with a cost of €16.60 
per chip, an incremental cost-effectiveness ratio (ICER) of 34,856 €/QALY was found. 
Sensitivity analysis revealed that the threshold for the costs per chip was €19.30 in 
order to maintain a positive net monetary benefit. Also, model results are very sensitive 
to the utility of hyperkalaemia and to the probability to develop severe hyperkalaemia
Conclusions: The question whether or not a POC chip to measure potassium 
concentrations in order to avoid a severe potassium imbalance is likely to be cost-
effective cannot be definitively answered with the information at our disposal. Further 
research should focus on HF patients at particularly high risk of severe life-threatening 
hyperkalaemia, for instance in the presence of significant renal dysfunction. It may be 
expected that the use of the chip in such patient populations may render this point-of-
care application very cost-effective.
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Introduction
Health Technology Assessment (HTA) was originally defined as “a policy research 
approach that examines the short- and long-term social consequences of the application 
or use of technology” [1]. Internationally different institutions have translated this 
definition to local contexts [2]. In this study the definition of the society for Health 
Technology Assessment International (HTAi) is used. HTAi defines HTA as “research-
based, practice-oriented assessments of relevant available knowledge on the direct 
and intended consequences of technologies, as well as the indirect and unintended 
consequences” [3]. 
Early assessment of a new technology is a difficult process in every kind of industry, 
but especially in the health care sector. This is because new technologies in this sector 
require extensive clinical trialing before they are approved, as well as the fact that 
this trialing is very difficult to perform without prototypes of the device or drug. As 
healthcare costs in many countries absorb a large part of the gross domestic product, 
early HTA receives increased attention from governments as well as industries [4, 5]. 
By identifying, in an early development stage, those health care technologies that are 
most likely to generate ‘value for money’, manufacturers can steer their R&D more 
effectively. Governments have an interest in early HTA to anticipate on future coverage 
and reimbursement decisions as well as for steering their innovation funds towards 
those areas of med tech development that are most likely to increase quality and 
decrease costs of care. 
An excellent candidate for early HTA is point-of-care (POC) testing. This way of testing 
clinically important parameters at or near the site of patient care is a relatively new 
approach in healthcare. Decrease in therapeutic turnaround time, unnecessary 
testing, and hospitalization, as well as improvement in measurement accuracy are 
advantages of such patient care [6]. By providing patients and healthcare professionals 
the possibility of performing decentralized measurements and even self-monitoring, 
quality of life can be increased and costs can be reduced at the same time [7-9]. Park 
and Kricka [10] previously pointed out that POC testing, although taking advantage from 
rapid technological advances in the field, faces challenges during the implementation 
in the clinical environment. In fact, not only safety and user-friendliness of the new 
technology, but also health insurance issues and social acceptance codetermine the 
success of POC applications [11]. These factors are dependent on anticipated costs and 
effects. It is therefore of paramount importance to analyze both costs and effects of any 
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POC application before proceeding with its construction. In this phase of development, 
many uncertainties exist regarding the parameters underlying cost-effectiveness of 
such an application. This study gives an example of how an early health technology 
assessment can provide POC developers and reimbursement agencies with valuable 
insight into the chances of this product in the market. 
A novel POC application for self-testing is currently being developed at the University 
of Twente. This application operates using capillary electrophoresis with conductivity 
detection (CE-CD). Capillary electrophoresis separates substances based on their size to 
charge ratio in the interior of a small capillary filled with an electrolyte (see figure 1). First 
the sample is loaded into the sample well (injection stage). After this a current is applied 
on the capillary which separates the sample components (separation stage). Using 
conductivity detection, concentrations of a broad spectrum of substances in human 
blood and urine can now be determined. Examples of substances that can be detected 
using CE-CD are electrolytes, amino acids and peptides [12]. In the healthcare sector 
this technique enables measurements of substances outside the hospital laboratory. 
The actual POC-application basically consists of two parts: a multi-reader and a 
disposable chip. The multi-reader is a measuring instrument and the interface for the 
user (Figure 2). Furthermore it operates the chip and saves the measurement results. 
The disposable chip actually measures the concentration of the substance. In the near 
future, this application should be able to determine and display concentrations of a 
broad spectrum of substances in human blood and urine in less than two minutes. 
Figure 1 Principle of chip capillary electrophoresis
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Figure 2 Point of care Multireader
This POC application can be a valuable addition to the wide range of high-tech products 
already present in the health care sector. However, as is the case with all technologies 
and their associated products, it is of eminent importance to develop the application 
for the market for which it creates the most, or at least sufficient value. This study 
models potential clinical as well as economic gains for one distinct patient population. 
With no comparable product yet on the market and no clinical trials yet underway, this 
research is a good example of early HTA. In a market scan, a chip for the monitoring of 
potassium in patients suffering from heart failure was identified as potentially attractive 
to develop. In order to decide whether or not to develop this chip the decision maker 
may want to perform a cost-effectiveness analysis and subsequently decide on 
implementation depending on the cost-effectiveness outcome for the application. 
However, there is limited data available on both costs as well as effectiveness of this 
application. This causes much uncertainty which makes it difficult to make a decision 
regarding development based on a formal cost-effectiveness analysis. Hence, in order 
to support the technology developer in the earliest development stages, a decision-
support model is requested that focuses on identifying critical factors which determine 
the application’s success as well as determining the added value of further research. 
Consequently, in this study a method is developed that allows the technology developer 
to make an early-stage assessment of the cost-effectiveness of the potassium POC 
application. Because the technology is in its infant stages, many uncertainties exist 
regarding important parameters. We therefore propose a stepwise approach starting 
with simple methods and progressing to greater analytical depth based on the results 
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of the previous step(s). This approach mainly aims at determining the expected 
economic viability of the chip and identifying the key variables that determine the cost-
effectiveness of the application under study. 
Materials and methods
Cost-effectiveness analysis (CEA) in health care
Due to the high costs associated with the diffusion of new medical technologies and 
therapies, implementation of cost-effective interventions in clinical practice is a crucial 
process in healthcare. Cost-effectiveness is determined by comparing the relative value 
of various clinical strategies or technologies. Ultimately a CEA produces an incremental 
cost-effectiveness ratio (ICER). The ICER is defined as the ratio of the change in costs 
of a therapeutic intervention (compared to an alternative, such as usual care or doing 
nothing) to the change in effects of the intervention. Effects are most commonly 
expressed as quality-adjusted life-years (QALY). The resulting ICER is made operational 
by linking the outcome to a range of reference values expressed as the willingness-
to-pay for a unit of effect. In healthcare economic evaluations, this willingness-to-pay 
(WTP) value reflects the amount of money society is willing to pay for one additional 
QALY. If the ICER is lower or equal than the WTP value, the new strategy is considered 
cost-effective.
Clinical case
In patients suffering from systolic heart failure, the heart is unable to adequately 
respond to physical activity by supplying the body with sufficient blood flow. In this 
situation, the human body activates various compensatory mechanisms (via the nervous 
system and hormonal control systems) which  may lead to tachycardia, retention of 
sodium chloride and fluid, and vasoconstriction. Fluid retention and vasoconstriction 
result in an increase in hydrostatic pressure in the vasculature, which presses fluid out 
into the interstitial space of the surrounding tissue. Ultimately, this pathophysiological 
mechanism leads to the formation of edemas in the lower extremities, if the amount 
of interstitial fluid is critically increased. These edemas can be relieved by diuretics, a 
class of drugs which increase renal water secretion of the body. However, an important 
side-effect of the mechanism of action of diuretics is their interaction with the body’s 
potassium level. Depending on the class of diuretics used, they may be associated with 
loss or accumulation of potassium; as a side effect of treatment this can therefore 
lead to either hypo- or hyperkalaemia. Besides using diuretics, which is a symptomatic 
treatment only, patients with heart failure are generally treated with several other 
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drugs, most notably ACE inhibitors or AT blockers, beta blockers, and – in more 
advanced stages – aldosterone receptor antagonists [13]. Published in September 1999, 
the Randomized Aldactone Evaluation Study (RALES) demonstrated that treatment with 
spironolactone substantially reduced morbidity and mortality in patients with severe 
heart failure [14]. However, although spironolactone is inexpensive and generally 
well tolerated, it can provoke life-threatening hyperkalaemia when combined with 
ACE inhibitors [15-18]. Risks for developing hyperkalaemia are increased because 
physicians may neglect baseline attributes that predispose patients to hyperkalaemia 
(e.g., diabetes mellitus), and may overlook conditions that develop during therapy 
(e.g., renal dysfunction). Furthermore some patients may purposefully increase their 
dietary potassium intake, as is often recommended during treatment with diuretics 
such as furosemide [19]. Patients with potassium imbalance may experience - besides 
other symptoms - muscle weakness and respiratory problems. However, most patients 
remain asymptomatic until the potassium level is severely disturbed which may cause 
cardiac arrhythmias and even cardiac arrest [20]. In this paper we study both forms of 
potassium imbalance: severe hypokalaemia (defined as a serum potassium level of less 
than 2.5 mmol/L) and severe hyperkalaemia (defined as a serum potassium level of 
more than 6.5 mmol/L) [20]. Regular and frequent monitoring of the potassium level 
will greatly prevent the occurrence of a severe potassium imbalance. Therefore, an 
application which can provide patients suffering from heart failure with the possibility 
of frequent check-ups of their potassium levels at their GP, an outpatient clinic, or even 
self-monitoring could significantly increase both safety and quality of life and provide a 
valuable asset to current treatment. 
Early assessment methods
A Bayesian approach [21] is adopted for early assessment of the potential cost-
effectiveness of the POC chip. First, a cost-effectiveness gap analysis is performed to 
identify the maximum reimbursable price of the chip. Basically, this analysis considers 
the economic viability of a new technology, from the producer’s point of view, by 
comparing the expectations about the chip’s cost-effectiveness against the prevailing 
willingness-to-pay threshold for one unit of additional effectiveness (in this study QALYs). 
Such analysis can help to decide whether or not to take the concept of a POC chip in 
development. In fact, it provides a first assessment to test the application in which failure 
will result in a strong advice to discontinue the development of the technology. In other 
words, the development of the chip should (rationally) only proceed if the expected unit 
cost (including development costs) of one POC chip is smaller than the anticipated cost-
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effectiveness gap (or ‘headroom’). Suffice to say, abandoning development of the chip 
is indicated when its expected unit cost exceeds this ‘headroom’. A price margin exists 
to the extent that the expected unit costs of one chip are lower than the anticipated 
‘headroom’. 
If the POC chip successfully passes this first early assessment, subsequently, a simple 
health economic model is developed that combines all available evidence regarding 
costs and effects. This model aims to support decision-making regarding prototype 
development and identifies the parameters for which the cost-effectiveness estimate 
is most sensitive. At this stage, the analysis identifies the parameters (e.g. costs or 
effectiveness) that cause the greatest decision-uncertainty. Yet, in this early development 
stage the prototype chip design or some of its functions may still be eligible for alteration 
and doing so can positively influence the parameters that drive the chip’s expected cost-
effectiveness. Such early assessment may thus lead to better and more affordable POC 
chips at the end of the development cycle.
Cost-effectiveness gap analysis
The cost-effectiveness gap analysis relies on optimistic assumptions for the performance 
of the POC chip to derive maximum headroom for its commercial prospects. The health 
benefit turns on avoiding disutility associated with severe hypo- or hyperkalaemia 
(ΔU). In addition, potential cost savings of avoiding severe hypo- and hyperkalaemia 
treatment are identified (ΔC). The calculation assumes the prevailing willingness-to-
pay threshold for one additional QALY, which is €30,000, with the benefits extending 
over an (undiscounted) average patient life-expectancy of five years. Following this, the 
headroom can be calculated using Equation 1.1:
    €30,000  * ΔU + ΔC   (1.1)
Model structure
In order to determine cost-effectiveness a Markov model was constructed. A Markov 
model describes several discrete health states in which a person can be at time t = n, 
as well as the health states into which the person may move at time t = n + 1. The 
progression from t = n to t = n + 1 is called a cycle. All clinically important events are 
modeled as transitions from one state to another state. Each transition between two 
states has an associated probability; these are termed transition probabilities. Each 
transition probability is a function of the health state and the treatment. Each health 
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state is assigned a cost (in Euros) and a utility (in QALYs), and the overall contribution 
of these costs and utilities depends on the length of time spent in the health state. 
Expected clinical and economic outcomes can be determined as a probability-weighted 
sum of costs and outcomes occurring beyond the initial treatment decision. The time 
horizon of the model is set at the remaining life expectancy which is five years and the 
perspective of the analysis is that of the healthcare system. In the Markov state diagram 
shown below, each state is represented using an oval. Arrows represent transitions and 
arrows indicate possible transitions. Based on the clinical problem three health states 
were identified. Figure 3 displays the model for patients suffering from heart failure 
with a distinction made for the presence or absence of edema. Although the basic 
model only has three states, each state consists of multiple dependent transitions. For 
example, a patient that moves from the health state “HF; edema” to the state “Death” 
can die of heart failure or hypokalaemia.
Figure 3 Markov model for patients suffering from heart failure using non-potassium sparing diuretics
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Patients start either in the health state “HF; Edema” or “HF; No edema”, which means 
they are suffering from heart failure, with or without edemas, respectively. For all 
patients suffering from heart failure, medical treatment is prescribed that bears the 
risk of severe hyperkalaemia, which is considered a complication in the model. Patients 
that develop hyperkalaemia will return to their original health state or die. Applying 
non potassium-sparing diuretics to patients suffering from edemas can lead to severe 
hypokalaemia. The probability to develop severe hypokalaemia during treatment is 
independent of diuretic effectiveness. If this complication occurs, diuretic treatment 
must be halted immediately which will cause the edemas to either stay or reappear, 
causing the patient to stay in the health state “HF; Edema”, or die. However, if the 
diuretic treatment is effective and severe potassium imbalances do not occur, the 
diuretics can help to relieve the edemas which means that the patient moves from 
the health state “HF; Edema” to “HF; No edema”. If the treatment is not effective, 
treatment modifications will be applied. Consequently, the patient remains in the “HF; 
Edema” state. There is also the possibility that a patient will die due to heart failure. 
In our model it is assumed that this possibility is independent of the effectiveness of 
the diuretics, as diuretics are a symptomatic therapy. This means that we assume that 
diuretics increase the patient’s quality of life but do not prolong it, hereby neglecting 
potentially fatal cardiovascular events associated with fluid overload. This is a somewhat 
conservative assumption, as not taking into account this gain in life years will decrease 
the effectiveness gain of the innovation.
Parameter estimation
As the technology is new for this kind of application and no existing therapy is replaced, 
there is no data available from clinical trials. Most transition probabilities as well as costs 
and utilities could be obtained from different sources of literature. In addition, some 
parameters were estimated using related literature data and interviews. An overview 
of parameter estimates is provided in tables 1 and 2. The probability to develop 
hyperkalaemia while using non potassium-sparing diuretics was assumed to be zero, as 
these class of diuretics promote potassium excretion from the body. The probabilities to 
develop severe potassium imbalances were estimated from data obtained in hospitalized 
patients, as data on outpatients was neither available in the literature nor available from 
other sources. Costs for edema therapy were estimated assuming an average of four 
treatments per month. Costs for severe potassium imbalances were estimated using 
cost data for life-threatening ventricular arrhythmias, the most abundant consequence 
of this condition. It was assumed that the development of either a severe hypokalaemia 
or hyperkalaemia would lead to an average reduction in quality of life for one month 
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of 50%. This assumption was made based on the fact that the immediate consequence 
of a severe cardiac arrhythmia is a drop in utility to almost zero. This condition will 
improve rapidly (unless the patient dies), but still it is assumed that the patient will need 
one month to get back to the utility value present before the hypo- or hyperkalaemia. 
The probability for dying represents an average for heart failure patients over all age 
categories, not taking into account NYHA classification. 
Defining probability distributions
Transition probabilities follow a Dirichlet distribution (i.e. the multinomial version of 
the beta-distribution was employed to generate random probabilities for all Markov 
transitions in the model) [22]. As costs are confined between zero at the lower end 
and positive infinity at the upper end, and are usually skewed to the right, a gamma 
distribution was fitted to generate random cost estimations [23]. Utilities are confined 
between one at the upper end and negative infinity at the lower end, and therefore a 
beta distribution was used to generate random utility values [23]. Standard deviations 
(SD) were set at 10% for costs and 20% for utilities. The parameters of the distributions 
were solved using analytic methods (method-of-moments [23]). Method-of-moments 
fitting involves equating the mean and SE observed in the trial data to the expressions 
for the mean and SE of the relevant distribution. The parameters of the distribution (α, 
β) can then be solved analytically.  
Introducing the POC chip in the model
When the chip is introduced, changes will occur in the current disease process. In order 
to introduce these changes in the model for the current situation, two adaptations are 
needed: First, the probability to develop severe potassium imbalances are assumed to 
become zero and second, the costs for using the POC application are added to the health 
state “Edema present”. The increase in costs is determined by using cost data obtained 
from a similar application for the monitoring of lithium level in patients suffering from 
MDI. The model assumes a patient can use the Multireader for five years, leading to 
a yearly cost of €130 for this device. Costs per chip are estimated at €16.60, based on 
information provided by the technology developer. 
Simulation and assessing cost-effectiveness uncertainty
Simulation was carried out using the health care module of TreeAge Pro 2009™. A 
5-year cohort simulation for 1000 patients suffering from heart failure as well as a 
Monte Carlo simulation with 20,000 trials was carried out. This number of trials roughly 
corresponds to the number of patients suffering from heart failure in the Netherlands 
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[24]. Effectiveness was expressed in Quality Adjusted Life Years (QALYs) and costs in 
Euros. The changes in outcomes between the current treatment and treatment using the 
POC chip were expressed by the incremental cost-effectiveness ratio. The willingness-
to-pay (WTP) value was set at €40,000 [25]. Costs and QALYs were discounted at 3.5 
percent rate [26]. In order to represent the uncertainty in the costs and effects of the 
treatment a scatter plot of simulated incremental costs and effectiveness pairs on the 
cost-effectiveness plane was drawn. Subsequently, a cost-effectiveness acceptability 
curve (CEAC) was constructed to obtain more information about the probability that 
the treatment using the POC chip will be cost-effective [27, 28].  
Sensitivity analysis and expected value of information
Sensitivity analyses were carried out to identify the parameters most crucial to the 
application’s cost-effectiveness outcomes. One-way sensitivity analyses were carried 
out to analyze costs per chip (range: €6 - €26), quality of life measures for developing 
severe hyperkalaemia (range: 0.1 – 0.4) and probability to develop this complication 
(range: 0.001 – 0.01). Hyperkalaemia has a significantly higher incidence combined 
with a higher mortality rate than hypokalaemia which is why only this complication is 
analyzed (this is confirmed by a two-way sensitivity analysis on utility hyperkalaemia 
vs. utility hypokalaemia). Costs per chip were chosen because it is, apart from being 
of utmost importance for commercial success, also considered to be influenceable 
by the technology developer. This parameter therefore represents uncertainty in 
the developmental process, as opposed to post market uncertainties that were also 
analyzed [29]: These include 1) quality of life measures of hyperkalaemia which were 
analyzed because these parameters had to be estimated, which makes them uncertain 
by definition and 2) information regarding the probabilities to develop potassium 
imbalances in usual care that was considered to be less reliable because this information 
was obtained in hospitalized patients, which are not the main target group of the 
application under study. 
In addition, probabilistic sensitivity analysis (PSA), using second order Monte-Carlo 
simulation techniques, was employed to handle uncertainty in the model as described 
by the distributions of costs, health outcomes and the resulting cost-effectiveness 
estimates. The benefit of propagating distributions through the model, instead of using 
a single point estimate, is that the cost-effectiveness results indicate the uncertainty 
surrounding the decision, rather than the uncertainty surrounding a single input. The 
PSA randomly selects values from each of the parameter distributions, and evaluates 
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the model results for that combination of parameter values. This process was repeated 
20,000 times to obtain a representative range of cost and effect pairs for the two 
strategies and hence a distribution of incremental costs and effects (QALYs). These 
estimates are then presented graphically on a cost-effectiveness plane, to show the 
estimated joint distribution of incremental costs against incremental effects. To avoid 
potential problems with interval estimates for incremental cost-effectiveness ratios 
(ICERs), net benefit analysis was performed. This involves the calculation of a net benefit 
(NB) statistic for each of the 20,000 simulations, from the formula NMB = λΔE - ΔC, 
where λ is the societal willingness-to-pay for one additional unit of effect and ΔE and 
ΔC are the incremental differences in effectiveness (QALYs) and costs, respectively. A 
positive monetary net benefit indicates that a strategy is cost effective for a given value 
of λ. A cost-effectiveness acceptability curve [24] is obtained by plotting the proportion 
of the 20,000 simulations that have positive net benefits as a function of λ.
Apart from identifying those parameters crucial to the application’s cost-effectiveness 
it is also vital for the technology developer to know for which specific parameters more 
or better data is needed. In other words, in addition to reducing the uncertainty as 
a consequence of uncertain individual parameters influencing model outcomes as is 
done in sensitivity analysis, there is also a need to reduce the uncertainty surrounding 
the ultimate decision whether or not to continue developing the innovation. The 
latter is done using value of information analysis: In order to inform the technology 
developer about the expected value of conducting more research to better support the 
decision instead of making the decision to proceed with the chip’s development with 
the information available today, an estimation of the partial expected value of perfect 
information (pEVPI) was determined [30].The pEVPI is based on the results of  the PSA. 
It is the maximum price that one would be willing to pay in order to gain access to 
perfect information (i.e. no decision uncertainty) regarding a specific parameter of the 
model. If the costs of acquiring the additional information are lower than the pEVPI, 
the rational decision would be to do so. If, however, the costs of acquiring additional 
information would be higher than the expected value of that information, the rational 
decision would be either to decide today based on available information, or focus the 
future research to other uncertain parameters and as such reduce the costs of future 
studies below the expected value of information as can be obtained from these studies. 
The choice was made to obtain pEVPI values for the parameters that in sensitivity 
analyses were proven to be vital to the cost-effectiveness outcome.  
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Results
Cost-effectiveness gap analysis
The difference in costs (ΔC) and the difference in utility (ΔU) following introduction 
of the POC chip in (otherwise) usual care are optimistically estimated at €752 (cost 
associated to treating severe potassium imbalance; table 2) and 0.51-0.225 =0.285 
(instantaneous utility decrement for potassium imbalance additional to edema; table 
2), respectively. Yet, given the low probabilities for severe potassium imbalance of 0.005 
(severe hyperkalaemia) and 0.0022 (severe hypokalaemia) per cycle (see table 2) a 
patient is assumed to spend maximum 0.432  (= 60 cycles * 0.0072) months per 5 years 
in a state of severe potassium imbalance. The expected utility decrement is therefore 
maximum (0.285/12) * 0.432 =0.010. Following Equation 1.1 this leads to a headroom 
of: (€30.000 * 0.010 + 0.432 * €752) * 5 = €633. Although no opinion on the precision 
of the estimates was elicited, the total headroom of €633 is considered to offer good 
prospects for a commercially viable price since unit costs (including development costs) 
are unlikely to exceed this value. Therefore, the economic evaluation was continued.
Transition probabilities
One-month transition probabilities are displayed in table 1. The probability that a patient 
with heart failure develops severe hyperkalaemia is approximately 0.5%, assuming a 
mean frequency of two cases of severe hyperkalaemia for patients who experience 
hyperkalaemia at least once [31]. However, this is only the case for patients who are not 
using non potassium-sparing diuretics. Patients using non potassium-sparing diuretics 
have a probability to develop severe hypokalaemia which is approximately 0.22% [32]. 
Chances of dying of severe hypokalaemia are 20.4% [32], for severe hyperkalaemia this 
is 30.64% [33].
Costs and utilities
Average monthly costs for heart patients are €173.33 [35]. Average costs for non-
potassium-sparing diuretics, edema therapy and severe hypokalaemia were €37.42 
[36], €156.00 [37], and €752 [38], respectively.  Utility values range from 0.77 [39] for 
patients without edema to 0.255 for patients with severe potassium imbalances (table 2). 
Cost-effectiveness
Cohort simulation yielded an ICER of €35,000/QALY for 10 measurements per month 
at a cost of €16.60 per chip, Figure 4 shows incremental costs and effectiveness of the 
treatment using the POC chip compared to the current treatment. On the horizontal 
axis the differences in effectiveness are depicted between the current treatment as 
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baseline scenario and treatment using the POC chip. On the vertical axis the differences 
in costs are depicted for the treatment using the POC chip vs. current treatment. The 
oblique dotted line represents the WTP threshold.
Table 1. One-month transition probabilities HF patients.
Transition Probability 
standard 
care
Source Probability 
after chip 
introduction
HF; edema => HF; no edema 0.7916 Estimated* 0.7933
HF; edema => HF; edema 0.1979 Estimated* 0.1984
HF; edema => Severe hypokalaemia | HF; edema 0.0022 [32] 0
HF; edema => Death 0.0083 [34] 0.0083
HF; no edema => HF; edema 0.1990 Estimated* 0.2001
HF; no edema => HF; no edema 0.7877 Estimated* 0.7916
HF; no edema => Severe hyperkalaemia | HF; no edema 0.0050 [32] 0
HF; no edema => Death 0.0083 [34] 0.0083
Severe hyperkalaemia | HF; no edema => HF; no edema 0.6936 [33] NA
Severe hyperkalaemia | HF; edema => HF; edema 0.6936 [33] NA
Severe hyperkalaemia | HF; edema => Death 0.3064 [33] NA
Severe hyperkalaemia | HF; no edema => Death 0.3064 [33] NA
Severe hypokalaemia | HF; edema => HF; edema 0.7960 [32] NA
Severe hypokalaemia | HF; edema => Death 0.2040 [24] NA
* Estimates corrected for other probabilities at the same node
Table 2. Estimated costs and utilities of health states with associated complications and therapy.
Markov health state Costs (€) Source Utility Source
HF; edema 173 [35] 0.51 Estimated
Severe hypokalaemia 752 [38] 0.255 Estimated
Non potassium-sparing diuretics 37 [36] NA
Edema therapy 156 [37] NA
HF; no edema 173 [35] 0.77 [39]
Severe hyperkalaemia 752 [38] 0.255 Estimated
Death 0 Assumed 0 Assumed
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Figure 4 Incremental cost-effectiveness scatter plot for treatment using a POC chip vs. current 
treatment for a simulation horizon of 5 years.
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Approximately 50% of the data points are located below the WTP threshold, which 
represents cost-effectiveness. This means there is a high uncertainty regarding cost-
effectiveness. A cost-effectiveness acceptability curve (CEAC) confirms this. Figure 5 
presents the CEAC for WTP values ranging from 0 to €100,000/QALY. It can be seen 
that if the value placed on a life year is €40,000, as is the WTP, the probability that the 
current treatment compared with the chip is cost-effective is  approximately 50%, as 
50% of the simulated ICERS fall below this threshold. 
Sensitivity analysis and pEVPI
A one-way sensitivity analysis was carried out on costs per chip. The cost-effectiveness 
threshold for the costs per chip was €19.30. This means that if the technology developer 
decides to raise the costs per chip to this value, the chip will still be cost-effective. 
Regarding the number of measurements per month 1-way sensitivity analysis showed 
that the application fails to be cost-effective when there are over 11 measurements 
necessary per month. Figure 6 below displays a 2-way sensitivity analysis on costs per 
chip versus number of measurements per month. The technology developer can use this 
plot to make an assessment of the expected profit when the number of measurements 
varies. This is a good example of a developmental uncertainty (price per chip) versus 
Figure 5   Cost-effectiveness acceptability curves for the current treatment and treatment using POC chip. 
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a post market uncertainty (number of measurements). If development of the POC 
application proceeds, the model can be updated just prior to market implementation 
by more accurate estimates for the costs per chip [29].
Sensitivity analysis furthermore revealed that the results are very sensitive to the utility 
of hyperkalaemia as a rise from 0.26 (ICER = €34,000/QALY) to 0.28 (ICER = €42,000/
QALY) leads to an ICER above the WTP threshold. Furthermore results are also sensitive 
to the probability to develop severe hyperkalaemia while not using a chip: a decrease 
in probability to 0.004 leads to a cost-inefficient outcome. Partial EVPI values for the 
utility of hyperkalaemia and probability to develop hyperkalaemia were €53 and €539 
per patient, respectively. These values represent the costs for the health system to 
obtain perfect information about these parameters and consequently to make a better 
founded decision.
Figure 6 Two-way sensitivity analysis on costs per chip versus number of measurements
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Discussion
POC applications are promising to be valuable additions to the wide range of high-
tech products already present in the health care sector. However, as is the case with all 
technologies and their associated products, it is of eminent importance to develop the 
applications for the markets for which they create the most, or at least sufficient value. 
This study modeled the potential clinical as well as economic gains for a POC chip for 
one distinct patient population (i.e. severe heart failure). The initial cost-effectiveness 
gap analysis showed sufficient ‘headroom’ for recouping the development costs of 
the chip after market launch. Subsequently, with a simple health economic model 
that was populated with the preliminary data available and expert opinions, even in 
this early development stage an estimation could be obtained regarding the likely 
cost-effectiveness of the chip – which will increasingly be a factor determining market 
success. As the expected incremental cost-effectiveness of the POC chip versus standard 
medical treatment without such a chip lies below the prevailing cost-QALY threshold, 
a positive advice could be given to continue developing this technology. However, as 
these estimates are uncertain, the identification of key parameters influencing the 
cost-effectiveness of the chip seems more valuable at this pre-development stage. A 
valuable addition to the identification of these key parameters is the determination of 
the expected value of information of doing further research to obtain better estimates 
for these parameters. This in turn helps the technology developer direct future R&D 
efforts to further optimize the cost-effectiveness of the chip at a time when there is still 
room for making changes in the design or functionality of the product. This is considered 
one of the core strengths of early assessment; as such changes are impossible at the 
latest stages of development. 
Assumptions and limitations
As this paper was an early HTA exercise, this will inevitably bring about several 
assumptions that can have a major impact on model outcomes. When looking at the 
method, data selection is an important point of concern. Considering the limited amount 
of research into POC applications, not all data is available from literature. Especially, 
utility values are hard to assess when they are not yet investigated in existing cost-
effectiveness studies. Furthermore, certain costs cannot be uniformly calculated but 
should instead be based on estimations. Good examples of this are the costs for hypo- 
or hyperkalaemia, since treatment is not uniform because there are different degrees 
of severity and different kinds of symptoms associated with these complications. 
Therefore, costs will vary over a broad range. Using sensitivity analysis, the influence 
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of these estimations can be assessed. Another very important issue is the patient 
population under consideration. In this study it was assumed that the patients were 
not suffering from other diseases. This means that for comorbidities that increase the 
risk of developing potassium imbalances our model provides an underestimation of the 
cost-effectiveness of the POC application. For example, many patients with heart failure 
also suffer from renal failure. These patients have a much greater risk to develop severe 
hyperkalaemia. Therefore, we can say that the outcomes of our model provide the 
technology developer with a lower bound of the cost-effectiveness of the innovation 
under study. Given the uncertainty surrounding the innovation, a lower bound seems 
appropriate as for example revenues for the technology developer can be lower than 
anticipated.
It is obvious that this kind of modeling does not give enough information on which 
the decision maker can solely base the decision whether or not to adopt and/or 
reimburse the technology under study. Apart from that, the model does not anticipate 
on the use of potassium supplements which can minimize the probability to develop 
hypokalaemia. However, as the most important population seems to be hyperkalaemia 
patients, this limitation will have minor consequences. Furthermore external factors 
like implementation costs, learning effects and acceptation of the new technology by 
the physicians are not taken into account as these factors are very hard to quantify. 
Also, the probabilities to develop severe potassium imbalances had to be obtained 
from estimates for hospitalized patients. Hospitalized patients are likely to have more 
complications, and thus a higher probability to develop either hyper- or hypokalaemia. 
This may give biased estimations on these particular parameters and thus on model 
outcomes. Perhaps the most important limitation of this study is that the frequency 
of measurements cannot be analyzed. After consulting experts in the field it was 
determined that for ten measurements per month the probability to develop potassium 
severe imbalances is reduced to zero. However, this remains an educated guess which 
affects the costs per month using the POC application. 
Implications for existing technologies
As the chip in this study has the potential to measure other substances in the blood and 
urine as well, this innovation can potentially be quite disruptive as it has the potential to 
shift a significant portion of the production of the hospital laboratory either extramural 
or to a specific department in the hospital. Because it is very likely that high-volume 
laboratory tests will be major candidates for point-of-care applications outside of the 
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hospital, diseconomies of scale and scope will inevitably arise for hospital laboratories. 
Diseconomies of scale refer to the relationship of average costs with volume of 
production and will arise when marginal costs of production get, with increasing volume 
of production, higher than average cost. Diseconomies of scope are conceptually similar 
to diseconomies of scale but refer to the multipurpose use of capital investments. It 
can be readily seen that the use of point of care technology introduces diseconomies of 
scope as demand for specific laboratory tests will decrease. Hence, in the short run, the 
hospital laboratory can no longer operate at minimal cost levels. This prospect can be a 
reason for the laboratory to prevent or abandon the implementation of potentially cost-
effective point of care technology, both in-hospital as for outpatient care. Therefore it 
is important that any diseconomies are quantified in order to assess their influence on 
outcomes of economic evaluations. This will help to obtain a more realistic assessment 
of the cost-effectiveness of the point-of-care application, and might also assist the 
hospital laboratories in the development of an optimal implementation strategy. 
Conclusions
This study did not intend to provide a final judgment about the economic viability of 
the technology under study. Instead, it aimed to explain the methodology to use early 
health technology assessment to give an advice whether or not to continue with the 
development of a technology when limited data is available on both the technology itself 
as well as its intended market. This paper indeed demonstrates that this kind of early 
stage modeling can be very useful in the early development stages of a new medical 
technology and that the technology developer can be provided with a comprehensive 
advice based on accumulating data about the further actions to be taken in anticipation 
of a final (reimbursement) assessment of the emerging technology.
For patients suffering from heart failure, the question whether or not a POC chip to help 
avoid a severe potassium imbalance is likely to be cost-effective cannot be definitively 
answered with the information at our disposal. This conclusion is supported by the 
ICER as well as CEAC which shows that a relatively small decrease in WTP reduces the 
probability that the application is cost-effective to below 50%. One-way sensitivity 
analysis revealed that the chip’s cost-effectiveness is highly dependent on the probability 
to develop hyperkalaemia and the corresponding utility of this complication. Value of 
information analysis provides the technology developer with the necessary information 
on which he can decide whether or not to do more extensive research into these 
parameters.  
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9
General discussion
138       
Until recently, little to no attention was paid to the role of time in CEA. Probably this 
is because of the long run and steady state orientation towards CEA and the resulting 
assumption that costs and effects are constant over time [1]. In this thesis this 
assumption is critically studied, the notion that the traditional CEA provides a good 
reflection of the entire lifecycle of a technology is challenged, and multiple factors 
are identified that influence both the occurrence and the impact of variations in cost-
effectiveness outcomes over time. By using mathematical modeling these variations 
can be quantified, but modeling is also a means to make the mechanisms leading to 
inefficiencies transparent. This is in fact a repetitive process, as using mathematics to 
describe real world phenomena brings new insights, which subsequently can be used 
to expand the models. 
This discussion starts with a reflection on the contribution of the studies to this 
objective and the research aims as formulated in chapter 1. After this, methodological 
issues will be highlighted, with a particular focus on an evaluation of the strengths and 
weaknesses of the models developed. Finally, as obtaining accurate cost-effectiveness 
outcomes in a timely manner is getting more and more important, perspectives on 
future research into the role of time in CEA as well as potential applications in research 
and policy guidelines will be discussed. 
Sources and consequences of short run inefficiencies
Several important factors causing short run inefficiencies have been identified in 
chapters 3, 4, and 5. Fixed factors of production for the old technology combined with 
capacity constraints (chapters 3 and 4), delayed benefits for the innovation (chapter 4), 
and learning effects (chapter 5) are investigated by means of mathematical modeling. 
The models developed here as well as the results of the real world cases show that 
the degree and impact of short run inefficiencies vary greatly depending on the 
characteristics of both the alternative technologies and substitution process under 
consideration. However, considering the fact that inefficiencies are potentially very 
substantial and the fact that the drivers leading to these inefficiencies are present for 
a considerable part of the technological substitutions, it seems unwise to continue to 
ignore the influence of time on cost-effectiveness outcomes. 
The vast majority of health care innovations that are deemed cost-effective using a 
standard CEA will have long run efficiency gains that, when added up over the economic 
lifetime of the innovation, outweigh any short run efficiency losses. Moreover, in the long 
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run, the cost-effectiveness of an innovation will indeed be constant [2, 3]. As is explained 
in chapter 6, the problem is that decision makers often have a myopic orientation and 
are prone to stop implementing an innovation when in the short run this proves to be 
much more costly and much less effective than was predicted [4]. In these situations 
the provision of information on the occurrence and impact of the inefficiencies during 
and shortly after implementation are important to prevent decision makers to switch 
back to the old technology. In fact, only for innovations where the economic lifetime 
is expected to be short due to newer innovations already on the horizon, short run 
inefficiencies might be a sound reason to not invest in a new technology with a 
favorable cost-effectiveness in the long run. So in including information on the relation 
between short run and long run cost-effectiveness outcomes, the connection should be 
made with the expected economic lifetime of the innovation. All in all, a total revision 
of the CEA framework to make the cost-effectiveness outcome time-dependent over 
the entire economic lifetime of a technology is not recommended. Instead, this thesis 
recommends that the CEA framework should be complemented with a short run cost-
effectiveness outcome, in which information is provided on both the mechanism(s) 
leading to, as well as the magnitude of short run inefficiencies. Moreover, the length 
of the short run time period and its relation to the expected economic lifetime of the 
innovation should also be taken into account, along with any recommendations that 
can be made to prevent short run inefficiencies.
Chapters 7 and 8 investigate another important topic related to time and CEAs, namely 
timing, both in terms of adoption (chapter 7) and evaluation (chapter 8). In chapter 7 a 
model is constructed to illustrate the possibility to determine, from a local perspective, 
the optimal moment to adopt an innovation. This is in essence an extension to the 
basic question a standard CEA framework is meant to answer as using this model not 
only the question ‘whether’, but also ‘when’ to adopt the innovation can be answered. 
Chapter 8 focuses on an early economic evaluation, which is a CEA that is carried out 
when an innovation is still in its developmental stage. Here it is shown that using a 
stepwise approach involving headroom analysis, probabilistic sensitivity analysis, and 
expected value of information analysis, a reasonable estimate can be given with regard 
to the potential cost-effectiveness of the innovation. It also becomes clear however, 
that performing an economic evaluation at such an early stage causes much uncertainty 
regarding model input parameters and that a definitive answer to the question whether 
the innovation is cost-effective, without doing further research, is doubtful at best. 
140       
Modeling time in CEA: strengths and weaknesses
Before going into the main strengths of using mathematical modeling to assess the role 
of time in cost-effectiveness analysis, it is important to note that modeling in general 
is probably the only available method that enables the decision maker to actually 
quantify the efficiency losses that will occur, given a specific set of empirical data and 
assumptions. As the decision maker can adjust these assumptions according to their 
own expectations, a relatively clear picture can be provided regarding the occurrence 
and impact of short run inefficiencies. 
Strengths
One of the core strengths of using models is that besides giving the decision maker 
actual figures about the amount of short run inefficiencies, the models also give insight 
into the processes and mechanisms that ultimately lead to inefficiencies in the short 
run. This information is probably even more valuable to the decision maker than the 
outcome itself, as it enables them to take measures to reduce the impact of short 
run inefficiencies. Examples of measures that can be taken include postponing the 
implementation of an innovation (in order to decrease losses due to capacity for the 
old technology not yet written off), and extra training to reduce inefficiencies due to 
learning effects.
Although making models requires making certain assumptions, the amount of subjective 
information and reliance on expert opinion should be kept at a minimum. If, for our 
models, enough empirical data sources are available, there is only the need to involve 
expert opinion in the estimation of performance at expert level as part of the learning 
curve. As evidence-based practice is (becoming) the standard in regulation regarding 
the health care sector, models that are based on empirical data are preferred above 
those that require subjective and weak evidence to generate outcomes [5].
Another important strength of the models developed in this thesis is their flexibility. 
For every driver of inefficiencies, a general framework is constructed that allows the 
decision maker to adapt the model to suit the (local) situation. An example is the 
implementation strategy planned or used for the innovation, which in the model can 
be adapted both in terms of rate of implementation but also in terms of whether the 
process of implementation follows a linear or a non-linear (e.g. exponential) pattern. 
The models also allow for deterministic sensitivity analysis on the input parameters.
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Weaknesses
However, mathematical modeling as a tool to help decision makers make better 
informed decisions also has its drawbacks. An important point of concern is the 
availability of data to populate the models. This requires local health care providers to 
maintain a good administration (e.g. in order to determine remaining economic lifetime 
of existing technology), trials to have collected data exceeding those strictly necessary 
to determine the clinical endpoints of the trial (e.g. data on surgery duration), and 
access to data that might be competitively sensitive (e.g. total costs made for a certain 
treatment from a hospital perspective). 
Another serious issue is the relative complexity of the models, making them hard to 
understand for decision makers and therefore not very user-friendly. This problem 
can be alleviated by the development of for example a user friendly Microsoft Excel 
application that calculates short run inefficiencies for a given set of input variables. 
Working with such a tool does not require a deeper understanding of the mathematics 
behind the model and can still give the decision maker a good notion of both the 
existence and the impact of short run inefficiencies. A drawback of this approach is that 
information regarding the mechanisms leading to inefficiencies will be harder to convey, 
although providing outcomes on the relative contribution of the different drivers to the 
total inefficiency loss will provide the decision maker with some clue as to where to aim 
preventive measures at.
The models developed in this thesis are deterministic, which means that stochastic 
uncertainty is not yet taken into account. As the input parameters are uncertain by 
nature, the deterministic character of the models cannot be considered optimal, and an 
extension to a probabilistic form will improve the accuracy of the models.
Considering the strengths and weaknesses discussed it seems that mathematical 
modeling as a means to assess the role of time in CEAs is promising, but that a number 
of hurdles still need to be overcome. In times where transparency regarding research 
outcomes is getting more and more important, an objective and quantitative approach 
to deal with the consequences of including time in CEAs seems best suited to fulfill the 
decision maker’s needs.
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Perspectives on future research and policy
In order to keep health care provision sustainable, cost-effectiveness analysis is 
becoming increasingly important. With power comes responsibility, and therefore it 
is imperative that decision makers can trust the outcomes generated by these kind of 
analyses. This thesis has strived to contribute to the development of more accurate 
cost-effectiveness outcomes and to more transparency regarding the assumptions and 
methodological drawbacks of the cost-effectiveness framework. Regarding the subject 
of this thesis the first step has been taken by adding a paragraph on potential short run 
inefficiencies to the new version of the Dutch manual for costing research in health care 
[6]. Yet more challenges remain. These challenges can be divided into methodological 
issues, difficulties surrounding the applicability of the models, and last but not least 
implications of this research on the use of CEAs in general. 
To allow for second-order uncertainty in the models. 
It is important to realize that the models developed in this thesis are fully deterministic. 
As we are studying variations over time in costs and effects, and these parameters are 
uncertain by nature, an important next step in this research would be to extend these 
models and make them probabilistic.
To combine the various models in a single overarching model that is applicable in every 
situation. 
Although the models developed in this thesis all cover a different element that is 
contributing to short run inefficiencies, it is important to realize that the interactions 
between these different elements should also be taken into account. For example, 
the inefficiencies modeled in chapter 2 due to fixed factors of production of the old 
technology are dependent on the rate of implementation of the new technology. Taking 
these sorts of interactions into account when developing such an overarching model may 
prove challenging, but since the different interactions can reasonably be predicted this 
should not be an impossible task. When such an overarching model will be developed, 
the construction of an Excel application that can be used by decision makers should be 
one of the main priorities. Such an application, if properly designed, will improve the 
user-friendliness of the model and consequently will increase its uptake by decision 
makers.
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To emphasize a local perspective complementary to the currently prevailing societal 
perspective. 
Thus far only the accuracy of the models and their applicability have been considered. The 
question arises if this is all there is to it. Is providing better cost-effectiveness outcomes 
for decision makers all that is to be done or has this research more implications? In my 
opinion the latter is true. This thesis has shown that short run inefficiencies can lead to 
significant variation in cost-effectiveness outcomes on a local level, which might make 
one wonder whether outcomes of CEAs that are carried out using a societal perspective 
are representative for the situation local decision makers face in their environment. 
Therefore, we should ask ourselves the question if the societal approach to allocation 
problems is still justified as the only relevant one. A lot of variation exists between health 
care providers, not only in for example size of a hospital or quality of care provided but 
also in cost structure of capital goods and expertise on different medical specialties. 
Furthermore, the outcomes of an economic evaluation can vary greatly on a local level, 
and local decision makers henceforth are wary of outcomes obtained in a setting that 
does not reflect their local situation [4, 7, 8]. For example, providers where fixed factors 
of production for the old technology are nearing the end of their economic life time or 
where staff has extensive prior experience with an innovative surgical procedure, will 
suffer less efficiency losses than providers where this is not the case. These variations 
between providers might lead to a situation where an innovation is calculated to be 
cost-effective using a societal perspective, but fails to be cost-effective for some local 
providers.
Furthermore, providing complementary information on cost-effectiveness outcomes 
for the local situation makes CEA also a tool that can guide the decision maker in 
both the decisions whether, when, and how to implement a new technology in their 
organization. Even one step further would be to use a regional perspective, in which 
neighboring providers can evaluate an innovation on a regional level. This would be 
especially useful for very expensive equipment, an example being the Da Vinci surgical 
system, which only has added value for a limited patient group and is thus prone to 
overcapacity [9]. By adopting a regional perspective, these capacity problems can be 
prevented. The same goes for learning effects where innovations can be centralized at 
the provider within the region which has the most prior experience with the innovation 
under study. The idea of ‘downscaling’ the perspective of a CEA adheres well to the 
Dutch government’s instructions and incentives given to the sector to focus more on 
concentration and specialization [10, 11].
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Summary
Health care in the Netherlands consumes a large and continuously growing part of the 
gross national budget. More or less the same can be noticed in other Western countries. 
If this trend continues it would mean that almost one third of national income will 
be spent on health care in 2040. A major driver for increasing health care costs is the 
continuous development of expensive innovative medical technology. In order to curb 
health care spending the assessment of medical innovations on cost-effectiveness 
criteria is becoming more and more important. Cost-effectiveness analysis (CEA) has 
become the most important technique to help decision makers allocate resources 
in health care. This method however, is not without criticism as several simplifying 
assumptions are made. One important assumption is that costs and effects, and hence 
the cost-effectiveness outcome, are constant over time. In this thesis this assumption 
is challenged and critically studied, and the potential consequences of deviations from 
this assumption are assessed, both in a quantitative as well as in a qualitative manner.
Chapter 1 contains the general introduction of this thesis and includes a description 
of the large increase in health care spending over the last decades along with causes 
and possible measures to alleviate this problem. Also, the standard cost-effectiveness 
framework, its underlying assumptions and resulting limitations, and the way by which 
this thesis aims to improve this framework are described. This chapter also includes the 
objectives and the outline of this thesis. 
Chapter 2 starts with a theoretical discussion about the role of time in CEA, and makes 
a case for the inclusion of information on short run outcomes in economic evaluations 
in health care. Here it is shown that short run cost-effectiveness outcomes may 
deviate considerably from the outcomes of a conventional long run oriented CEA. The 
most important drivers leading to these deviations are identified, as well as possible 
implications of the resulting inefficiencies that may occur in the short run. Chapter 2 also 
makes clear that the drivers and mechanisms leading to short run inefficiencies should 
be made more explicit and the impact of these inefficiencies should be quantified and 
complemented to the traditional CEA outcome.  
The first step in actually quantifying short run inefficiencies is set in chapter 3, which 
features a model that takes into account inflexibility of production factors for the old 
technology and associated reallocation problems. Here the amount of capacity for the 
old technology that is freed up, the resulting overcapacity, and the associated proportion 
of fixed factors of production are identified as important determinants of short run 
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inefficiencies. This is illustrated by the switch from a long run positive incremental net 
monetary benefit (INB) to a short run negative INB in the digitalization of a hospital 
radiography department. Although the model developed in this study allows for writing 
off old technology and for refilling freed capacity, essentially making it time-dependent, 
this model is limited by the fact that it only considers inefficiencies caused by the old 
technology and does not look at the effect side of the cost-effectiveness model. 
In light of the limitations of chapter 3, chapter 4 extends the range of inefficiency drivers 
by investigating the influence of capacity constraints for the new technology due to a 
gradual implementation process. It is shown that during gradual implementation of an 
innovation serious inefficiencies during the short run time frame may become manifest, 
both in terms of fixed factors of production for the old technology and health benefits 
foregone for the new technology. This is illustrated in a real-world case concerning 
the transition of analog to digital breast cancer screening where the INB during the 
transition period amounted up to minus €488,000 instead of the anticipated positive 
value of €985,000. An interesting finding in examining the rate of implementation is 
that gradually implementing a new technology leads to lower inefficiencies on account 
of the old technology but increases the inefficiencies on account of the new technology 
due to a delay in efficiency gains associated with this new technology. In trying to 
find an optimal implementation pattern for an innovation for which its predecessor 
has a relevant proportion of fixed factors of production it seems impossible to find an 
optimal implementation pattern that would simultaneously minimize both sources of 
inefficiencies. Instead, the model shows that the decision maker has to find out which 
of both sources for inefficiencies contributes the most, and adapt the implementation 
rate of the innovation accordingly. 
In studying a delay in efficiency gains, the effect side of the cost-effectiveness model 
was only partially taken into account. However, an important and well-known driver 
of reduced effectiveness in the short run, namely the learning curve, has not yet been 
considered. Consequently, chapter 5 models inefficiencies due to learning. Learning is 
a major issue in randomized controlled trials for surgical procedures and can lead to a 
significant underestimation of an innovation’s cost-effectiveness as it both increases 
costs and decreases effects in the short run. In quantifying the effects of learning on 
cost-effectiveness outcomes, a general model for the learning curve is used, adapted 
from the Plateau model, involving expert opinion to approximate the performance at 
expert level. Here it becomes clear that the duration of the trial is an important predictor 
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of the effects of learning on short run inefficiencies, as well as the prior experience 
of personnel involved. When personnel will perform a relevant number of procedures 
before the trial starts, learning effects will greatly diminish. The most challenging aspect 
of determining short run inefficiencies due to learning is determining the shape of the 
learning curve. Often trial data is scarce and fuzzy, and contains outliers. In this chapter, 
expert opinion is used as a means to alleviate this problem.
Chapter 6 focuses on a more policy-related subject that arises as a consequence of short 
run inefficiencies. This chapter explains the problems that may arise when policy makers 
and funding bodies demand proof on cost-effectiveness in a too short time frame. By 
reducing the length of outcome measurements, outcomes will represent a period in the 
life cycle of the innovation where short run inefficiencies are most impactful, namely 
during the earliest stages of implementation and adoption. Therefore, cutting back on 
the length of outcome measurements will result in cost-effectiveness outcomes that 
are biased even more against the innovation. Policy makers and researchers are urged 
to identify any factors present that might lead to short run inefficiencies, and adapt the 
design of cost-effectiveness studies accordingly. 
In chapter 7 the scope of the original question that a CEA is supposed to answer is 
extended to include the question ‘when’ to implement instead of only the question 
‘whether’ to implement an innovation. This chapter focuses on the local perspective, 
as timing of adoption for an innovation is highly dependent on the local situation of a 
decision maker. A decision rule is derived that facilitates decision making on whether 
to adopt an innovation or postpone adoption, taking into account discounting and 
possible variations in net monetary benefits for the alternative technologies over time. 
This approach is illustrated using a hypothetical case in which several parameters are 
varied.
Chapter 8 describes an early economic evaluation of a point-of-care (POC) chip. Here, 
the term ‘early’ means that this economic evaluation is carried out at an early moment 
in the development phase of the innovation. This approach is especially useful when 
development of the innovation is costly, and when little information is available 
about the innovation itself as well as its intended market. This was indeed the case 
for the POC chip, as many uncertainties existed regarding important parameters that 
determined the cost-effectiveness of the chip. Early economic evaluations bring about 
their own challenges, most notably the lack of empirical data concerning costs and 
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effects. In this chapter a stepwise approach was used to alleviate this problem. This 
approach starts with a simple headroom analysis and progresses to greater analytical 
depth adding deterministic and probabilistic analyses to assess the economic viability 
of the chip. Despite this approach much uncertainty surrounds the anticipated cost-
effectiveness outcome, and it seems that the identification of parameters which are key 
to success of the innovation in terms of cost-effectiveness is more important in the early 
development stage. This is done using both deterministic and probabilistic sensitivity 
analysis. Moreover, expected value of information research to direct efforts for further 
research is needed, especially because at the early stages of technology development 
there is still time to adjust the innovation in terms of design and functionality.
Chapter 9 discusses the contribution of this thesis in light of its objectives. It is concluded 
that short run inefficiencies can have important consequences, such that extending the 
cost-effectiveness framework with information on short run outcomes is warranted. 
Also, the strengths and weaknesses of the models are discussed further, both going into 
methodological issues as well as more general factors such as applicability in the real 
world. Indeed the main weakness of using models to quantify short run inefficiencies is 
the complexity and resulting limited user-friendliness for decision makers. However, a 
related issue and great strength of using models is that these can actually give decision 
makers quantitative insight into the mechanisms leading to short run inefficiencies, 
and consequently options to prevent or reduce these inefficiencies. The discussion is 
concluded with some perspectives on future research and policy. Here, the possibility 
of developing one overarching model is discussed, as well as the notion that for medical 
technologies a switch from a global to a more local perspective should be considered.  
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Samenvatting
De zorgsector in Nederland verbruikt een groot en alsmaar groeiend deel van de 
nationale begroting. Min of meer dezelfde ontwikkeling is zichtbaar in andere westerse 
landen. Als deze trend zich doorzet, zou dat betekenen dat bijna een derde van het 
nationaal inkomen wordt besteed aan gezondheidszorg in 2040. Een belangrijke motor 
voor het verhogen van kosten van de gezondheidszorg is de voortdurende ontwikkeling 
van dure innovatieve medische technologie. Teneinde de zorguitgaven te beteugelen 
wordt de beoordeling van medische innovaties op kosteneffectiviteitcriteria steeds 
belangrijker.
Kosteneffectiviteitsanalyse (KEA) is uitgegroeid tot de belangrijkste techniek om beslissers 
in de zorg te helpen met het toewijzen van (financiële) middelen. Deze methode is echter 
niet onomstreden omdat een aantal vereenvoudigende veronderstellingen worden 
gemaakt. Een belangrijke veronderstelling is dat de kosten en effecten, en daarmee de 
kosteneffectiviteit van een innovatie, constant is in de tijd. In dit proefschrift wordt deze 
veronderstelling kritisch onderzocht, en worden de mogelijke gevolgen van afwijkingen 
van deze veronderstelling beoordeeld, zowel in kwantitatieve als in kwalitatieve zin.
Hoofdstuk 1 bevat de algemene introductie van dit proefschrift en omvat een beschrijving 
van de grote toename van de zorguitgaven in de afgelopen decennia, alsmede een 
aantal oorzaken en mogelijke maatregelen om dit probleem te verminderen. Ook wordt 
het kader van de standaard KEA geschetst alsmede de onderliggende aannames en 
de daaruit voortvloeiende beperkingen, en wordt de manier waarop dit proefschrift 
probeert een verbetering van dit kader te realiseren beschreven. Dit hoofdstuk omvat 
eveneens de doelstellingen en een overzicht van de inhoud van dit proefschrift.
Hoofdstuk 2 begint met een theoretische discussie over de rol van tijd in KEA, en 
maakt zich sterk voor het opnemen van informatie over korte termijn uitkomsten in 
economische evaluaties in de gezondheidszorg. In dit hoofdstuk wordt aangetoond 
dat korte termijn kosteneffectiviteit resultaten aanzienlijk kunnen afwijken van de 
resultaten van een conventionele, op de lange termijn gerichte KEA. De belangrijkste 
factoren die leiden tot deze afwijkingen worden vastgesteld, evenals mogelijke 
gevolgen van inefficiënties die kunnen optreden op korte termijn en die het gevolg zijn 
van deze afwijkingen. Hoofdstuk 2 maakt ook duidelijk dat de stuwende krachten en 
mechanismen die leiden tot korte termijn inefficiënties moeten worden geëxpliciteerd, 
en dat de impact van deze inefficiënties moet worden gekwantificeerd en toegevoegd 
aan het resultaat van de traditionele KEA.
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De eerste stap in het daadwerkelijk kwantificeren van korte termijn inefficiënties 
wordt gezet in hoofdstuk 3, waarin een model is ontworpen dat rekening houdt 
met inflexibiliteit van productiefactoren van de oude technologie en bijbehorende 
allocatieproblemen. Hier worden de hoeveelheid capaciteit voor de oude technologie 
die wordt vrijgemaakt, de daaruit voortvloeiende overcapaciteit, en het bijbehorende 
aandeel vaste productiefactoren geïdentificeerd als belangrijke determinanten 
van korte termijn inefficiënties. Dit wordt geïllustreerd door de overgang van een 
positieve incrementele netto baat (INB) op de lange termijn naar een negatieve INB 
op de korte termijn bij de digitalisering van een radiografie afdeling. Hoewel het model 
tijdsafhankelijk is doordat het rekening houdt met afschrijving van oude technologie 
en opvulling van vrijgekomen capaciteit, wordt het beperkt door het feit dat alleen 
inefficiënties als gevolg van de oude technologie worden meegenomen en er niet wordt 
gekeken naar de effectkant van het kosteneffectiviteit model.
In het licht van de beperkingen van hoofdstuk 3, wordt in hoofdstuk 4 de invloed van 
capaciteitsbeperkingen voor de nieuwe technologie als gevolg van een geleidelijk 
implementatieproces onderzocht. Er wordt aangetoond dat tijdens de geleidelijke 
implementatie van een innovatie er ernstige korte termijn inefficiënties kunnen 
ontstaan, zowel in termen van vaste productiefactoren voor de oude technologie 
als uitgestelde gezondheidszorgopbrengsten voor de nieuwe technologie. Dit wordt 
geïllustreerd in een real-world casus die de overgang van analoge naar digitale 
borstkankerscreening beschrijft en waarbij de INB tijdens de overgangsperiode minus 
€ 488.000 bedroeg in plaats van de verwachte positieve waarde van € 985.000. Een 
interessante bevinding wanneer er wordt gekeken naar de implementatiesnelheid is 
dat geleidelijke invoering van een nieuwe technologie leidt tot lagere inefficiënties als 
gevolg van de oude technologie, maar tot hogere inefficiënties als gevolg van de nieuwe 
technologie. Dit laatste is het gevolg van de vertraging in efficiëntiewinst die optreedt 
als deze nieuwe technologie vertraagd wordt ingevoerd. Het lijkt onmogelijk om een 
optimaal implementatiepatroon te vinden voor een innovatie die een technologie 
vervangt met een relevant aandeel vaste productiefactoren dat tegelijkertijd beide 
bronnen van inefficiënties minimaliseert. In plaats daarvan toont het model aan dat 
de beslisser zelf moet bepalen welke van beide bronnen van inefficiënties het meeste 
bijdraagt, en dat de beslisser afhankelijk hiervan de implementatiesnelheid van de 
innovatie aan moet passen.
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Bij het bestuderen van een vertraging in efficiëntiewinsten is de effectkant van het 
kosteneffectiviteitmodel tot nu toe slechts gedeeltelijk meegenomen. Echter een 
belangrijke en algemeen bekende factor die leidt tot verminderde effectiviteit op de 
korte termijn, namelijk de leercurve, is nog niet bekeken. Daarom is in hoofdstuk 5 
een model ontwikkeld dat inefficiënties in kaart brengt die het gevolg zijn van leren. 
Leren is een belangrijk verschijnsel in gerandomiseerde gecontroleerde studies 
voor chirurgische ingrepen en kan leiden tot een significante onderschatting van de 
kosteneffectiviteit van een innovatie omdat leren leidt tot zowel hogere kosten als 
verminderde effecten op de korte termijn. Bij het kwantificeren van de invloed van leren 
op kosteneffectiviteituitkomsten is een algemeen model voor de leercurve gebruikt, 
gebaseerd op Wright’s model voor cumulatieve gemiddelden, waarbij gebruik is gemaakt 
van de mening van deskundigen om de prestaties op expertniveau in te schatten. Hier 
wordt duidelijk dat de duur van de studie een belangrijke voorspeller is van de invloed 
van leren op korte termijn inefficiënties, evenals eerder opgedane ervaring van het 
betrokken personeel. Wanneer het personeel een relevant aantal procedures heeft 
uitgevoerd voordat de studie begint, zullen leereffecten sterk verminderen. Het meest 
uitdagende aspect van het bepalen van korte termijn inefficiënties als gevolg van leren 
is het bepalen van de vorm van de leercurve. Vaak zijn onderzoeksgegevens schaars en 
vaag, en bevat deze uitschieters. In dit hoofdstuk wordt de mening van deskundigen 
gebruikt als een middel om met deze problematiek om te gaan.
Hoofdstuk 6 richt zich op een meer beleidsmatige onderwerp dat ontstaat als gevolg 
van korte termijn inefficiënties. Dit hoofdstuk stipt de problemen aan die kunnen 
ontstaan wanneer beleidsmakers uitkomsten van kosteneffectiviteitstudies verwachten 
binnen een te kort tijdsbestek. Door het verminderen van de lengte van uitkomststudies 
zullen resultaten een periode in de levenscyclus van de innovatie representeren, waar 
korte termijn inefficiënties de meeste impact hebben, namelijk tijdens de vroegste 
stadia van implementatie en adoptie van de innovatie. Daarom zal het verkorten van 
de lengte van uitkomststudies resulteren in resultaten voor de kosteneffectiviteit die 
nog meer gebiased zijn tegen de innovatie. In dit hoofdstuk worden beleidsmakers 
en onderzoekers aangespoord om alle factoren die mogelijk kunnen leiden tot korte 
termijn inefficiënties te identificeren, en aan de hand van de uitkomsten hiervan het 
ontwerp van kosteneffectiviteitstudies aan te passen. 
In hoofdstuk 7 wordt de scope van de oorspronkelijke vraag die een KEA dient te 
beantwoorden uitgebreid met de vraag ‘wanneer’ te implementeren in plaats van 
alleen de vraag ‘of’ een innovatie moet worden geïmplementeerd. Dit hoofdstuk 
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richt zich op het lokale perspectief, omdat timing van adoptie van een innovatie sterk 
afhankelijk is van de lokale situatie van een beslisser. Er wordt een beslisregel afgeleid 
welke de besluitvorming kan ondersteunen over het al dan niet in gebruik nemen 
van een innovatie of om ingebruikname uit te stellen, hierbij rekening houdend met 
verdiscontering en mogelijke variaties in de netto monetaire baten in de tijd voor 
potentiële alternatieve technologieën. Deze benadering wordt geïllustreerd door een 
hypothetische casus waarin meerdere parameters worden gevarieerd.
Hoofdstuk 8 beschrijft een vroege economische evaluatie van een point-of-care (POC) 
chip. Hier wordt met de term ‘vroege’ bedoeld dat deze economische evaluatie wordt 
uitgevoerd in de beginfase van de ontwikkeling van de innovatie. Deze benadering is 
vooral nuttig wanneer de ontwikkeling van de innovatie kostbaar is, en wanneer er 
weinig informatie beschikbaar is over de innovatie zelf en over de beoogde markt. Dit 
was inderdaad het geval voor de POC chip, omdat er veel onzekerheid bestond ten 
aanzien van belangrijke parameters die de kosteneffectiviteit van de chip bepaalden. 
Vroege economische evaluaties brengen extra uitdagingen met zich mee, welke 
met name liggen in het gebrek aan empirische gegevens ten aanzien van kosten en 
effecten. In dit hoofdstuk wordt een stapsgewijze benadering gebruikt om met deze 
problematiek om te gaan. Deze aanpak begint met een eenvoudige headroom analyse 
en krijgt daarna meer analytische diepgang door het toevoegen van deterministische 
en probabilistische analyses om de economische levensvatbaarheid van de chip te 
beoordelen. Ondanks deze aanpak blijft de verwachte kosteneffectiviteit uitkomst 
erg onzeker, en het lijkt erop dat de identificatie van parameters die cruciaal zijn voor 
het succes van de innovatie in termen van kosteneffectiviteit belangrijker is in de 
vroege ontwikkelingsfase. Dit wordt gedaan met behulp van zowel deterministische 
als probabilistische gevoeligheidsanalyse. Ook is onderzoek naar de expected value of 
information om richting te geven aan inspanningen voor verder onderzoek noodzakelijk, 
vooral omdat in de vroege stadia van de ontwikkeling van de technologie er nog tijd is 
om de innovatie aan te passen op het gebied van ontwerp en functionaliteit.
Hoofdstuk 9 gaat in op de bijdrage van dit proefschrift in het licht van de oorspronkelijke 
doelstellingen. Geconcludeerd wordt dat korte termijn inefficiënties belangrijke 
gevolgen kunnen hebben, zodanig dat de uitbreiding van het kosteneffectiviteitmodel 
met informatie over korte termijn uitkomsten gerechtvaardigd is. Ook worden de 
sterke en zwakke punten van de modellen verder besproken, zowel door in te gaan 
op methodologische kwesties als meer algemene factoren, zoals de toepasbaarheid 
van de modellen in de praktijk. De voornaamste zwakte van het gebruik van modellen 
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om op korte termijn inefficiënties te kwantificeren is de complexiteit en de 
daaruit voortvloeiende beperkte gebruiksvriendelijkheid voor beleidsmakers. 
Echter, hieraan gerelateerd ligt ook de grote kracht van het gebruik van modellen, 
namelijk dat deze beslissers daadwerkelijk kwantitatief inzicht kunnen geven in de 
mechanismen die leiden tot korte termijn inefficiënties, en dus mogelijkheden om 
deze te voorkomen of te verminderen. De discussie wordt afgesloten met een aantal 
toekomstperspectieven op onderzoek en beleid. Hier wordt de mogelijkheid voor de 
ontwikkeling van één overkoepelend model besproken, evenals het idee dat voor 
medische technologieën een verschuiving van een globaal naar een meer lokaal 
perspectief moet worden overwogen.
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Dankwoord
En dan nu het deel van mijn proefschrift dat door de meesten van jullie als eerste, en 
misschien wel als enige zal worden gelezen: het dankwoord! Om maar direct met een 
cliché in huis te vallen: een proefschrift maken doe je niet alleen. Ook tijdens het maken 
van dit proefschrift heb ik veel hulp gehad, zowel direct als indirect, en zonder deze hulp 
had dit boekwerk nu niet voor jullie gelegen. Een aantal personen wil ik in het bijzonder 
bedanken.
Eddy, als ik aan jou als copromotor denk zijn er twee zaken die mij direct te binnen 
schieten: toegankelijkheid en enthousiasme. Jouw deur stond letterlijk en figuurlijk 
altijd open. Ik kon altijd bij je terecht als ik even was vastgelopen of als ik een ingeving 
had die ik wilde toetsen. Als ik je kantoor verliet had ik meestal weer ideeën en 
motivatie te over. Ook jouw enthousiasme voor je vakgebied is iets waar ik veelvuldig 
van meegeprofiteerd heb, al was het alleen maar vanwege de vele wetenschappelijke 
discussies die we gevoerd hebben. Hartelijk dank voor je steun en vertrouwen, ook 
nadat ik aan je kenbaar maakte dat ik het vervolg van mijn loopbaan toch niet in de 
wetenschap zag liggen.
Heel veel dank ook aan mijn promotoren Gert Jan van der Wilt en Marcel Olde 
Rikkert. Jullie feedback en ideeën heb ik als zeer inspirerend en waardevol ervaren. 
De input die dikwijls net uit een wat andere invalshoek kwam werkte voor mij vaak 
erg verfrissend! Dank voor het vertrouwen dat jullie in mij gesteld hebben en de zeer 
prettige samenwerking.
Willem, zonder jou had dit boekwerk een stuk minder wiskunde bevat. En die 
wiskunde is toch de ‘backbone’ van de modellen, en dus van dit proefschrift. Heel erg 
bedankt voor je hulp met de modellen, voor je soms briljante ingevingen tijdens onze 
brainstormsessies, maar vooral ook voor je geduld en altijd heldere uitleg.
Ik wil uiteraard ook alle medewerkers van de afdeling Health Evidence bedanken voor 
alle gezelligheid tijdens de dagjes uit, borrels, bowlingavonden en andere sociale 
activiteiten. Speaking of which, Marleen, Sander, en Hans, het was me een waar 
genoegen tezamen de SOA activiteiten te organiseren, en alsnog bedankt voor jullie 
geduld als de bowling beker soms met enige vertraging gegrafeerd werd. Ook wil ik de 
promovendi bedanken voor alle gezellige avondjes karaoke, twister, Sinterklaas, party 
& co, en andere spellen. En last but not least, natuurlijk mijn kamergenoten! Janine en 
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Martine, bedankt voor de vrolijkheid op de maandag- dan wel dinsdagmorgen en de 
goede en soms goed foute gesprekken! Audrey, I learned a lot from you, most notably 
speaking better English but also things such as the views of foreign PhD students on the 
Netherlands. We had a lot of fun and even adopted een hele new language, Anglodutch. 
Bedankt voor alles, medewerker! Anne, het laatste jaar van mijn PhD traject heb ik 
jou lastig mogen vallen op de derde verdieping. Naast alle grappen en grollen en de 
gezelligheid heb ik veel respect gekregen voor de manier waarop jij werkt en 1001 
dingen tegelijk lijkt te kunnen doen. En dankzij jou ben ik nu ook expert op het gebied 
van Manhattanplots! Super bedankt voor de leuke tijd!
In mijn tijd als promovendus heb ik ook meegewerkt aan het project ‘De Zorg- en 
Welzijnsstandaard’ in samenwerking met de afdelingen Eerstelijnsgeneeskunde en 
Geriatrie. Hier wil ik ook graag een aantal mensen noemen. Allereerst Franca en Franka: 
jullie passie voor je vakgebied en doorzettingsvermogen zijn een voorbeeld voor mij 
geweest. Ik heb onze samenwerking altijd als zeer positief en prettig ervaren. Ik wens 
jullie veel succes met jullie eigen promoties, maar dat gaat zeker lukken! Ook zijn er 
een aantal andere mensen erg belangrijk geweest in het mij wegwijs maken in de soms 
wondere wereld van de (ouderen)zorg. Kees, Anke, Sytse, Raymond, en Marcel, ik heb 
van jullie kennis en expertise mogen profiteren en ben jullie daar erg dankbaar voor!
Uiteraard wil ik ook mijn huidige collega’s bij Pharmerit bedanken voor alle support. 
Bij een nieuwe werkgever beginnen is altijd spannend, maar ik voelde me direct thuis 
en op mijn gemak. Ook in de drukte die het afronden van een promotietraject met 
daarnaast een fulltime baan met zich meebrengt kon ik altijd een beroep op jullie doen. 
Dank hiervoor!
Promoveren kan niet zonder afleiding en ontspanning. Beste vrienden, allemaal 
hartstikke bedankt voor jullie belangstelling en de gezelligheid! Sjoerd, Sander, en 
Sten: bedankt voor de klaverjasavonden, dat deze ondanks onze volle agenda’s maar 
gecontinueerd mogen worden! En jullie weten het hé: klaverjassen is géén geluksspel! 
Beste “Enschede-alumni”, ik hoop nog vele ‘corrupte’ avonden en weekenden te beleven 
in Leuven, Beltrum, of Davos! ANW-ers, ik zie uit naar ons volgende ‘sectieoverleg’! 
Beste oud-Hercules-ers, we zien elkaar weer bij de volgende Jeker-Dommel reünie, 
wellicht in Engeland?
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Lieve pa en ma. Jullie hebben mij gemaakt tot wie ik ben. Dankzij jullie heb ik een 
zorgeloze jeugd gehad, en jullie hebben mij altijd gesteund in wat ik deed en doe. 
Bedankt daarvoor! Ook Toke en Kees, die pas in een wat latere periode mijn leven 
zijn binnengewandeld, super bedankt voor de interesse en steun. Lieve Hanneke, ik 
bewonder jouw doorzettingsvermogen en vastberadenheid. We moeten eens vaker 
wat afspreken! Beste Riet, Charles, Michiel, en Robin, bedankt voor jullie steun en 
vertrouwen. Een betere schoonfamilie zou ik me niet kunnen wensen.
Lieve Sabine, wij zijn in veel dingen tegenpolen, en misschien dat het daarom wel zo 
goed klikt. Woorden kunnen eigenlijk niet beschrijven wat jij voor mij betekent. Ik ben 
niet altijd de gemakkelijkste, maar dankzij jouw liefde en geduld weet jij perfect met 
mijn nukken om te gaan. Ik hoop dat we samen nog veel mogen genieten van elkaar. 
Volgens mij kunnen wij de hele wereld aan! Ik hou van je! 
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